

DUKE UNIVERSITY MEDICAL CENTER

CURRICULUM VITAE

Date Prepared: April 28, 2026

Name: Daniel K. Benjamin, Jr., M.D., M.P.H, Ph.D.

Primary Academic Appointment: Department of Pediatrics, Division of Infectious Disease

Secondary Appointment: Duke Clinical Research Institute

Academic Rank and Title: Kiser-Arena Distinguished Professor of Pediatrics

Medical Licensure: North Carolina License # 2001-00833

Date of License: July 19, 2001

Specialty Certifications and Dates: Pediatrics 1998; 2005; 2015
(Meeting Maintenance of Certification)
Pediatrics Infectious Disease 2001; 2008; 2018
(Meeting Maintenance of Certification)

Date of Birth: March 18, 1968

Place: Charlottesville, Virginia, United States of America

Citizen of: United States of America

Education	Institution	Date	Degree
High School	DW Daniel	1986	Diploma
College	University of Virginia	1990	B.A.
Medical School	University of Virginia	1995	M.D.
Graduate School	University of North Carolina	2001	M.P.H.
Graduate School	University of North Carolina	2003	Ph.D.

Scholarly Societies:

Association of American Physicians
American Academy of Pediatrics
American Academic Society
American Pediatric Society
American Society for Clinical Investigation
American Society for Clinical Pharmacology and Therapeutics
American Society for Microbiology
European Society for Developmental, Perinatal, and Pediatric Pharmacology
Infectious Disease Society of America
North Carolina Pediatric Society
Pediatric Infectious Disease Society
Society for Pediatric Research

Professional Training and Academic Career:

Institution	Position/Title	Dates
University of Virginia	Pediatric Resident	1995–1998
Duke University	Pediatric Fellow, Infectious Disease	1998–2001
Duke University	Instructor Pediatric Infectious Disease	2001–2002
Duke University	Assistant Professor, Pediatrics	2002–2004
Duke University	Associate Professor, Pediatrics	2005–2007
Food and Drug Administration	Medical Officer	2005–2007
Food and Drug Administration	Scientific Advisor, Office of the Commissioner	2005–2007
Duke University	Associate Professor with Tenure, Pediatrics	2007–2010
Duke University	Director, Clinical Research Fellowship Program	2004–2010
Duke University	Chief, Division of Quantitative Sciences	2007–2010
Duke University	Director, Pediatric Duke Clinical Research Unit	2009–2014
Duke University	Professor with Tenure, Pediatrics	2010–
Duke University	DCRI Faculty Associate Director	2010–
Duke University	Kiser-Arena Distinguished Professor of Pediatrics	2014-

Affiliate Appointments

Institution	Position/Title	Dates
UNC School of Pharmacy	Adjunct Professor	2013-
Montana State University	Affiliate Professor	2025-

PUBLICATIONS

Peer-Reviewed Original Research Articles: (trainees underlined)

- 1) **Benjamin DK Jr.**, Benjamin DK, Fisher RG, McKinney RE Jr. Candidal mycetomata in neonates *Pediatrics*. 1999;104:1126–1129. PMID10545558.
- 2) **Benjamin DK Jr.**, Ross K, Benjamin DK, McKinney RE Jr., Auten R, Fisher RG. When to suspect fungal infections in neonates: a clinical comparison of *Candida albicans* and *Candida parapsilosis* fungemia with coagulase-negative staphylococcal bacteremia. *Pediatrics*. 2000;106:712–718. PMID11015513.
- 3) **Benjamin DK Jr.**, Miller W, Garges H, Benjamin DK, McKinney RE Jr., Cotten M, Fisher RG, Alexander K. Bacteremia, central catheters and neonates: when to pull the line. *Pediatrics*. 2001;107:1272–1276. PMID11389242.
- 4) **Benjamin DK Jr.**, Miller WC, Fiscus SA, Benjamin DK, Morse M, Valentine M, McKinney Jr. RE. Rational testing of the HIV exposed infant. *Pediatrics*. 2001;108:E3. PMID11433082.
- 5) **Benjamin DK Jr.**, Miller WC, Bayliff S, Martel L, Alexander KA, Martin P. Infections from 510 pediatric bone marrow transplants. *Pediatric Infect Dis J*. 2002;21:227–234. PMID12005087.
- 6) Steinbach WJ, Sectish TC, **Benjamin DK Jr.**, Chang KW, Messner A. Pediatric residents' clinical diagnostic accuracy of otitis media and a proposal for improved resident education and competency. *Pediatrics*. 2002;109:993–998. PMID12042534.
- 7) **Benjamin DK Jr.** Integration of statistical theory and clinical expertise: PCR testing of the HIV exposed infant. *Minerva Pediatr*. 2002;54:105–111. PMID11981525.
- 8) Calland JF, Adams RB, **Benjamin DK Jr.**, O'Connor MJ, Chandresekhara V, Guerlain S, Jones RS. Thirty-day postoperative mortality at an academic medical center. *Ann Surg*. 2002;235:690–696. PMC1422495.
- 9) Beaty RM, Jackson M, Peterson D, Bird A, Brown T, **Benjamin DK Jr.**, Juopperi T, Kishnan P, Boney A, Chen YT, Koeberl DD. Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors. *Gene Ther*. 2002;9:1015–1022. PMID12101432.
- 10) Fisher RG, **Benjamin DK Jr.** Facial cellulitis in children: a changing spectrum. *South Med J*. 2002;95:672–667. PMID12144069.
- 11) Weintrob AC, Giner J, Menezes P, Patrick E, **Benjamin DK Jr.**, Lennox J, Pilcher CD, Eron JJ, Hicks CB. Delayed diagnosis of primary HIV infection: public health and clinical implications. *Arch Intern Med*. 2003;163:2097–2100. PMID14504125.
- 12) **Benjamin DK Jr.**, DeLong ER, Steinbach WJ, Cotten CM, Walsh TJ, Clark R. Empirical therapy for neonatal candidemia in very low birth weight infants. *Pediatrics*. 2003;112:543–547. PMID12949281.
- 13) **Benjamin DK Jr.**, Poole C, Steinbach WJ, Rowen JL, Walsh TJ. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. *Pediatrics*. 2003;112:634–640. PMID12949295.

- 14) **Benjamin DK Jr.**, Miller WC, Benjamin DK, Ryder RW, Weber DJ, Walter E, McKinney RE Jr. A comparison of height and weight velocity to predict laboratory and clinical progression in pediatric HIV. *AIDS*. 2003;17:2331–2336. PMID14571184.
- 15) Koeberl DD, Young SP, Gregersen NS, Vockley J, Smith WE, **Benjamin DK Jr.**, An Y, Weavil SD, Chaing SH, Bali D, McDonald MT, Kishnani PS, Chen YT, Millington DS. Rare disorders of metabolism with elevated butyryl- and isobutyryl-carnitine detected by tandem mass spectroscopy newborn screening. *Pediatr Res*. 2003;54:219–223. PMID12736383.
- 16) **Benjamin DK Jr.**, DeLong ER, Steinbach WJ. Latent class analysis: an illustrative application for education in the assessment of resident otoscopic skills. *Ambul Pediatr*. 2004;4:13–17. PMID14731098.
- 17) **Benjamin DK Jr.**, Miller WC, Ryder RW, Weber DJ, Walter E, McKinney RE Jr. Growth patterns reflect response to antiretroviral therapy in HIV positive infants: potential utility in resource-poor settings. *AIDS Patient Care STDS*. 2004;18:35–43. PMID15006193.
- 18) Drew RH, Duane RD, Palmer SM, **Benjamin DK Jr.**, Perfect JR. Comparative safety of aerosolized treatments of amphotericin B lipid complex and amphotericin B deoxycholate as antifungal prophylaxis in lung transplant recipients: a randomized, double-blind study. *Transplantation*. 2004;77:232–237. PMID14742987.
- 19) Miller JL, Schell WA, Wills EA, Toffaletti DL, Boyce M, **Benjamin DK Jr.**, Bartroli J, Perfect JR. In vitro and in vivo efficacy of the new triazole albaconazole (UR-9825) against *Cryptococcus neoformans*. *Antimicrob Agents Chemother*. 2004;48:384–387. PMC321550.
- 20) Weintrob AC, Hamilton JD, Hahn C, Klinzman D, Moyo G, Zdunek D, Hess G, **Benjamin DK Jr.**, Stapleton JT. Active or prior GB virus C infection does not protect against vertical transmission of HIV in co-infected women from Tanzania. *Clin Infect Dis*. 2004;38:e46–48. PMID14999645.
- 21) Chu V, Cabell CH, **Benjamin DK Jr.**, Kuniholm EF, Fowler VG Jr., Engemann J, Sexton DJ, Corey GR, Wang A. Early predictors of in-hospital mortality in infective endocarditis. *Circulation*. 2004;109:1745–1749. PMID15037538.
- 22) **Benjamin DK Jr.**, DeLong ER, Cotten MC, Garges HP, Clark RH. Mortality following blood culture in premature infants: increased with gram-negative bacteremia and candidemia, but not gram-positive bacteremia. *J Perinatol*. 2004;24:175–180. PMID14985775.
- 23) **Benjamin DK Jr.**, DeLong ER, Cotten MC, Garges HP, Clark RH. Postconception age and other risk factors associated with mortality following gram-negative rod bacteremia. *J Perinatol*. 2004;24:169–174. PMID14985773.
- 24) Cunnion KM, **Benjamin DK Jr.**, Hester CG, Frank MM. Complement receptor 1 (CD35) and C3 influence murine survival of *Staphylococcus aureus* bacteremia. *J Lab Clin Med*. 2004;143:358–365. PMID15192652.
- 25) Clark R, Powers R, White R, Bloom B, Sanchez P, **Benjamin DK Jr.** Nosocomial infection in the NICU: a medical complication or unavoidable problem? *J Perinatol*. 2004;24:382–388. PMID15116140.

- 26) Steinbach WJ, **Benjamin DK Jr.**, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to *Aspergillus terreus*: multicenter retrospective analysis of 83 cases. *Clin Infect Dis*. 2004;39:192–198. PMID15307028.
- 27) **Benjamin DK Jr.**, Miro JM, Hoen B, Steinbach WJ, Fowler V, Olaison L, Habib G, Abrutyn E, Perfect J, Zass A, Corey GR, Eykyn S, Thuny F, Jiménez-Expósito MJ, Cabell CH, and the ICE-MD Study Group. *Candida* endocarditis: contemporary cases from the International Collaboration of Infectious Endocarditis Merged Database (ICE-MD). *Scand J Infect Dis*. 2004;36:453–455. PMID15307567.
- 28) Steinbach WJ, Schell WA, Perfect JR, Walsh TJ, **Benjamin DK Jr.** Review of *in vitro* analyses, animal models, and 60 clinical cases of invasive *Aspergillus terreus* infection. *Antimicrob Agents Chemother*. 2004;48:3217–3225. PMC514747.
- 29) Clark R, Powers R, White R, Bloom B, Sanchez P, **Benjamin DK Jr.** Prevention and treatment of nosocomial sepsis in the NICU. *J Perinatol*. 2004;24:446–453. PMID15129228.
- 30) Steinbach WJ, **Benjamin DK, Jr.**, Trasi SA, Miller JL., Schell WA, Zaas AK, Foster WM, Perfect JR. Value of an inhalational model of invasive aspergillosis. *Med Mycol*. 2004;42:417–425. PMID15552643.
- 31) **Benjamin DK Jr.**, Hirschfeld S, Cunningham CK, McKinney RE Jr. Growth as a part of the composite endpoint in pediatric antiretroviral clinical trials. *J Antimicrob Chemother*. 2004;54:701–703. PMID15355940.
- 32) Steinbach WJ, Singh N, Miller JL, **Benjamin DK Jr.**, Schell WA, Heitman J, Perfect JR. In vitro interactions between antifungals and immunosuppressants against *Aspergillus fumigatus* isolates from transplant and non-transplant patients. *Antimicrob Agents and Chemother*. 2004;48:4922–4925. PMC529228.
- 33) Tiffany KF, **Benjamin DK Jr.**, Palasanthiran P, O'Donnell K, Gutman LT. Improved neurodevelopmental outcomes following long-term high-dose oral acyclovir therapy in infants with central nervous system and disseminated herpes simplex disease. *J Perinatol*. 2005;25:156–161. PMID15605069.
- 34) Steinbach WJ, Perfect JR, Cabell CH, Fowler VG, Corey GR, Li JS, Zaas AK, **Benjamin DK Jr.** A meta-analysis of medical versus surgical therapy for *Candida* endocarditis. *J Infect*. 2005;51:230–247. PMID16230221.
- 35) Fowler VG Jr., Justice A, Moore C, **Benjamin DK Jr.**, Woods CW, Reller LB, Corey RG, Day NPJ, Peacock SJ. Risk factors for hematogenous complications of intravascular catheter-associated *Staphylococcus aureus* bacteremia. *Clin Infect Dis*. 2005;40:695–703. PMID15714415.
- 36) El-Ahdab F, **Benjamin DK Jr.**, Wang A, Cabell CH, Chu V, Stryjewski ME, Corey GR, Sexton DJ, Reller LB, Fowler VG, Jr. Risk of endocarditis among patients with prosthetic valves and *Staphylococcus aureus* bacteremia. *Am J Med*. 2005;118:225–229. PMID15745719.
- 37) Nielsen K, Cox GM, Litvintseva AP, Mylonakis E, Malliaris SD, **Benjamin DK Jr.**, Giles SS, Mitchell TG, Casadevall A, Perfect JR, Heitman J. *Cryptococcus neoformans* {alpha} strains

preferentially disseminate to the central nervous system during co-infection. *Infect Immun.* 2005;73:4922–4933. PMC1201212.

- 38) Schelonka RL, Katz B, Waites KB, **Benjamin DK Jr.** A critical appraisal of the role of ureaplasma in the development of bronchopulmonary dysplasia using meta-analytic techniques. *Pediatr Infect Dis J.* 2005;24:1033–1039. PMID16371861.
- 39) **Benjamin DK Jr.**, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins R, Duara S, Poole K, Laptook A, Goldberg R. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality, and neurodevelopmental outcomes at 18–22 months. *Pediatrics.* 2006;117:84–92. PMID16396864.
- 40) Garges HP, Moody MA, Cotten CM, Smith PB, Tiffany KF, Lenfestey R, Li JS, Fowler VG Jr., **Benjamin DK Jr.** Neonatal meningitis: what is the correlation between cerebrospinal fluid cultures, blood cultures, and CSF parameters? *Pediatrics.* 2006;117:1094–1100. PMID16585303.
- 41) Ward RM, Benitz WE, **Benjamin DK Jr.**, Blackmon L, Giacoia G, Hudak M, Lasky T, Rodriguez W, Selen A. Criteria supporting the study of drugs in the newborn. *Clin Ther.* 2006;28:1385–1398. PMID17062311.
- 42) Menon S, Berezny KY, Kilaru R, **Benjamin DK Jr.**, Kay JD, Hazan L, Portman R, Hogg R, Deitchman D, Califf RM, Li JS. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. *Am Heart J.* 2006;152:394–399. PMID16875928.
- 43) **Benjamin DK Jr.**, Driscoll T, Siebel NL, Gonzalez CE, Roden MM, Kilaru R, Clark K, Dowell JA, Schranz J, Walsh TJ. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. *Antimicrob Agents Chemother.* 2006;50:632–638. PMC1366891.
- 44) Smith PB, Cotten CM, Garges HP, Tiffany KF, Lenfestey RA, Moody MA, Li JS, **Benjamin DK Jr.** A comparison of neonatal gram-negative rod and gram-positive cocci meningitis. *J Perinatol.* 2006;26:111–114. PMID16435007.
- 45) Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, **Benjamin DK Jr.** The association of third generation cephalosporin use and invasive candidiasis in extremely low birth weight infants. *Pediatrics.* 2006;118:717–722. PMID16882828.
- 46) Nageswaran S, Woods CR, **Benjamin DK Jr.**, Givner LB, Shetty AK. Orbital cellulitis in children. *Pediatr Infect Dis J.* 2006;25:695–699. PMID16874168.
- 47) **Benjamin DK Jr.**, Schelonka R, White R, Holley HP, Jr., Bifano E, Cummings J, Adcock K, Kaufman D, Puppala B, Riedel P, Hall B, White J, Cotten CM, on behalf of the *S. aureus* Prevention investigators. A blinded, randomized, multicenter study of an intravenous *Staphylococcus aureus* immune globulin. *J Perinatol.* 2006;26:290–295. PMID16598296.
- 48) Freedman J, Guller U, **Benjamin DK Jr.**, Higgins LD, Pan D, Cook C, Pietrobon R. National trends in health care utilization and racial and socio-economic disparities in pediatric pyogenic arthritis. *J Pediatr Orthop.* 2006;26:709–715. PMID17065931.

- 49) Brooks R, Woods CW, **Benjamin DK Jr.**, Rosenstein NE. Increased case-fatality associated with *Neisseria meningitidis* outbreaks compared with sporadic meningococcal disease in the United States, 1994–2002. *Clin Infect Dis*. 2006;43:49–54. PMID16758417.
- 50) Steinbach WJ, Cramer RA Jr, Perfect BZ, Asfaw YG, Sauer TC, Najvar LK, Kirkpatrick WR, Patterson TF, **Benjamin DK Jr.**, Heitman J, Perfect JR. Calcineurin controls growth, morphology, and pathogenicity in *Aspergillus fumigatus*. *Eukaryot Cell*. 2006;5:1091–1103. PMC1489296.
- 51) Sun B, Zhang H, **Benjamin DK Jr.**, Brown T, Bird A, Young SP, McVie-Wylie A, Chen YT, Koeberl DD. Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. *Mol Ther*. 2006;14:822–830. PMC2709843.
- 52) **Benjamin DK Jr.**, Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, Califf RM, Li JS. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. *JAMA*. 2006;296:1266–1273. PMC2773660.
- 53) Smith PB, Benjamin DK, Morgan J, Fridkin SK, Sanza LT, Harrison LH, Sofair AN, Huie-White S, **Benjamin DK Jr.** Excess costs associated with candidiasis in neonates. *Pediatr Infect Dis J*. 2007;26:197–200. PMID17484214.
- 54) Stryjewski ME, Szczech LA, **Benjamin DK Jr.**, Inrig J, Kanafani ZA, Engemann JJ, Chu VH, Reller LB, Corey GR, Fowler VG Jr. Use of vancomycin or first generation cephalosporins in the treatment of hemodialysis-dependent patients with methicillin-susceptible *Staphylococcus aureus* bacteremia. *Clin Infect Dis*. 2007;44:190–196. PMID17173215.
- 55) Koeberl DD, Sun BD, Damodaran TV, Brown T, Millington DS, **Benjamin DK Jr.**, Bird A, Schneider A, Hillman S, Jackson M, Beaty RM, Chen YT. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia. *Gene Ther*. 2006;13:1281–1289. PMID16672983.
- 56) Cohen-Wolkowicz M, Smith PB, Mangum B, Steinbach WJ, Alexander BD, Cotten CM, Clark RH, Walsh TJ, **Benjamin DK Jr.** Neonatal *Candida* meningitis: significance of cerebrospinal fluid parameters and blood cultures *J Perinatol*. 2007;27:97–100. PMID17080094.
- 57) Smith PB, Steinbach WJ, Cotten CM, Schell WA, Perfect JR Walsh TJ, **Benjamin DK Jr.** Caspofungin for the treatment of azole resistant candidemia in a premature infant. *J Perinatol*. 2007;27:127–129. PMID17262048.
- 58) Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, Goldsmith JV, Murphy MD, Califf RM, **Benjamin DK Jr.** Economic return of clinical trials performed for pediatric exclusivity. *JAMA*. 2007;297:480–488. PMC2773665.
- 59) Smith PB, **Benjamin DK Jr.**, Alexander BD, Johnson MD, Finkelman MA, Steinbach WJ. 1,3- β -D-glucan levels in pediatric patients: preliminary data for use of the β -glucan diagnostic assay in children. *Clin Vaccine Immunol*. 2007;14:924–925. PMC1951061.
- 60) Lenfesty RW, Smith PB, Moody MA, Clark RH, Cotten CM, Seed PC, **Benjamin DK Jr.** Predictive value of cerebrospinal fluid parameters in neonates with intraventricular drainage devices. *J Neurosurg*. 2007;107(3 Suppl):209–212. PMID17918526.

- 61) Cohen-Wolkowicz M, **Benjamin DK Jr.**, Fowler VG Jr., Wade KC, Alexander BD, Worley G, Goldstein RF, Smith PB. Mortality and neurodevelopmental outcome after *Staphylococcus aureus* bacteremia in infants. *Pediatr Infect Dis J*. 2007;26:1159–1161. PMID18043460.
- 62) Thornburg CD, Smith PB, Smithwick ML, Cotten CM, **Benjamin DK Jr.** Association between thrombosis and bloodstream infection in neonates with peripherally inserted catheters. *Thromb Res*. 2008;122:782–785. PMID17997477.
- 63) Crowley AL, Peterson GE, **Benjamin DK Jr.**, Rimmer SH, Todd C, Cabell CH, Reller LB, Ryan T, Corey GR, Fowler VG Jr. Venous thrombosis in patients with short- and long-term central venous catheter-associated *Staphylococcus aureus* bacteremia. *Crit Care Med*. 2008;36:385–390. PMID18091541.
- 64) Hope WW, Mickiene D, Petraitis V, Petraitiene R, Kelaher AM, Hughes JE, Cotten MP, Bacher J, Keirns JJ, Buell D, Heresi G, **Benjamin DK Jr.**, Groll AH, Drusano GL, Walsh TJ. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous *Candida* meningoenitis: implications for echinocandin therapy in neonates. *J Infect Dis*. 2008;197:163–171. PMC2732769.
- 65) Smith PB, Li JS, Murphy DM, Califf RM, **Benjamin DK Jr.** Adverse events in placebo-controlled pediatric hypertension trials. *Hypertension*. 2008;51:829–833. PMC2755192.
- 66) **Benjamin DK Jr.**, Smith PB, Jadhav P, Gobburu JV, Murphy D, Hasselblad V, Baker-Smith C, Califf RM, Li JS. Pediatric antihypertensive trial failures: analysis of endpoints and dose range. *Hypertension*. 2008;51:834–840. PMC2782749.
- 67) Baddley JW, **Benjamin DK Jr.**, Patel M, Miró J, Athan E, Barsic B, Bouza E, Clara L, Elliott T, Kanafani Z, Klein J, Lerakis S, Levine D, Spelman D, Rubinstein E, Tornos P, Morris AJ, Pappas P, Fowler VG Jr, Chu VH, Cabell C; The International Collaboration on Endocarditis—Prospective Cohort Study Group (ICE-PCS). *Candida* infective endocarditis. *Eur J Clin Microbiol Infect Dis*. 2008;27:519–529. PMC2757733.
- 68) Cohen-Wolkowicz M, Smith PB, **Benjamin DK Jr.**, Fowler VG Jr., Wade KC. Daptomycin use in infants: report of two cases with peak and trough drug concentrations. *J Perinatol*. 2008;28:233–234. PMC2752140.
- 69) Smith PB, **Benjamin DK Jr.**, Cotten CM, Schultz S, Guo R, Nowell L, Smithwick ML, Thornburg CD. Is an increased dwell time of a peripherally inserted catheter associated with an increased risk of bloodstream infection in infants? *Infect Control Hosp Epidemiol*. 2008;29:749–753. PMC2768571.
- 70) Koeberl DD, Pinto C, Sun B, Sontago L, Kozink DM, **Benjamin DK Jr.**, Demaster AK, Kruse MA, Vaughn V, Hillman S, Bird A, Jackson M, Brown T, Kishnani PS, Chen YT. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. *Mol Ther*. 2008;16:665–672. PMID18362924.
- 71) Yanni SB, Annaert PP, Augustijns P, Bridges A, Gao Y, **Benjamin DK Jr.**, Thakker DR. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. *Drug Metab Dispos*. 2008;36:1119–1125. PMC2737669.

- 72) Wratney AT, **Benjamin DK Jr.**, Slonim AD, He J, Cheifetz IM. The endotracheal tube air leak test does not predict extubation outcome in critically ill pediatric patients. *Pediatr Crit Care Med*. 2008;9:490–496. PMC2782931.
- 73) Baker-Smith CM, **Benjamin DK Jr.**, Grabowski HG, Reid ED, Mangum B, Goldsmith JV, Edwards R, Eisenstein EL, Sun J, Califf RM, Li JS The economic returns of pediatric clinical trials of antihypertensive drugs. *Am Heart J*. 2008;156:682–688. PMC3334305.
- 74) Li JS, Baker-Smith CM, Smith PB, Hasselblad V, Murphy MD, Califf RM, **Benjamin DK Jr.** Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis. *Clin Pharmacol Ther*. 2008;84:315–319. PMC2614386.
- 75) Smith PB, **Benjamin DK Jr.**, Murphy MD, Johann-Liang R, Iyasu S, Gould B, Califf RM, Li JS, Rodriguez W. Safety monitoring of drugs receiving pediatric marketing exclusivity. *Pediatrics*. 2008;122:e628–633. PMC2561901.
- 76) Smith PB, Garges HP, Cotten CM, Walsh TJ, Clark RH, **Benjamin DK Jr.** Meningitis in preterm neonates: importance of cerebrospinal fluid parameters. *Am J Perinatol*. 2008;25:421–426. PMC2715150.
- 77) Greenberg R, Smith PB, Cotten CM, Moody MA, Clark RH, **Benjamin DK Jr.** Traumatic lumbar punctures in neonates: test performance of the cerebrospinal fluid white count. *Pediatr Infect Dis J*. 2008;27:1047–1051. PMC2730657.
- 78) Wade KC, Wu D, Kaufman DA, Ward RM, **Benjamin DK Jr.**, Sullivan JE, Ramey N, Jayaraman B, Hoppu K, Adadmsen PC, Gastonguay MR, Barrett JS on behalf of the NICHD Pediatric Pharmacology Research Unit. Population pharmacokinetics of fluconazole in young infants. *Antimicrob Agents Chemother*. 2008;52:4043–4049. PMC2573107.
- 79) Wilfret DA Baker BT, Palavecino E, Moran C, **Benjamin DK Jr.**, for the NC RSV Study Team. Epidemiology of respiratory syncytial virus in various regions within North Carolina during multiple seasons. *NC Med J*. 2008;69:447–452. PMID19256181.
- 80) McDowell R, Li JS, **Benjamin DK Jr.**, Morgan C, Becker A, Kishnani PS, Kanter RJ. Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease. *Genet Med*. 2008;10:758–762. PMID18813140; NIHMSID454523.
- 81) Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NI, Sánchez PJ, Ambalavanan N, **Benjamin DK Jr.**; NICHD Neonatal Research Network. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. *Pediatrics*. 2009;123:58–66. PMC2760222.
- 82) Pappas PG, Kauffman CA, Andes D, **Benjamin DK Jr.**, Calandra TF, Edwards JE Jr., Filler SG, Fisher JF, Kulberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Disease Society of America. *Clin Infect Dis*. 2009;48:503–535. PMID19191635.
- 83) Stryjewski ME, Kanafani ZA, Chu VH, Pappas PA, Harding T, Drew LA, **Benjamin DK Jr.**, Reller LB, Lee BA, Corey GR, Fowler VG Jr. *Staphylococcus aureus* bacteremia among patients with healthcare-associated fever. *Am J Med*. 2009;122:281–289. PMID19272489.

- 84) Schultz ED, Tanaka DT, Goldberg RN, **Benjamin DK Jr.**, Smith PB. Effect of methicillin-resistant *Staphylococcus aureus* colonization in the neonatal intensive care unit on total hospital cost. *Infect Control Hosp Epidemiol*. 2009;30:383–385. PMC2756112.
- 85) Roilides E, Zaoutis TE, Katragkou A, **Benjamin DK Jr.**, Walsh TJ. Zygomycosis in neonates: an uncommon but life-threatening infection. *Am J Perinatol*. 2009;26:565–573. PMID19391079.
- 86) Smith PB, Walsh TJ, Hope W, Arrieta A, Akitsugu T, Kovanda LL, Kearns GL, Kaufman D, Sawamoto T, Buell DN, **Benjamin DK Jr.** Pharmacokinetics of an elevated dosage of micafungin in premature neonates *Pediatr Infect Dis J*. 2009;28:412–415. PMC2747507.
- 87) Moran C, Grussemeyer CA, Spalding JR, **Benjamin DK Jr.**, Reed SD. *Candida albicans* and non-*albicans* bloodstream infections in adult and pediatric patients: comparison of mortality and costs. *Pediatr Infect Dis J*. 2009;28:433–435. PMC2731430.
- 88) Johnson OO, Benjamin DK, **Benjamin DK Jr.**, Schimana W, Tillekeratne LG, Crump JA, Landman KZ, Kinabo GD, Mmbaga BT, Msuya LJ, Shao JF, Swai ME, Cunningham CK. Total lymphocyte count and World Health Organization pediatric clinical stage as markers to assess need to initiate antiretroviral therapy among human immunodeficiency virus-infected children in Moshi, Northern Tanzania. *Pediatr Infect Dis J*. 2009;28:493–497. PMC2724760.
- 89) Wade KC, **Benjamin DK Jr.**, Kaufman DA, Ward RM, Smith PB, Jayaraman B, Adamson PC, Gastonguay MR, Barrett JS. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. *Pediatr Infect Dis J*. 2009;28:717–723. PMC2771384.
- 90) Mofenson LM, Brady MT, Danner SP, Dominguez KL, Harra R, Handelsman F, Havens P, Nesheim S, Read JS, Serchuck L, Van Dyke R, Center for Disease Control and Prevention: National Institutes of Health: HIV Medicine Association of the Infectious Disease Society of America: Pediatric Infectious Disease Society: American Academy of Pediatrics. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children; recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Disease Society of America, the Pediatric Infectious Disease Society, and the American Academy of Pediatrics. *MMWR Recomm Rep*. 2009;58(RR-11):1–166. PMC2821196.
- 91) Ansong AK, Smith PB, Benjamin DK, Clark RH, Li JS, Cotten CM, Mangum B, Garges HP, **Benjamin DK Jr.** Group B streptococcal meningitis: cerebrospinal fluid parameters in the era of intrapartum antibiotic prophylaxis. *Early Hum Dev*. 2009;85(10 Suppl):S5–7. PMC2783609.
- 92) Michelson PH, Williams LW, **Benjamin DK**, Barnato AE. Obesity, inflammation, and asthma severity in childhood: data from the National Health and Nutrition Examination Survey 2001–2004. *Ann Allergy Asthma Immunol*. 2009 Nov;103(5):381–5.
- 93) Moran C, Smith PB, Cohen-Wolkowicz M, **Benjamin DK Jr.** Clinical trial design in neonatal pharmacology: effect of center differences with lessons from the pediatric oncology cooperative research experience. *Clin Pharmacol Ther*. 2009;86:589–591. PMC2782890.
- 94) **Benjamin DK Jr.**, Smith PB, Sun MJ, Murphy MD, Avant D, Mathis L, Rodriguez W, Califf RM, Li JS. Safety and transparency of pediatric drug trials *Arch Pediatr Adolesc Med*. 2009;163:1080–1086. PMC2792563.

- 95) Cohen-Wolkowicz M, Moran C, Benjamin DK, Cotten CM, Clark RH, **Benjamin DK Jr.**, Smith PB. Early and late onset sepsis in 2 infants. *Pediatr Infect Dis J*. 2009;28:1052–1056. PMC2798577.
- 96) **Benjamin DK Jr.**, Smith PB, Arrieta A, Castro L, Sánchez PJ, Kaufman D, Arnold LJ, Kovanda LL, Sawamoto T, Buell DN, Hope WW, Walsh TJ. Safety and pharmacokinetics of repeat-dose micafungin in young infants. *Clin Pharmacol Ther*. 2010;87:93–99. PMC2824925.
- 97) Yanni SB, Annaer PP, Augustijns P, Ibrahim JG, **Benjamin DK Jr.**, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. *Drug Metab Dispos*. 2010;38:25–31. PMC2802422.
- 98) Moran C, Grussemeyer CA, Spalding JR, **Benjamin DK Jr.**, Reed SD. Comparison of costs, length of stay, and mortality associated with *Candida glabrata* and *Candida albicans* bloodstream infections. *Am J Infect Control*. 2010;38:78–80. PMC3319041.
- 99) Barker GM, O'Brien SM, Welke KF, Jacobs ML, Jacobs JP, **Benjamin DK Jr.**, Peterson ED, Jagers J, Li JS. Major infection after pediatric cardiac surgery: a risk estimation model. *Ann Thorac Surg*. 2010;89:843–850. PMC3319976.
- 100) Kehl-Fie TE, Porsch EA, Yagupsky P, Grass EA, Olbert C, **Benjamin DK Jr.**, St Geme JW 3rd. Examination of type IV pilus expression and pilus-associated phenotypes in *Kingella kingae* clinical isolates. *Infect Immun*. 2010;78:1692–1699. PMC2849430.
- 101) Greenberg RG, Moran C, Ulshen M, Smith PB, **Benjamin DK Jr.**, Cohen-Wolkowicz M. Outcomes of catheter-associated infections in pediatric patients with short bowel syndrome. *J Pediatr Gastroenterol Nutr*. 2010;50:460–462. PMC2847645.
- 102) Lalani T, Cabell CH, **Benjamin DK**, Lasca O, Naber C, Fowler VG Jr, Corey GR, Chu VH, Fenely M, Pachirat O, Tan RS, Watkin R, Ionac A, Moreno A, Mestres CA, Casabé J, Chipigina N, Eisen DP, Spelman D, Delahaye F, Peterson G, Olaison L, Wang A; International Collaboration on Endocarditis-Pro prospective Cohort Study (ICE-PCS) Investigators. Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. *Circulation*. 2010 Mar 2;121(8):1005-13. PMC3597944.
- 103) Nowell L, Moran C, Smith PB, Seed P, Alexander BD, Cotten CM, Wiener JS, **Benjamin DK Jr.** Prevalence of renal anomalies after urinary tract infections in hospitalized infants less than 2 months of age. *J Perinatol*. 2010;30:281–285. PMC2847635.
- 104) Baker-Smith CM, **Benjamin DK Jr.**, Califf RM, Murphy MD, Li JS, Smith PB. Cough in Pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. *Clin Pharmacol Ther*. 2010;87:668–671. PMC2874085.
- 105) Hope WW, Smith PB, Arrieta A, Buell DN, Roy M, Kaibara A, Walsh TJ, Cohen-Wolkowicz M, **Benjamin DK Jr.** Population pharmacokinetics of micafungin in neonates and young infants *Antimicrob Agents Chemother*. 2010;54:2633–2637. PMC2876406.

- 106) Pasquali SK, Burstein DS, **Benjamin DK Jr.**, Smith PB, Li JS. Globalization of pediatric research: analysis of clinical trials completed for pediatric exclusivity. *Pediatrics*. 2010;126:e687–692. PMC2932835.
- 107) Yanni SB, Augustijns P, **Benjamin DK Jr.**, Brouwer KLR, Thakker DR, Annaert PP. In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats. *Drug Metab Dispos*. 2010;38:1848–1856. PMC2957167.
- 108) Manzoni P, Rizzollo S, Franco C, Gallo E, Galletto P, Boano E, Mostert M, **Benjamin DK Jr.**, Jacqz-Aigrain E, Farina D. Role of echinocandins in the management of fungal infections in neonates. *J Matern Fetal Neonatal Med*. 2010;23 Suppl 3:49–52. PMID20858036.
- 109) **Benjamin DK Jr.**, Stoll BJ, Gantz MG, Walsh MC, Sánchez PJ, Das A, Shankaran S, Higgins RD, Auten KJ, Miller NA, Walsh TJ, Laptook AR, Carlo WA, Kennedy KA, Finer NN, Duara S, Schibler K, Chapman RL, Van Meurs KP, Frantz ID 3rd, Phelps DL, Poindexter BB, Bell EF, O'Shea TM, Watterberg KL, Goldberg RN; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. *Pediatrics*. 2010;126:e865–873. PMC3045840.
- 110) Ascher S, Smith PB, **Benjamin DK Jr.** Safety of micafungin in infants: insights into optimal dosing. *Expert Opin Drug Saf*. 2011;10:281–286. Review. PMC3073303.
- 111) Piper L, Smith PB, Hornik CP, Cheifetz IM, Barrett JS, Moorthy G, Hope WW, Wade KC, Cohen-Wolkowicz M, **Benjamin DK Jr.** Fluconazole loading dose pharmacokinetics and safety in infants. *Pediatr Infect Dis J*. 2011;30:375–378. PMC3078721.
- 112) Yanni SB, Smith PB, **Benjamin DK Jr.**, Augustijns PF, Thakker DR, Annaert PP. Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. *Biopharm Drug Dispos*. 2011;32:222–232. PMC3080470.
- 113) Cohen-Wolkowicz M, **Benjamin DK Jr.**, Piper L, Cheifetz IM, Moran C, Liu P, Aram J, Kashuba AD, Capparelli E, Walsh TJ, Hope WW, Smith PB. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. *Clin Pharmacol Ther*. 2011;89:702–707. PMC3124385.
- 114) Wallace MC, Jagers J, Li JS, Jacobs ML, Jacobs JP, **Benjamin DK**, O'Brien SM, Peterson ED, Smith PB, Pasquali SK. Center variation in patient age and weight at Fontan operation and impact on postoperative outcomes. *Ann Thorac Surg*. 2011 May;91(5):1445-52. PMC3242354.
- 115) Greenberg RG, **Benjamin DK Jr.**, Cohen-Wolkowicz M, Clark RH, Cotten CM, Laughon MM, Smith PB. Repeat lumbar punctures in infants with meningitis in the neonatal intensive care unit. *J Perinatol*. 2011;31:425–429. PMC3103623.
- 116) Jean-Baptiste N, **Benjamin DK Jr.**, Cohen-Wolkowicz M, Fowler VG Jr, Laughon M, Clark RH, Smith PB. Coagulase-negative staphylococcal infections in the neonatal intensive care unit. *Infect Control Hosp Epidemiol*. 2011;32:679–686. PMC3238054.

- 117) Laughon MM, **Benjamin DK Jr.**, Capparelli EV, Kearns GL, Berezny K, Paul IM, Wade K, Barrett J, Smith PB, Cohen-Wolkowicz M. Innovative clinical trial design for pediatric therapeutics. *Expert Rev Clin Pharmacol*. 2011;4:643–652. PMC3184526.
- 118) Smith PB, Cohen-Wolkowicz M, Castro LM, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Ward RM, Wade K, Valencia G, Burchfield D, Arrieta A, Bhatt-Mehta V, Walsh M, Kantak A, Rasmussen M, Sullivan JE, Finer N, Brozanski BS, Sanchez P, van den Anker J, Blumer J, Kearns GI, Capparelli EV, Anand R, **Benjamin DK Jr**; on behalf of the Meropenem Study Team. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. *Pediatr Infect Dis J*. 2011;30:844–849. PMC3173561.
- 119) Cohen-Wolkowicz M, White NR, Bridges A, **Benjamin DK Jr.**, Kashuba AD. Development of a liquid chromatography-tandem mass spectrometry assay of six antimicrobials in plasma for pharmacokinetic studies in premature infants. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2011;879:3497–3506. PMC3210405.
- 120) Watt KM, Massaro MM, Smith B, Cohen-Wolkowicz M, **Benjamin DK Jr.**, Laughon MM. Pharmacokinetics of moxifloxacin in an infant with *Mycoplasma hominis* meningitis. *Pediatr Infect Dis J*. 2012;31:197–199. PMC3358780.
- 121) Warn PA, Livermore J, Howard S, Felton TW, Sharp A, Gregson L, Goodwin J, Petraitiene R, Petraitis V, Cohen-Wolkowicz M, Walsh TJ, **Benjamin DK Jr.**, Hope WW. Anidulafungin for neonatal hematogenous *Candida* meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. *Antimicrob Agents Chemother*. 2012;56:708–714. PMC3264209.
- 122) Wynn JL, Tan S, Gantz MG, Das A, Goldberg RN, Adams-Chapman I, Stoll BJ, Shankaran S, Walsh MC, Auten KJ, Miller NA, Sánchez PJ, Higgins RD, Cotten CM, Smith PB, **Benjamin DK Jr.**; the NICHD Neonatal Research Network. Outcomes following candiduria in extremely low birth weight infants. *Clin Infect Dis*. 2012;54:331–339. PMC3258271.
- 123) Schell WA, Benton JL, Smith PB, Poore M, Rouse JL, Boles DJ, Johnson MD, Alexander BD, Pamula VK, Eckhardt AE, Pollack MG, **Benjamin DK Jr.**, Perfect JR, Mitchell TG. Evaluation of a digital microfluidic real-time PCR platform to detect DNA of *Candida albicans* in blood. *Eur J Clin Microbiol Infect Dis*. 2012;31:2237–2245. PMC3939829.
- 124) Greenberg RG, **Benjamin DK Jr.**, Gantz MG, Cotten CM, Stoll BJ, Walsh MC, Sánchez PJ, Shankaran S, Das A, Higgins RD, Miller NA, Auten KJ, Walsh TJ, Laptook AR, Carlo WA, Kennedy KA, Finer NN, Duara S, Schibler K, Ehrenkranz RA, Van Meurs KP, Frantz III ID, Phelps DL, Poindexter BB, Bell EF, O’Shea TM, Watterberg KL, Goldberg RN, and Smith PB, for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Empirical antifungal therapy and outcomes in extremely-low-birth-weight infants with invasive candidiasis. *J Pediatr*. 2012;161:264–269. PMC3380169.
- 125) Cohen-Wolkowicz M, Ouellet D, Smith PB, James LP, Ross A, Sullivan JE, Walsh MC, Zadell A, Newman N, White NR, Kashuba AD, **Benjamin DK Jr.** Population pharmacokinetics of metronidazole using scavenged samples from preterm infants. *Antimicrob Agents Chemother*. 2012;56:1828–1837. PMC3318328.

- 126) Wynn JL, **Benjamin DK Jr.**, Benjamin DK, Cohen-Wolkowicz M, Clark RH, Smith PB. Very late onset infections in the neonatal intensive care unit. *Early Human Dev.* 2012;88:217–225. PMC3248995.
- 127) Ascher SB, Smith PB, Watt K, Benjamin DK, Cohen-Wolkowicz M, Clark RH, **Benjamin DK Jr.**, Moran C. Antifungal therapy and outcomes in infants with invasive *Candida* infections. *Pediatr Infect Dis J.* 2012;31:439–443. PMC3329577.
- 128) Stewart RD, Pasquali SK, Jacobs JP, **Benjamin DK**, Jaggars J, Cheng J, Mavroudis C, Jacobs ML. Contemporary Fontan operation: association between early outcome and type of cavopulmonary connection. *Ann Thorac Surg.* 2012 Apr;93(4):1254-60; discussion 1261. PMC3427600.
- 129) Bliss JM, Wong AY, Bhak G, Laforce-Nesbitt SS, Taylor S, Tan S, Stoll BJ, Higgins RD, Shankaran S, **Benjamin DK Jr.**; *Candida* Subcommittee of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. *Candida* virulence properties and adverse clinical outcomes in neonatal candidiasis. *J Pediatr.* 2012;161:441–447. PMC3419788.
- 130) Hornik CP, Benjamin DK, Becker KC, **Benjamin DK Jr.**, Li J, Clark RH, Cohen-Wolkowicz M, Smith PB. Use of the complete blood cell count in early-onset neonatal sepsis. *Pediatr Infect Dis J.* 2012;31:799–802. PMC3399972.
- 131) Hornik CP, Benjamin DK, Becker KC, **Benjamin DK Jr.**, Li J, Clark RH, Cohen-Wolkowicz M, Smith PB. Use of the complete blood cell count in late-onset neonatal sepsis. *Pediatr Infect Dis J.* 2012;31:803–807. PMC3399981.
- 132) Manzoni P, Mostert M, Latino MA, Pugin L, Stolfi I, Decembrino L, Vagnarelli F, Corona G, Tridapalli E, Vetrano G, Memo L, Priolo C, Galletto P, Giovannozzi C, Gallo E, Pedicino R, Barberi I, Faldella G, Mosca F, Saia O.S., Bollani L, Maragliano R, Ruffinazzi G, Tziella C, Stronati M, Rizzollo S, Farina D, **Benjamin DK Jr.**, Smith PB, Jacqz-Aigrain E, Kaguelidou F, Cohen-Wolkowicz M, on behalf of the Italian Task Force for the Study and Prevention of Neonatal Fungal Infections; the Italian Society of Neonatology. Clinical characteristics and response to prophylactic fluconazole of preterm VLBW neonates with baseline and acquired fungal colonisation in NICU: data from a multicentre RCT. *Early Hum Dev.* 2012;88 Suppl 2:S60–S64. PMID22633517.
- 133) Ascher SB, Smith PB, Clark RH, Cohen-Wolkowicz M, Li JS, Watt K, Jacqz-Aigrain E, Kaguelidou F, Manzoni P, **Benjamin DK Jr.** Sepsis in young infants with congenital heart disease. *Early Hum Dev.* 2012;88 Suppl 2:S92–S97. PMC3513769.
- 134) Hornik CP, Fort P, Clark RH, Watt K, **Benjamin DK Jr.**, Smith PB, Manzoni P, Jacqz-Aigrain E, Kaguelidou F, Cohen-Wolkowicz M. Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. *Early Hum Dev.* 2012;88 Suppl 2:S69–S74. PMC3513766.
- 135) Hsieh E, Smith PB, Jacqz-Aigrain E, Kaguelidou F, Cohen-Wolkowicz M, Manzoni P, **Benjamin DK Jr.** Neonatal fungal infections: when to treat? *Early Hum Dev.* 2012;88 Suppl 2:S6–S10. PMC3512570.

- 136) Watt KM, **Benjamin DK Jr.**, Cheifetz IM, Moorthy G, Wade KC, Smith PB, Brouwer K, Capparelli EV, Cohen-Wolkowicz M. Pharmacokinetics and safety of fluconazole in infants supported with extracorporeal membrane oxygenation. *Pediatr Infect Dis J*. 2012;31:1042–1047. PMC3444624.
- 137) Cohen-Wolkowicz M, **Benjamin DK Jr.**, Ross A, James LP, Sullivan JE, Walsh MC, Zadell A, Newman N, White NR, Kashuba AD, Ouellet D. Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. *Ther Drug Monit*. 2012;34:312–319. PMC3354042.
- 138) Watt KM, Cohen-Wolkowicz M, Ward RM, **Benjamin DK Jr.** Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future. *Pediatr Infect Dis J*. 2012;31:635–637. PMC3356443.
- 139) Doby EH, **Benjamin DK Jr.**, Blaschke AJ, Ward RM, Pavia AT, Martin PL, Driscoll TA, Cohen-Wolkowicz M, Moran C. Therapeutic monitoring of voriconazole in children less than 3 years of age: a case report and summary of voriconazole concentrations for 10 children. *Pediatr Infect Dis J*. 2012;31:632–635. PMC3356483.
- 140) Lin CB, Hornik CP, Clark R, Cotten CM, **Benjamin DK Jr.**, Cohen-Wolkowicz M, Smith PB, Wynn JL. Very low birth weight neonates who survive early-onset sepsis do not have an increased risk of developing late-onset sepsis. *Early Hum Dev*. 2012;88:905–909. PMC3462255.
- 141) Turner K, Manzoni P, **Benjamin DK Jr.**, Cohen-Wolkowicz M, Smith PB, Laughon MM. Fluconazole pharmacokinetics and safety in premature infants. *Curr Med Chem*. 2012;19:4617–4620. PMC3522083.
- 142) Cohen-Wolkowicz M, Watt KM, Hornik CP, **Benjamin DK Jr.**, Smith PB. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. *Pediatr Infect Dis J*. 2012;31:935–937. PMC3421038.
- 143) Watt K, Manzoni P, Cohen-Wolkowicz M, Rizzollo S, Boano E, Jacqz-Aigrain E, **Benjamin DK Jr.** Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. *Curr Drug Metab*. 2013;14:193–202. PMC3541435.
- 144) Manzoni P, **Benjamin DK Jr.**, Franco C, Rizzollo S, Stronati M, Watt K, Cohen-Wolkowicz M, Jacqz-Aigrain E. Echinocandins for the nursery: an update. *Curr Drug Metab*. 2013;14:203–207. PMID22935065.
- 145) Downey LC, **Benjamin DK Jr.**, Clark RH, Watt KM, Hornik CP, Laughon MM, Cohen-Wolkowicz M, Smith PB. Urinary tract infection concordance with positive blood and cerebrospinal fluid cultures in the neonatal intensive care unit. *J Perinatol*. 2013 Apr;33(4):302–6. PMC3549035.
- 146) Spellberg B, Brass EP, Bradley JS, Lewis RJ, Shlaes D, Ambrose PG, Das A, Boucher HW, Doi Y, Bertlett JG, Bonomo RA, Larosa SP, Talbot GH, **Benjamin DK Jr.**, Guidos RJ, Jezek A, Gilbert DN; developed for and approved by the IDSA Board of Directors. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. *Clin Infect Dis*. 2012;55:1031–1046. PMC3657525.

- 147) Cohen-Wolkowicz M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Randolph DA, Ward RM, Wade K, Valencia G, Burchfield D, Arrieta A, Mehta V, Walsh M, Kantak A, Rasmussen M, Sullivan JE, Finer N, Rich W, Brozanski BS, van den Anker J, Blumer J, Laughon M, Watt KM, Kearns GL, Capparelli EV, Martz K, Berezny K, **Benjamin DK Jr.**, Smith PB; on behalf of the Meropenem Study Team. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. *Clin Infect Dis*. 2012;55:1495–1502. PMC3491861.
- 148) Steinbach WJ, Roilides E, Berman D, Hoffman JA, Groll AH, Bin-Hussain I, Palazzi DL, Castagnola E, Halasa N, Velegriaki A, Dvorak CC, Charkabarti A, Sung L, Danziger-Isakov L, Lachenauer C, Arrieta A, Knapp K, Abzug MJ, Ziebold C, Lehrnbecher T, Klingspor L, Warris A, Leckerman K, Martling T, Walsh TJ, **Benjamin DK Jr.**, Zaoutis TE; the International Pediatric Fungal Network. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. *Pediatr Infect Dis J*. 2012;31:1252–1257. PMID22982980.
- 149) DiBardino DJ, Pasquali SK, Hirsch JC, **Benjamin DK**, Kleeman KC, Salazar JD, Jacobs ML, Mayer JE, Jacobs JP. Effect of sex and race on outcome in patients undergoing congenital heart surgery: an analysis of the society of thoracic surgeons congenital heart surgery database. *Ann Thorac Surg*. 2012 Dec;94(6):2054-9; discussion 2059-60. PMC3838919.
- 150) Bauserman MS, Laughon MM, Hornik CP, Smith PB, **Benjamin DK Jr.**, Clark RH, Engmann C, Cohen-Wolkowicz M. Group B *Streptococcus* and *Escherichia coli* infections in the intensive care nursery in the era of intrapartum antibiotic prophylaxis. *Pediatr Infect Dis J*. 2013;32(3):208-12. PMC3572304.
- 151) Sampson MR, **Benjamin DK Jr.**, Cohen-Wolkowicz M. Evidence-based guidelines for pediatric clinical trials: focus on StaR Child Health. *Expert Rev Clin Pharmacol*. 2012;5:525–531. PMC3566240.
- 152) Cotten CM, **Benjamin DK Jr.**, Smith PB, Stoll BJ, Spitzer AR, Clark RH. Empirical antibiotic therapy for suspected early-onset bacterial sepsis. *Pediatrics*. 2012;130:e1052–1053. PMID23035239.
- 153) Tripathi N, Watt K, **Benjamin DK Jr.** Treatment and prophylaxis of invasive candidiasis. *Semin Perinatol*. 2012;36:416–423. PMC3582379.
- 154) Lee JH, Hornik CP, **Benjamin DK Jr.**, Herring AH, Clark RH, Cohen-Wolkowicz M, Smith PB. Risk factors for invasive candidiasis in infants >1500 g birth weight. *Pediatr Infect Dis J*. 2013;32(3):222-6. PMC3578110.
- 155) Wynn JL, Hansen NI, Das A, Cotten CM, Goldberg RN, Sánchez PJ, Bell EF, Van Meurs KP, Carlo WA, Laptook AR, Higgins RD, **Benjamin DK Jr.**, Stoll BJ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Early sepsis does not increase the risk of late sepsis in very low birth weight neonates. *J Pediatr*. 2013;162(5):942-948. PMC3622770.
- 156) Boucher HW, Talbot GH, **Benjamin DK Jr**, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D; for the Infectious Diseases Society of America. 10 x '20 Progress--

Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America. *Clin Infect Dis*. 2013; 56(12):1685-94. PMC3707426.

- 157) Lestner JM, Smith PB, Cohen-Wolkowicz M, **Benjamin DK Jr.**, Hope WW. Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. *Br J Clin Pharmacol*. 2013 Jun;75(6):1381-95. PMC3690098.
- 158) Cotet AM, **Benjamin DK**. Medical regulation and health outcomes: the effect of the physician examination requirement. *Health Econ*. 2013 Apr;22(4):393-409.
- 159) Buzzi E, Manzoni P, Castagnola E, **Benjamin DK Jr**, Beghini R, Dall'agnola A. Candida pneumonia in a term infant after prolonged use of inhaled corticosteroids for bronchopulmonary dysplasia (BPD). *Early Hum Dev*. 2013 Jun;89 Suppl 1:S62-3. PMID23809354.
- 160) Picone S, Manzoni P, Bedetta M, Mostert M, **Benjamin DK Jr**, Paolillo P. Pharmacological resolution of a multiloculated Candida spp. liver abscess in a preterm neonate. *Early Hum Dev*. 2013 Jun;89 Suppl 1:S47-50. PMID23809351.
- 161) Ericson J, Manzoni P, **Benjamin DK Jr**. Old and new: appropriate dosing for neonatal antifungal drugs in the nursery. *Early Hum Dev*. 2013 Jun;89 Suppl 1:S25-7. PMC3806495.
- 162) Hill KD, Tunks RD, Barker PC, **Benjamin DK Jr**, Cohen-Wolkowicz M, Fleming GA, Laughon M, Li JS. Sildenafil Exposure and Hemodynamic Effect After Stage II Single-Ventricle Surgery. *Pediatr Crit Care Med*. 2013 Jul;14(6):593-600. PMC3782306.
- 163) Hornik CP, Herring AH, **Benjamin DK Jr.**, Capparelli EV, Kearns GL, Van Den Anker J, Cohen-Wolkowicz M, Clark RH, Smith PB, on behalf of the Pediatric Trials Network Executive Committee, Adverse Events Associated with Meropenem versus Imipenem/Cilastatin Therapy in a Large Retrospective Cohort of Hospitalized Infants, *Pediatr Infect Dis J*, 2013 Jul;32(7):748-53. PMC3708263.
- 164) Cohen-Wolkowicz M, Sampson M, Bloom BT, Arrieta A, Wynn JL, Martz K, Harper B, Kearns GL, Capparelli EV, Siegel D, **Benjamin DK Jr**, Smith PB; on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network. Determining Population and Developmental Pharmacokinetics of Metronidazole Using Plasma and Dried Blood Spot Samples from Premature Infants. *Pediatr Infect Dis J*. 2013 Sep;32(9):956-61. PMC3769518.
- 165) Testoni D, Hornik CP, Smith PB, **Benjamin DK Jr**, McKinney RE Jr., Sports Medicine and Ethics, *Am J Bioeth*, 2013 Oct;13(10):4-12 PMC3899648.
- 166) Adams-Chapman I, Bann CM, Das A, Goldberg RN, Stoll BJ, Walsh MC, Sánchez PJ, Higgins RD, Shankaran S, Watterberg KL, Duara S, Miller NA, Heyne RJ, Peralta-Carcelen M, Goldstein RF, Steichen JJ, Bauer CR, Hintz SR, Evans PW, Acarregui MJ, Myers GJ, Vohr BR, Wilson-Costello DE, Pappas A, Vaucher YE, Ehrenkranz RA, McGowan EC, Dillard RG, Fuller J, **Benjamin DK Jr**; Eunice Kennedy Shriver National Institutes of Child Health and Human Development Neonatal Research Network. Neurodevelopmental Outcome of Extremely Low Birth Weight Infants with Candida Infection. *J Pediatr*. 2013 Oct;163(4):961-7. PMC3786056.

- 167) **Benjamin DK Jr.**, Deville J, Arrieta A, Safety and Pharmacokinetic Profiles of Repeated-Dose Micafungin in Children and Adolescents Treated for Invasive Candidiasis, *Pediatr Infect Dis J*. 2013 Nov;32(11):e419-25. PMC3818701.
- 168) Sampson MR, Bloom BT, Lenfestey RW, Harper B, Kashuba AD, Anand R, **Benjamin DK Jr**, Capparelli E, Cohen-Wolkowicz M, Smith PB. Population Pharmacokinetics of Intravenous Acyclovir in Preterm and Term Infants. *Pediatr Infect Dis J*. 2014 Jan;33(1):42-9 PMC3904301.
- 169) Sampson MR, Bloom BT, Arrieta A, Capparelli E, **Benjamin DK Jr**, Smith PB, Kearns GL, van den Anker J, Cohen-Wolkowicz M. Intestinal fatty-acid binding protein and metronidazole response in premature infants. *J Neonatal Perinatal Med*. 2014 Jan 1;7(3):223-8.PMC4225165.
- 170) Tunks RD, Barker PC, **Benjamin DK Jr**, Cohen-Wolkowicz M, Fleming GA, Laughon M, Li JS, Hill KD. Sildenafil exposure and hemodynamic effect after Fontan surgery. *Pediatr Crit Care Med*. 2014 Jan;15(1):28-34. PMC3887448
- 171) Aliaga S, Clark RH, Laughon M, Walsh TJ, Hope WW, Benjamin DK, Kaufman D, Arrieta A, **Benjamin DK Jr**, Smith PB. Changes in the incidence of candidiasis in neonatal intensive care units. *Pediatrics*. 2014 Feb;133(2):236-42. PMC3904270.
- 172) Beam KS, Laughon MM, Hornik CP, Cohen-Wolkowicz M, Clark RH, **Benjamin DK Jr**, Smith PB. Predictors of positive cerebrospinal fluid cultures in infants with bacteremia. *Pediatr Infect Dis J*. 2014 Apr;33(4):360-5. PMC3960289.
- 173) Ericson JE, **Benjamin DK Jr**. Fluconazole prophylaxis for prevention of invasive candidiasis in infants. *Curr Opin Pediatr*. 2014 Apr;26(2):151-6. PMC4042246
- 174) Bain J, **Benjamin DK Jr**, Hornik CP, Benjamin DK, Clark R, Smith PB. Risk of necrotizing enterocolitis in very-low-birth-weight infants with isolated atrial and ventricular septal defects. *J Perinatol*. 2014 Apr;34(4):319-21 PMC3969778.
- 175) Cohen-Wolkowicz M, Watt KM, Zhou C, Bloom BT, Poindexter B, Castro L, Gao J, Capparelli EV, **Benjamin DK Jr**, Smith PB. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. *Antimicrob Agents Chemother*. 2014 May;58(5):2856-65. PMC3993246.
- 176) **Benjamin DK Jr**, Hudak ML, Duara S, Randolph DA, Bidegain M, Mundakel GT, Natarajan G, Burchfield DJ, White RD, Shattuck KE, Neu N, Bendel CM, Kim MR, Finer NN, Stewart DL, Arrieta AC, Wade KC, Kaufman DA, Manzoni P, Prather KO, Testoni D, Berezny KY, Smith PB; Fluconazole Prophylaxis Study Team. Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. *JAMA*. 2014 May 7;311(17):1742-9. PMC4110724
- 177) Autmizguine J, **Benjamin DK**, Smith PB, Sampson M, Ovetchkine P, Cohen-Wolkowicz M, Watt KM. Pharmacokinetic Studies in Infants Using Minimal-risk Study Designs. *Curr Clin Pharmacol*. 2014;9(4):350-8. PMC4703884.

- 178) Autmizguine J, Guptill JT, Cohen-Wolkowicz M, **Benjamin DK Jr**, Capparelli EV. Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. *Drugs*. 2014 Jun;74(8):891-909. PMC4073603.
- 179) Tremoulet A, Le J, Poindexter B, Sullivan JE, Laughon MM, Delmore P, Salgado A, Chong SI, Melloni C, Gao J, **Benjamin DK Jr**, Capparelli EV, Cohen-Wolkowicz M; on behalf of the Administrative Core Committee of the Best Pharmaceuticals for Children Act — Pediatric Trials Network. Population Pharmacokinetics of Ampicillin in Neonates Using an Opportunistic Study Design. *Antimicrob Agents Chemother*. 2014 Jun;58(6):3013-20. PMC4068432.
- 180) Camelo Castillo W, Boggess K, Stürmer T, Brookhart MA, **Benjamin DK Jr**, Jonsson Funk M. Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. *Obstet Gynecol*. 2014 Jun;123(6):1177-84. PMC4075168.
- 181) Johnson JN, Hornik CP, Li JS, **Benjamin DK Jr**, Yoshizumi TT, Reiman RE, Frush DP, Hill KD. Cumulative radiation exposure and cancer risk estimation in children with heart disease. *Circulation*. 2014 Jul 8;130(2):161-7. PMC4103421.
- 182) Gonzalez D, Paul IM, **Benjamin DK Jr**, Cohen-Wolkowicz M. Advances in Pediatric Pharmacology, Therapeutics, and Toxicology. *Adv Pediatr*. 2014 Aug;61(1):7-31. PMC4120955.
- 183) Laughon MM, **Benjamin DK Jr**. Mechanisms to provide safe and effective drugs for children. *Pediatrics*. 2014 Aug;134(2):e562-3. PMC4187241.
- 184) Greenberg RG, **Benjamin DK Jr**. Neonatal candidiasis: Diagnosis, prevention, and treatment. *J Infect*. 2014 Nov;69 Suppl 1:S19-22 PMC4252884.
- 185) Testoni D, Hayashi M, Cohen-Wolkowicz M, **Benjamin DK Jr**, Lopes RD, Clark RH, Benjamin DK, Smith PB. Late-Onset Bloodstream Infections in Hospitalized Term Infants. *Pediatr Infect Dis J*. 2014 Sep;33(9):920-3. PMC4160433.
- 186) Hsieh EM, Hornik CP, Clark RH, Laughon MM, **Benjamin DK Jr**, Smith PB; on Behalf of the Best Pharmaceuticals for Children Act—Pediatric Trials Network. Medication Use in the Neonatal Intensive Care Unit. *Am J Perinatol*. 2014 Oct;31(9):811-21. PMC4061287.
- 187) Gonzalez D, Melloni C, Yogev R, Poindexter BB, Mendley SR, Delmore P, Sullivan JE, Autmizguine J, Lewandowski A, Harper B, Watt KM, Lewis KC, Capparelli EV, **Benjamin DK Jr**, Cohen-Wolkowicz M. Use of Opportunistic Clinical Data and a Population Pharmacokinetic Model to Support Dosing of Clindamycin for Premature Infants to Adolescents. *Clin Pharmacol Ther*. 2014 Oct;96(4):429-37. PMC4169790.
- 188) Autmizguine J, Moran C, Gonzalez D, Capparelli EV, Smith PB, Grant GA, **Benjamin DK Jr**, Cohen-Wolkowicz M, Watt KM. Vancomycin Cerebrospinal Fluid Pharmacokinetics in Children with Cerebral Ventricular Shunt Infections. *Pediatr Infect Dis J*. 2014 Oct;33(10):e270-2. PMC4209191.
- 189) Zhao W, Le Guellec C, **Benjamin DK Jr**, Hope WW, Bourgeois T, Watt KM, van den Anker JN, Matrot B, Saxen H, Hoppu K, Manzoni P, Jacqz-Aigrain E. First Dose in Neonates: Are Juvenile Mice, Adults and In Vitro-In Silico Data Predictive of Neonatal Pharmacokinetics of Fluconazole. *Clin Pharmacokinet*. 2014 Nov;53(11):1005-18. PMC4703886.

- 190) Autmizguine J, Hornik CP, **Benjamin DK Jr**, Laughon MM, Clark RH, Cotten CM, Cohen-Wolkowicz M, Benjamin DK, Smith PB; on behalf of the Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee. Anaerobic Antimicrobial Therapy After Necrotizing Enterocolitis in VLBW Infants. *Pediatrics*. 2015 Jan;135(1):e117-25. PMC4279070.
- 191) Hope WW, Kaibara A, Roy M, Arrieta A, Azie N, Kovanda LL, **Benjamin DK Jr**. Population Pharmacokinetics of Micafungin and its Metabolites M1 and M5 in Children and Adolescents: Towards Further Certainty in Dosing. *Antimicrob Agents Chemother*. 2015 Feb;59(2):905-13. PMC4335897
- 192) Ericson JE, Thaden J, Cross HR, Clark RH, Fowler VG Jr, **Benjamin DK Jr**, Cohen-Wolkowicz M, Hornik CP, Smith PB; Antibacterial Resistance Leadership Group. No Survival Benefit With Empirical Vancomycin Therapy for Coagulase-negative Staphylococcal Bloodstream Infections in Infants. *Pediatr Infect Dis J*. 2015 Apr;34(4):371-5. PMC4357312.
- 193) Kelly MS, **Benjamin DK Jr**, Smith PB. The Epidemiology and Diagnosis of Invasive Candidiasis Among Premature Infants. *Clin Perinatol*. 2015 Mar;42(1):105-117. PMC4328135.
- 194) Johnson JN, Hornik CP, Li JS, **Benjamin DK Jr**, Yoshizumi T, Reiman RE, Frush DP, Hill KD. Response to letters regarding article, "cumulative radiation exposure and cancer risk estimation in children with heart disease". *Circulation*. 2015 Apr 21;131(16):e419-20. PMC4492515.
- 195) Castillo WC, Boggess K, Stürmer T, Brookhart MA, **Benjamin DK Jr**, Jonsson Funk M. Association of Adverse Pregnancy Outcomes With Glyburide vs Insulin in Women With Gestational Diabetes. *JAMA Pediatr*. 2015 May 1;169(5):452-8. PMID: 25822253.
- 196) Gonzalez D, Melloni C, Poindexter BB, Yogev R, Atz AM, Sullivan JE, Mendley SR, Delmore P, Delinsky A, Zimmerman K, Lewandowski A, Harper B, Lewis KC, **Benjamin DK Jr**, Cohen-Wolkowicz M; Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee. Simultaneous determination of trimethoprim and sulfamethoxazole in dried plasma and urine spots. *Bioanalysis*. 2015 May;7(9):1137-1149. PMC4455038.
- 197) Botero-Calderon L, **Benjamin DK Jr**, Cohen-Wolkowicz M. Advances in the treatment of invasive neonatal candidiasis. *Expert Opin Pharmacother*. 2015 May;16(7):1035-48. PMC4402277.
- 198) Arnold CJ, Ericson J, Kohman J, Corey KL, Oh M, Onabanjo J, Hornik CP, Clark RH, **Benjamin DK Jr**, Smith PB, Chu VH; on behalf of the Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee. Rifampin Use and Safety in Hospitalized Infants. *Am J Perinatol*. 2015 May;32(6):565-70. PMC4433596.
- 199) Watt KM, Gonzalez D, **Benjamin DK Jr**, Brouwer KL, Wade KC, Capparelli E, Barrett J, Cohen-Wolkowicz M. Fluconazole Population Pharmacokinetics and Dosing for Prevention and Treatment of Invasive Candidiasis in Children Supported with Extracorporeal Membrane Oxygenation. *Antimicrob Agents Chemother*. 2015 Jul;59(7):3935-43. PMC4468733
- 200) Harskamp-van Ginkel MW, Hill KD, Becker K, Testoni D, Cohen-Wolkowicz M, Gonzalez D, Barrett JS, **Benjamin DK Jr**, Siegel DA, Banks P, Watt KM; Best Pharmaceuticals for

Children Act–Pediatric Trials Network Administrative Core Committee. Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review. *JAMA Pediatr.* 2015 Jul 1;169(7):678-85. PMC4494887.

- 201) Ericson JE, Arnold C, Cheeseman J, Cho J, Kaneko S, Wilson E, Clark RH, **Benjamin DK Jr.**, Chu V, Smith PB, Hornik CP; Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee. Use and Safety of Erythromycin and Metoclopramide in Hospitalized Infants. *J Pediatr Gastroenterol Nutr.* 2015 Sep;61(3):334-9. PMC4553109.
- 202) Arnold CJ, Ericson J, Cho N, Tian J, Wilson S, Chu VH, Hornik CP, Clark RH, **Benjamin DK Jr.**, Smith PB; Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee. Cefepime and Ceftazidime Safety in Hospitalized Infants. *Pediatr Infect Dis J.* 2015 Sep;34(9):964-8. PMC4573537.
- 203) Rowe S, Siegel D, **Benjamin DK Jr.**; Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee. Gaps in Drug Dosing for Obese Children: A Systematic Review of Commonly Prescribed Emergency Care Medications. *Clin Ther.* 2015 Sep 1;37(9):1924-32. PMC4586086.
- 204) Bergin SP, Thaden J, Ericson JE, Cross H, Messina J, Clark RH, Fowler VG Jr, **Benjamin DK Jr.**, Hornik CP, Smith PB; Antibacterial Resistance Leadership Group. Neonatal Escherichia coli Bloodstream Infections: Clinical Outcomes and Impact of Initial Antibiotic Therapy. *Pediatr Infect Dis J.* 2015 Sep;34(9):933-6. PMC4581845.
- 205) Thaden JT, Ericson JE, Cross H, Bergin SP, Messina JA, Fowler VG Jr, **Benjamin DK Jr.**, Clark RH, Hornik CP, Smith PB; Antibacterial Resistance Leadership Group. Survival Benefit of Empirical Therapy for Staphylococcus aureus Bloodstream Infections in Infants. *Pediatr Infect Dis J.* 2015 Nov;34(11):1175-9. PMC4604046.
- 206) Ericson JE, Popoola VO, Smith PB, Benjamin DK, Fowler VG, **Benjamin DK Jr.**, Clark RH, Milstone AM. Burden of Invasive Staphylococcus aureus Infections in Hospitalized Infants. *JAMA Pediatr.* 2015 Dec 1;169(12):1105-11. PMC4694042.
- 207) Kelly MS, Benjamin DK, Puopolo KM, Laughon MM, Clark RH, Mukhopadhyay S, **Benjamin DK Jr.**, Smith PB, Permar SR. Postnatal Cytomegalovirus Infection and the Risk for Bronchopulmonary Dysplasia. *JAMA Pediatr.* 2015 Dec 7;169(12):e153785. PMC4699399.
- 208) Gonzalez D, Palazzi DL, Bhattacharya-Mithal L, Al-Uzri A, James LP, Bradley J, Neu N, Jasion T, Hornik CP, Smith PB, **Benjamin DK Jr.**, Keedy K, Fernandes P, Cohen-Wolkowicz M. Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents. *Antimicrob Agents Chemother.* 2016 Mar 25;60(4):2572-6. PMC4808196.
- 209) Gonzalez D, Delmore P, Bloom BT, Cotten CM, Poindexter BB, McGowan E, Shattuck K, Bradford KK, Smith PB, Cohen-Wolkowicz M, Morris M, Yin W, **Benjamin DK Jr.**, Laughon MM; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants. *Antimicrob Agents Chemother.* 2016 Apr 22;60(5):2888-94. PMC4862454.
- 210) Romaine A, Ye D, Ao Z, Fang F, Johnson O, Blake T, **Benjamin DK Jr.**, Cotten CM, Testoni D, Clark RH, Chu VH, Smith PB, Hornik CP; Best Pharmaceuticals for Children Act – Pediatric

Trials Network. Safety of histamine-2 receptor blockers in hospitalized VLBW infants. *Early Hum Dev.* 2016 Aug;99:27-30. PMC4969147.

- 211) Momper JD, Capparelli EV, Wade KC, Kantak A, Dhanireddy R, Cummings JJ, NedreLOW JH, Hudak ML, Mundakel GT, Natarajan G, Gao J, Laughon MM, Smith PB, **Benjamin DK Jr**; Fluconazole Prophylaxis Study Team. Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams. *Antimicrob Agents Chemother.* 2016 Aug 22;60(9):5539-45. PMC4997840.
- 212) Ericson JE, Kaufman DA, Kicklighter SD, Bhatia J, Testoni D, Gao J, Smith PB, Prather KO, **Benjamin DK Jr**; Fluconazole Prophylaxis Study Team on behalf of the Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee; Fluconazole Prophylaxis Study Team on behalf of the Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. Fluconazole Prophylaxis for the Prevention of Candidiasis in Premature Infants: A Meta-analysis Using Patient-level Data. *Clin Infect Dis.* 2016 Sep 1;63(5):604-10. PMC4981761.
- 213) Zimmerman K, Putera M, Hornik CP, Brian Smith P, **Benjamin DK Jr**, Mulugeta Y, Burckart GJ, Cohen-Wolkowicz M, Gonzalez D. Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval. *Clin Ther.* 2016 Sep;38(9):1995-2005. PMC5039072.
- 214) Folgari L, Bielicki J, Ruiz B, Turner MA, Bradley JS, **Benjamin DK Jr**, Zaoutis TE, Lutsar I, Giaquinto C, Rossi P, Sharland M. Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. *Lancet Infect Dis.* 2016 Sep;16(9):e178-89.
- 215) Autmizguine J, Hornik CP, **Benjamin DK Jr**, Brouwer KL, Hupp SR, Cohen-Wolkowicz M, Watt KM. Pharmacokinetics and Safety of Micafungin in Infants Supported with Extracorporeal Membrane Oxygenation. *Pediatr Infect Dis J.* 2016 Nov;35(11):1204-1210. PMC5071122.
- 216) Hornik CP, **Benjamin DK Jr**, Smith PB, Pencina MJ, Tremoulet AH, Capparelli EV, Ericson JE, Clark RH, Cohen-Wolkowicz M; Best Pharmaceuticals for Children Act—Pediatric Trials Network. Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates. *J Pediatr.* 2016 Nov;178:125-129.e1. PMC5085855.
- 217) Ku LC, Zimmerman K, **Benjamin DK Jr**, Clark RH, Hornik CP, Smith PB; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Safety of Enalapril in Infants Admitted to the Neonatal Intensive Care Unit. *Pediatr Cardiol.* 2017 Jan;38(1):155-161. PMC5288129.
- 218) Zimmerman KO, Smith PB, **Benjamin DK Jr**, Laughon M, Clark R, Traube C, Stürmer T, Hornik CP. Sedation, Analgesia, and Paralysis during Mechanical Ventilation of Premature Infants. *J Pediatr.* 2017 Jan;180:99-104.e1. PMC5183489.
- 219) Smith PB, **Benjamin DK Jr**, Reed AM. The Role of a Division of Quantitative Sciences Division in Enhancing Academic Productivity of a Department of Pediatrics. *J Pediatr.* 2017 Jan;180:4-5. PMC5183483.

- 220) Lloyd JC, Hornik CP, **Benjamin DK Jr**, Clark RH, Routh JC, Smith PB. Incidence of Breakthrough Urinary Tract Infection in Hospitalized Infants Receiving Antibiotic Prophylaxis. *Clin Pediatr (Phila)*. 2017 Mar;56(1):65-70. PMC5031513.
- 221) Parente V, Clark RH, Ku L, Fennell C, Johnson M, Morris E, Romaine A, Utin U, **Benjamin DK Jr**, Messina JA, Smith PB, Greenberg RG. Risk factors for group B streptococcal disease in neonates of mothers with negative antenatal testing. *J Perinatol*. 2017 Feb;37(2):157-161. PMC5282520.
- 222) Wang LA, Gonzalez D, Leeder JS, Tyndale RF, Pearce RE, **Benjamin DK Jr**, Kearns GL, Cohen-Wolkowicz M; Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee. Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation. *J Clin Pharmacol*. 2017 Feb;57(2):230-234. PMC5233579.
- 223) Smith MJ, Gonzalez D, Goldman JL, Yogev R, Sullivan JE, Reed MD, Anand R, Martz K, Berezny K, **Benjamin DK Jr**, Smith PB, Cohen-Wolkowicz M, Watt K; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Pharmacokinetics of Clindamycin in Obese and Non-obese Children. *Antimicrob Agents Chemother*. 2017 Mar 24;61(4). pii: e02014-16. PMC5365720.
- 224) Ericson JE, Gostelow M, Autmizguine J, Hornik CP, Clark RH, **Benjamin DK Jr**, Smith PB; Pediatric Trials Network Executive Committee and Investigators. Safety of High-Dose Acyclovir in Infants with Suspected and Confirmed Neonatal Herpes Simplex Virus Infections. *Pediatr Infect Dis J*. 2017 Apr;36(4):369-373. PMC5348260.
- 225) Lee JA, Sauer B, Tuminski W, Cheong J, Fitz-Henley J 2nd, Mayers M, Ezuma-Igwe C, Arnold C, Hornik CP, Clark RH, **Benjamin DK Jr**, Smith PB, Ericson JE; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Effectiveness of Granulocyte Colony-Stimulating Factor in Hospitalized Infants with Neutropenia. *Am J Perinatol*. 2017 Apr;34(5):458-464 PMC5359073.
- 226) Virkud YV, Hornik CP, **Benjamin DK**, Laughon MM, Clark RH, Greenberg RG, Smith PB. Respiratory Support for Very Low Birth Weight Infants Receiving Dexamethasone. *J Pediatr*. 2017 Apr;183:26-30.e3. PMC5368005.
- 227) Ward RM, **Benjamin DK Jr**, Barrett JS, Allegaert K, Portman R, Davis JM, Turner MA. Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates. *Pediatr Res*. 2017 May;81(5):692-711.
- 228) Wynn JL, Kelly MS, Benjamin DK, Clark RH, Greenberg R, **Benjamin DK Jr**, Smith PB. Timing of Multiorgan Dysfunction among Hospitalized Infants with Fatal Fulminant Sepsis. *Am J Perinatol*. 2017 Jun;34(7):633-639. PMC5604435
- 229) Patel RM, Zimmerman K, Carlton DP, Clark R, **Benjamin DK**, and Smith PB. Early Caffeine Prophylaxis and Risk of Failure of Initial Continuous Positive Airway Pressure in Very Low Birth Weight Infants. *Journal of Pediatrics*, 2017 Nov;190:108-111.e1. PMC5690812
- 230) Hwang M, Beechinor R, Wade KC, **Benjamin DK Jr**, Smith PB, Hornik CP, Capparelli EV, Duara S, Kennedy KA, Cohen-Wolkowicz M, Gonzalez D. External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models. *Antimicrob Agents Chemother*, 2017 Nov 22;61(12). PMC5700313

- 231) Greenberg RG, Gamel B, Bloom D, Bradley J, Jafri HS, Hinton D, Nambiar S, Wheeler C, Tiernan R, Smith PB, Roberts J, **Benjamin DK Jr**. Parents' perceived obstacles to pediatric clinical trial participation: Findings from the clinical trials transformation initiative. *Contemp Clin Trials Commun*, 2017 Nov 23;9:33-39. PMC5898566
- 232) Watt KM, Avant D, Sherwin J, Benjamin DK, Hornik C, **Benjamin DK Jr**, Li JS, Smith PB. Effect of renal function on antihypertensive drug safety and efficacy in children. *Pediatr Nephrol*. 2018 Jan;33(1):139-146. PMC5700840
- 233) Corneli A, Wheeler C, Bradley J, Gamel B, Nambiar S, Noel GJ, Lin L, Roberts JN, **Benjamin DK Jr**. Facilitators and barriers to the successful implementation of pediatric antibacterial drug trials: Findings from CTTI's survey investigators. *Contemp Clin Trials Commun*. 2018 Jan 31;9:115-120. PMC5898492
- 234) Le J, Poindexter B, Sullivan JE, Laughon M, Delmore P, Blackford M, Yogev R, James LP, Melloni C, Haper B, Mitchell J, **Benjamin DK Jr**, Boakye-Agyeman F, Cohen-Wolkowicz M. Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates. *Ther Drug Monit*. 2018 Feb; 40(1):103-108. PMC5764797
- 235) Testoni D, Hornik C, Guinsburg R, Clark RH, **Benjamin DK Jr**, and Smith PB. Early Lumbar Puncture and Risk of Intraventricular Hemorrhage in Very Low Birth Weight Infants. *Early Hum Dev*. 2018 Feb;117:1-6.
- 236) Smith PB, Knox S, **Benjamin DK Jr**. Coordination of the Environmental Influences on Child Health Outcomes program: so the whole is greater than the sum of its parts. *Curr Opin Pediatr*. 2018 Apr;30(2):263-268. PMC5884635
- 237) Kovanda LL, Walsh TJ, **Benjamin DK Jr**, Arrieta A, Kaufman DA, Smith PB, Manzoni P, Desai AV, Kaibara A, Bonate PL, Hope WW. Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials, *Pediatr Infect Dis J*, 2018 Jun;37(6):580-585. PMC6110378
- 238) Gonzalez D, James LP, Al-Uzri A, Bosheva M, Adler-Shohet FC, Mendley SR, Bradley JS, Espinosa C, Tsonkova E, Moffett K, Marquez L, Simonsen KA, Stoilov S, Boakye-Agyeman F, Jasion T, Hornik CP, Hernandez R, **Benjamin DK Jr**, Cohen-Wolkowicz M. Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents, *Antimicrob Agents Chemother*, Jul 27;62(8). PMC6105834
- 239) Ariagno RL, Lee HC, Stevenson DK, **Benjamin DK Jr**, Smith PB, Escobedo MB, Bhatt DR. A Directory for Neonatal Intensive Care: Potential for Facilitating Network-Based Research in Neonatology, *J Perinatol*, 2018 Aug;38(8):954-958.
- 240) Bernard GR, Harris PA, Pulley JM, **Benjamin DK Jr**, Michael J, Ford DE, Hanley DF, Selker HP, Wilkins CH. A collaborative, academic approach to optimizing the national clinical research infrastructure: The first year of the Trial Innovation Network. *J Clin Transl Sci*, 2018 Aug;2(4):187-192. PMC6474372
- 241) Autmizguine J, Tan S, Cohen-Wolkowicz M, Cotten CM, Wiederhold N, Fothergill A, Goldberg RN, Adams-Chapman I, Stoll B, Smith PB, **Benjamin DK Jr** for the NICHD Neonatal Research

Network. Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. *Pediatr Infect Dis J*, 2018 Sep;37(9):923-929. PMC6057841

- 242) Thaden JT, Chiswell K, Jaffe I, Bergin SP, Yang WE, Romaine A, Roberts J, Nambiar S, Farley J, **Benjamin DK Jr**, Smith PB, Tsalik EL. Pediatric Antibacterial and Antifungal Trials from 2007 to 2017, *Pediatrics*, 2018 Sep;142(3).
- 243) Tsakiri S, Aneji C, Domonoske C, Mazur L, **Benjamin DK Jr**, Wootton SH. Voriconazole Treatment for an Infant with Intractable Candida Glabrata Meningitis. *Pediatr Infect Dis J*. 2018 Oct;37(10):999-1001.
- 244) **Benjamin DK Jr.**, Kaufman DA, Hope WW, Smith PB, Arietta A, Manzoni P, Kovanda LL, Lademacher C, Isaacson B, Jednachowski D, Wu C, Kaibara A, Walsh TJ, A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants with Invasive Candidiasis, *Pediatr Infect Dis J*, 2018 Oct;37(10):992-998. PMC6155365
- 245) Wang LA, Smith PB, Laughon M, Goldberg RN, Ku LC, Zimmerman KO, Balevic S, Clark RH, **Benjamin DK Jr**, Greenberg RG. Prolonged Furosemide Exposure and Risk of Abnormal Newborn Hearing Screen in Premature Infants. *Early Human Development*, 2018 Oct;3;125:26-30. PMC6186186
- 246) Romaine A, Clark RH, Davis BR, Hendershot K, Kite V, Laughon M, Updike I, Miranda ML, Meier PP, Patel AL, Smith PB, Cotten CM, **Benjamin DK Jr**, Greenberg RG. Predictors of Prolonged Breast Milk Provision to Very Low Birth Weight Infants. *J Pediatr*, 2018 Nov;202:23-30.e1. PMC6203611
- 247) Kumar KR, Clark D, Kim E, Perry JD, Wright K, Thomas SA, Thompson EJ, Greenberg RG, Smith PB, **Benjamin DK Jr**, Laughon MM, Clark RH, Hornik CP. Association of Atrial Septal Defects and Bronchopulmonary Dysplasia in Premature Infants. *J Pediatr*, 2018 Nov;202:56-62.e2. PMC6317846
- 248) Gray KD, Dudash K, Escobar C, Freel C, Harrison T, McMillan C, Puia-Dumitrescu M, Cotten CM, Benjamin R, Clark RH, **Benjamin DK Jr**, Greenberg RG, Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. Prevalence and safety of diazoxide in the neonatal intensive care unit. *J Perinatol*, 2018 Nov;38(11):1496-1502. PMC6224295
- 249) Steinback WJ, **Benjamin DK Jr**, Sleasman JW. Funding Pediatric Subspecialty Training: Are T32 Grants the Future? *J Pediatr*, 2018 Nov;202:4-7.e1.
- 250) Autmizguine J, Smith PB, Prather K, Bendel C, Natarajan G, Bidegain M, Kaufman D, Burchfield D, Ross A, Pandit P, Schell W, Gao J, **Benjamin DK Jr**. Effect of Fluconazole Prophylaxis on Candida Fluconazole Susceptibility in Premature Infants. *J Antimicrob Chemother*, 2018 Dec 1;73(12):3482-3487. PMC6927883
- 251) Cohen-Wolkowicz M, **Benjamin DK Jr**. Development of Therapeutics for Children-A Tricky Balancing Act. *JAMA Pediatr*, 2019 Jan 1;173(1):18-19.
- 252) Rivera-Chaparro ND, Wu H, Cohen-Wolkowicz M, Smith PB, Clark RH, **Benjamin DK Jr**, Greenberg RG. Safety, Effectiveness and Exposure Response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records, *Pediatr Infect Dis J*, 2019 Feb;38(2):e26-e28. PMC6163100

- 253) Watt KM, Hornik CP, Balevic SJ, Mundakel G, Cotten CM, Harper B, **Benjamin DK Jr**, Anand R, Laughon M, Smith PB, Cohen-Wolkowicz M, on behalf of the Best Pharmaceuticals for Children Act — Pediatric Trials Network Steering Committee. Pharmacokinetics of ticarcillin-clavulanate in premature Infants. *Br J Clin Pharmacol*, 2019 May;85(5):1021-1027. PMC6475694
- 254) Smith PB, Cotten CM, Hudak ML, Sullivan JE, Poindexter BB, Cohen-Wolkowicz M, Boakye-Agyeman F, Lewandowski A, Anand R, **Benjamin DK Jr**, Laughon MM on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Rifampin Pharmacokinetics and Safety in Preterm and Term Infants. *Antimicrob Agents Chemother*, 2019 May 24;63(6). PMC6535522
- 255) Greenberg RG, Gayam S, Savage D, Tong A, Gorham D, Sholomon A, Clark RH, **Benjamin DK**, Laughon M, and Smith PB. Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants. *J Pediatr*, 2019 May;208:134-140.e2 PMC6486845.
- 256) Gerhart JG, Watt KM, Edginton A, Wade KC, Salerno SN, **Benjamin DK Jr**, Smith PB, Hornik CP, Cohen-Wolkowicz M, Duara S, Ross A, Shattuck K, Stewart DL, Neu N, Gonzalez D, Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. Physiologically-Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants. *CPT Pharmacometrics Syst Pharmacol*. 2019 Jul;8(7):500-510. PMC6656941.
- 257) Zimmerman KO, **Benjamin DK**, Becker ML. Neonatal Therapeutics: Considerations for Dosing. *Am J Perinatol*. 2019 Jul;36(S 02):S18-S21. PMC7481035
- 258) Balevic S, Smith PB, Testoni D, Wu H, Brouwer KLR, Zimmerman KO, Rivera-Chaparro ND, **Benjamin DK Jr**, Cohen-Wolkowicz M. Cefazolin pharmacokinetics in premature infants. *J Perinatol*. 2019 Sep;39(9):1213-1218 PMC6713589
- 259) Petraitis V, Petraitiene R, Valdez JM, Pyrgos V, Lizak MJ, Klaunberg BA, Kalasauskas D, Basevicius A, Bacher JD, **Benjamin DK Jr**, Hope WW, Walsh TJ. Amphotericin B Penetrates into the Central Nervous System Through Focal Disruption of the Blood Brain Barrier in Experimental Hematogenous *Candida* Meningoencephalitis. *Antimicrob Agents Chemother*. 2019 Dec; 63(12): e01626-19. PMC6879260.
- 260) Hornik CP, Gelfand AA, Szperka CL, Pezzuto T, Utevsky A, Kessel S, McCune S, Alexander JJ, **Benjamin DK Jr**, Cohen-Wolkowicz M. Development of a Prospective Real-World Data Clinical Registry of Children and Adolescents With Migraine. *Headache*. 2020 Feb;60(2):405-415. PMC7194169.
- 261) Puia-Dumitrescu M, Younge N, **Benjamin DK**, Lawson K, Hume C, Hill K, Mengistu J, Wilson A, Zimmerman KO, Ahmad K, Greenberg RG. Medications and in-hospital outcomes in infants born at 22-24 weeks of gestation. *J Perinatol*. 2020 May;40(5):781-789. PMC7293630.
- 262) Gray KD, Messina JA, Cortina C, Owens T, Fowler M, Foster M, Gbadegehin S, Clark RH, **Benjamin DK Jr**, Zimmerman KO, Greenberg RG. J. Probiotic Use and Safety in the Neonatal Intensive Care Unit: A Matched Cohort Study. *Pediatr*. 2020 Jul;222:59-64.e1. PMC7321859. **(R25 publication)**

- 263) Stark A, Childers J, England M, Clark RH, Laughon M, Cohen-Wolkowicz M, **Benjamin DK Jr**, Smith PB, Wade K, Greenberg RG. Dosing of Antimicrobials in the Neonatal Intensive Care Unit: Does Clinical Practice Reflect Pharmacokinetics-based Recommendations? *Pediatr Infect Dis J*. 2020 Aug;39(8):713-717.
- 264) Ericson JE, Hornik CP, Greenberg RG, Clark RH, Tremoulet AH, Le J, Cohen-Wolkowicz M, Smith PB, **Benjamin DK Jr**, Best Pharmaceuticals for Children Act – Pediatric Trials Network. Paradoxical Antibiotic Effect of Ampicillin: Use of a Population Pharmacokinetic Model to Evaluate a Clinical Correlate of the Eagle Effect in Infants With Bacteremia. *Pediatr Infect Dis J*. *Pediatr Infect Dis J*. 2020 Aug;39(8):725-729.
- 265) Xie R, McFadyen L, Raber S, Swanson R, Tawadrous M, Leister-Tebbe H, Cohen-Wolkowicz M, **Benjamin DK Jr**, Liu P. Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis. *Clin Pharmacol Ther*. *Clin Pharmacol Ther*. 2020 Aug;108(2):316-325.
- 266) Ericson JE, McGuire J, Michaels MG, Schwarz A, Frenck R, Deville JG, Agarwal S, Bressler AM, Gao J, Spears T, **Benjamin DK Jr**, Smith PB, Bradley JS; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee and the Clinical Trials Transformation Initiative. Hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Children: A Prospective Natural History and Case-Control Study. *Pediatr Infect Dis J*. *Pediatr Infect Dis J*. 2020 Aug;39(8):658-664.
- 267) Maharaj AR, Wu H, Hornik CP, Balevic SJ, Hornik CD, Smith PB, Gonzalez D, Zimmerman KO, **Benjamin DK Jr**, Cohen-Wolkowicz M; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. *JAMA Pediatr*. 2020 Jun 5:e202422. PMC7275264
- 268) Dorismond C, Hunter SE, McNaull PP, Zimmerman KO, **Benjamin DK**, Greenberg RG, Corey KM, Laughon MM, Jackson WM. Wide range of perioperative drugs and doses used in inguinal hernia repairs for premature infants. *J Perinatol*. 2021 Mar;41(3):577-581. PMC7954820.
- 269) Boutzoukas AE, Akinboyo IC, Wong CA, **Benjamin DK Jr**, Zimmerman KO. Impact of COVID-19-related School Closures on the Drivers of Child Health. *N C Med J*. 2021 Jan-Feb;82(1):50-56.
- 270) Williams PCM, Bradley J, Roilides E, Olson L, Kaplan S, Lutsar I, Giaquinto C, **Benjamin DK**, Sharland M. Harmonising regulatory approval for antibiotics in children. *Lancet Child Adolesc Health*. 2021 Feb;5(2):96-98.
- 271) Greenberg RG, Poole L, Ford DE, Hanley D, Selker HP, Lane K, Dean JM, Burr J, Harris P, Wilkins CH, Bernard G, Edwards T, **Benjamin DK Jr**. Response of the trial innovation network to the COVID-19 pandemic. *J Clin Transl Sci*. 2021 Apr 20;5(1):e100. PMC8185427.
- 272) Zimmerman KO, Akinboyo IC, Brookhart MA, Boutzoukas AE, McGann K, Smith MJ, Maradiaga Panayotti G, Armstrong SC, Bristow H, Parker D, Zadrozny S, Weber DJ, **Benjamin DK Jr**; ABC Science Collaborative. Incidence and Secondary Transmission of SARS-CoV-2 Infections in Schools. *Pediatrics*. 2021 Apr;147(4):e2020048090. PMC8015158.

- 273) Le J, Greenberg RG, **Benjamin DK**, Yoo Y, Zimmerman KO, Cohen-Wolkowicz M, Wade KC; Administrative Core Committee of the Best Pharmaceuticals for Children Act–Pediatric Trials Network. Prolonged Post-Discontinuation Antibiotic Exposure in Very Low Birth Weight Neonates at Risk for Early-Onset Sepsis. *J Pediatric Infect Dis Soc*. 2021 May 28;10(5):615-621. PMC8163059.
- 274) Corneli A, Perry B, **Benjamin DK Jr**, Zimmerman KO; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Pediatric Trials Network: Stakeholder views on thanking families and providing study findings on pragmatic pediatric clinical research. *Contemp Clin Trials Commun*. 2021 May 25;22:100792. PMC8181207.
- 275) Abdel-Rahman SM, Paul IM, Hornik C, Sullivan JE, Wade K, Delmore P, Sharma G, **Benjamin DK**, Zimmerman KO. Racial and Ethnic Diversity in Studies Funded Under the Best Pharmaceuticals for Children Act. *Pediatrics*. 2021 May;147(5):e2020042903.
- 276) Boutzoukas AE, **Benjamin DK Jr**, Zimmerman KO. Remdesivir: Preliminary Data and Clinical Use Versus Recommended Use. *Pediatrics*. 2021 May;147(5):e2021050212. PMC8085993.
- 277) Smith MJ, Boutzoukas A, Autmizguine J, Hudak ML, Zinkhan E, Bloom BT, Heresi G, Lavery AP, Courtney SE, Sokol GM, Cotten CM, Bliss JM, Mendley S, Bendel C, Dammann CEL, Weitkamp JH, Saxonhouse MA, Mundakel GT, Debski J, Sharma G, Erinjeri J, Gao J, **Benjamin DK Jr**, Hornik CP, Smith PB, Cohen-Wolkowicz M; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Antibiotic Safety and Effectiveness in Premature Infants With Complicated Intraabdominal Infections. *Pediatr Infect Dis J*. 2021 Jun 1;40(6):550-555.
- 278) Maharaj AR, Wu H, Zimmerman KO, Muller WJ, Sullivan JE, Sherwin CMT, Autmizguine J, Rathore MH, Hornik CD, Al-Uzri A, Payne EH, **Benjamin DK Jr**, Hornik CP; Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. Pharmacokinetics of Ceftazidime in Children and Adolescents with Obesity. *Paediatr Drugs*. 2021 Sep;23(5):499-513. PMC9706343.
- 279) Zimmerman KO, Brookhart MA, Kalu IC, Boutzoukas AE, McGann KA, Smith MJ, Maradiaga Panayotti GM, Armstrong SC, Weber DJ, Moorthy GS, **Benjamin DK Jr**; ABC Science Collaborative. Community SARS-CoV-2 Surge and Within-School Transmission. *Pediatrics*. 2021 Oct;148(4):e2021052686. PMC10071552.
- 280) Sauder KA, Harte RN, Ringham BM, Guenther PM, Bailey RL, Alshawabkeh A, Cordero JF, Dunlop AL, Ferranti EP, Elliott AJ, Mitchell DC, Hedderson MM, Avalos LA, Zhu Y, Breton CV, Chatzi L, Ran J, Hertz-Picciotto I, Karagas MR, Sayarath V, Hoover J, MacKenzie D, Lyall K, Schmidt RJ, O'Connor TG, Barrett ES, Switkowski KM, Comstock SS, Kerver JM, Trasande L, Tylavsky FA, Wright RJ, Kannan S, Mueller NT, Catellier DJ, Glueck DH, Dabelea D; Program Collaborators for Environmental influences on Child Health Outcomes (ECHO). Disparities in Risks of Inadequate and Excessive Intake of Micronutrients during Pregnancy. *J Nutr*. 2021 Nov 2;151(11):3555-3569. PMC8564697.
- 281) Stark A, Smith PB, Hornik CP, Zimmerman KO, Hornik CD, Pradeep S, Clark RH, **Benjamin DK Jr**, Laughon M, Greenberg RG. Medication Use in the Neonatal Intensive Care Unit and Changes from 2010 to 2018. *J Pediatr*. 2022 Jan;240:66-71.e4. PMC9394450.

- 282) Zimmerman KO, Goldman JL, Schuster JE, Mena A, Quiriconi M, Butteris SM, Koval S, DeMuri GP, Mueller NB, **Benjamin DK**, Armstrong SC, Kalu IC, Boutzoukas A, Moorthy GS, Lane H, Weber DJ, Newland JG. Building a National Framework to Pair Scientists and Schools During a Global Pandemic. *Pediatrics*. 2021 Nov 4:e2021054268D
- 283) Zimmerman KO, Jackman JG, **Benjamin DK Jr**; ABC Science Collaborative. From Research to Policy: Reopening K-12 Schools in North Carolina During the COVID-19 Pandemic. *Pediatrics*. 2021 Nov 4:e2021054268E.
- 284) Boutzoukas AE, Zimmerman KO, **Benjamin DK**, DeMuri GP, Kalu IC, Smith MJ, McGann KA, Koval S, Brookhart MA, Butteris SM. Secondary Transmission of COVID-19 in K-12 Schools: Findings From Two States. *Pediatrics*. 2021 Nov 4:e2021054268K.
- 285) Boutzoukas AE, Zimmerman KO, **Benjamin DK**. School Safety, Masking, and the Delta Variant. *Pediatrics*. 2021 Dec 7:e2021054396. PMC9645698.
- 286) Moorthy GS, Mann TK, Boutzoukas AE, Blakemore A, Brookhart MA, Edwards L, Jackman JG, Maradiaga Panayotti GM, Warren T, Pendleton J, Willis Garcés A, Corneli A, Weber DJ, Kalu IC, **Benjamin DK Jr**, Zimmerman KO. Masking Adherence in K-12 Schools and SARS-CoV-2 Secondary Transmission. *Pediatrics*. 2022 Feb 1;149(12 Suppl 2):e2021054268I.
- 287) Boutzoukas AE, Zimmerman KO, Mann TK, Moorthy GS, Blakemore A, McGann KA, Smith MJ, Nutting B, Kerley K, Brookhart MA, Edwards L, Rak Z, **Benjamin DK Jr**, Kalu IC. A School-Based SARS-CoV-2 Testing Program: Testing Uptake and Quarantine Length Following In-School Exposures. *Pediatrics*. 2022 Feb 1;149(12 Suppl 2):e2021054268J.
- 288) Boutzoukas AE, Zimmerman KO, **Benjamin DK Jr**, Chick KJ, Curtiss J, Høeg TB. Quarantine Elimination for K-12 Students With Mask-on-Mask Exposure to SARS-CoV-2. *Pediatrics*. 2022 Feb 1;149(12 Suppl 2):e2021054268L.
- 289) Goldman JL, Schuster JE, Maier VF, Anand R, Hill EE, Butteris SM, DeMuri GP, Omidfar SA, Brookhart MA, Pak J, **Benjamin DK Jr**, Zimmerman KO; ABC Science Collaborative. Urban Classification, Not COVID-19 Community Rates, Was Associated With Modes of Learning in US K-12 Schools. *Pediatrics*. 2022 Feb 1;149(12 Suppl 2):e2021054268M.
- 290) Thakkar PV, Zimmerman KO, **Benjamin DK Jr**, Kalu IC. SARS-CoV-2 Infections and Incidence at a North Carolina Pre-Kindergarten-12 School During In-Person Education: August 2020 to January 2021. *J Sch Health*. 2022 May;92(5):461-468.
- 291) Thakkar PV, Zimmerman KO, Brookhart MA, Erickson TR, **Benjamin DK Jr**, Kalu IC. COVID-19 Incidence Among 6th-12th Grade Students by Vaccination Status. *Pediatrics*. 2022 May 1;149(5):e2022056230.
- 292) Campbell MM, **Benjamin DK**, Mann T, Fist A, Kim H, Edwards L, Rak Z, Brookhart MA, Anstrom K, Moore Z, Tilson EC, Kalu IC, Boutzoukas AE, Moorthy GS, Uthappa D, Scott Z, Weber DJ, Shane AL, Bryant KA, Zimmerman KO. Test-to-Stay After Exposure to SARS-CoV-2 in K-12 Schools. *Pediatrics*. 2022 May 1;149(5):e2021056045.
- 293) Zimmerman KO, Perry B, Hanlen-Rosado E, Nsonwu A, Lane MD, **Benjamin DK**, Becker M, Corneli A; Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee.

Developing lay summaries and thank you notes in paediatric pragmatic clinical trials. *Health Expect.* 2022 Jun;25(3):1029-1037. PMC9122399.

- 294) Boutzoukas AE, Zimmerman KO, Inkelas M, Brookhart MA, Benjamin DK Sr, Butteris S, Koval S, DeMuri GP, Manuel VG, Smith MJ, McGann KA, Kalu IC, Weber DJ, Falk A, Shane AL, Schuster JE, Goldman JL, Hickerson J, Benjamin V, Edwards L, Erickson TR, **Benjamin DK Jr.** School Masking Policies and Secondary SARS-CoV-2 Transmission. *Pediatrics.* 2022 Jun 1;149(6):e2022056687.
- 295) Le J, Greenberg RG, Yoo Y, Clark RH, **Benjamin DK Jr**, Zimmerman KO, Cohen-Wolkowicz M, Wade KC; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Ampicillin dosing in premature infants for early-onset sepsis: exposure-driven efficacy, safety, and stewardship. *J Perinatol.* 2022 Jul;42(7):959-964. PMC9262754.
- 296) Boutzoukas AE, **Benjamin DK**. Author Response: Other Factors Potentially Contributing to the Number of Secondary Infections. *Pediatrics.* 2022 Jul 1;150(1):e2022057636B.
- 297) Lang JE, Hornik CP, Elliott C, Silverstein A, Hornik C, Al-Uzri A, Bosheva M, Bradley JS, Borja-Tabora CFC, Di John D, Mendez Echevarria A, Ericson JE, Friedel D, Gonczi F, Isidro MGD, James LP, Kalocsai K, Koutroulis I, Laki I, Ong-Lim ALT, Nad M, Simon G, Syed S, Szabo E, **Benjamin DK Jr**, Cohen-Wolkowicz M; SOLI-PEDS Program. Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia. *Pediatr Infect Dis J.* 2022 Jul 1;41(7):556-562. PMC9199591.
- 298) Ericson JE, **Benjamin DK Jr**, Boakye-Agyeman F, Balevic SJ, Cotten CM, Adler-Shohet F, Laughon M, Poindexter B, Harper B, Payne EH, Kaneshige K, Smith PB; Best Pharmaceuticals for Children Act - Pediatric Trials Network. Exposure-safety relationship for acyclovir in the treatment of neonatal herpes simplex virus disease. *Early Hum Dev.* 2022 Jul;170:105616. PMC9645023.
- 299) Randell RL, **Benjamin DK**, Greenberg RG. An Innovative Approach to Building an Effective and Efficient Pediatric Trial Network. *Hosp Pediatr.* 2022 Sep 1;12(9):e309-e311. PMC9558054.
- 300) Lang JE, Hornik CD, Martz K, Jacangelo J, Anand R, Greenberg R, Hornik C, Zimmerman K, Smith PB, **Benjamin DK**, Laughon M; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Safety of sildenafil in premature infants at risk of bronchopulmonary dysplasia: Rationale and methods of a phase II randomized trial. *Contemp Clin Trials Commun.* 2022 Oct 31;30:101025. PMC9636444.
- 301) Campbell MM, **Benjamin DK Jr**, Mann TK, Fist A, Blakemore A, Diaz KS, Kim H, Edwards LJ, Rak Z, Brookhart MA, Moore Z, Tilson EC, Kalu I, Boutzoukas AE, Moorthy GS, Uthappa D, Scott Z, Weber DJ, Shane AL, Bryant KA, Zimmerman KO. Test-to-Stay After SARS-CoV-2 Exposure: A Mitigation Strategy for Optionally Masked K-12 Schools. *Pediatrics.* 2022 Nov 1;150(5):e2022058200. PMC9647593.
- 302) Commander SJ, **Benjamin DK**, Wu H, Thompson EJ, Lane M, Clark RH, Greenberg RG, Hornik CP. Exposure-response Relationships of Metronidazole in Infants: Integration of Electronic Health Record Data With Population Pharmacokinetic Modeling-Derived Exposure Simulation. *Pediatr Infect Dis J.* 2023 Jan 1;42(1):27-31. PMC9742159.

- 303) Boutzoukas AE, Olson R, Sellers MA, Fischer G, Hornik CD, Alibrahim O, Iheagwara K, Abulebda K, Bass AL, Irby K, Subbaswamy A, Zivick EE, Sweney J, Stormorken AG, Barker EE, Lutfi R, McCrory MC, Costello JM, Ackerman KG, Munoz Pareja JC, Dean JM, Abdelsamad N, Hanley DF Jr, Mould WA, Lane K, Stroud M, Feger BJ, Greenberg RG, Smith PB, **Benjamin DK Jr**, Hornik CP, Zimmerman KO, Becker ML. Mechanisms to expedite pediatric clinical trial site activation: The DOSE trial experience. *Contemp Clin Trials*. 2023 Feb;125:107067. PMC9918704.
- 304) Kalu IC, Zimmerman KO, Goldman JL, Keener Mast D, Blakemore AM, Moorthy G, Boutzoukas AE, Campbell MM, Uthappa D, DeLaRosa J, Potts JM, Edwards LJ, Selvarangan R, **Benjamin DK**, Mann TK, Schuster JE. SARS-CoV-2 Screening Testing Program for Safe In-person Learning in K-12 Schools. *J Pediatric Infect Dis Soc*. 2023 Feb 27;12(2):64-72. PMC9969331.
- 305) Corneli A, McKenna K, Dombeck C, Molokwu N, Taylor J, Vergara L, **Benjamin DK Jr**, Zimmerman KO; ABC Science Collaborative Caregivers of Black and Latino/a/x Students and School Personnel Perspectives on School-Based SARS-CoV-2 Testing: Implications for Testing and Test-to-Stay Programs in K-12 Schools. *J Sch Health*. 2023 Mar;93(3):186-196. PMC9877910.
- 306) Moorthy GS, Boutzoukas AE, **Benjamin DK**, Polgreen PM, Beekmann SE, Bradley JS, Dehority W. Defining Variability in Evaluation and Management of Children with Chronic Osteomyelitis. *J Pediatric Infect Dis Soc*. 2023 Apr 28;12(4):226-229.
- 307) Scott Z, Uthappa DM, Mann TK, Kim H, Brookhart MA, Edwards L, Rak Z, **Benjamin DK Jr**, Zimmerman KO; ABC Science Collaborative. Test-to-Stay in Kindergarten Through 12th Grade Schools After Household Exposure to Severe Acute Respiratory Syndrome Coronavirus 2. *J Sch Health*. 2023 May;93(5):360-369. PMC10261908.
- 308) Eisenstein EL, Zozus MN, Garza MY, Lanham HJ, Adagarla B, Walden A, **Benjamin DK**, Zimmerman KO, Kumar KR; Best Pharmaceuticals for Children Act: Pediatric Trials Network Steering Committee. Assessing clinical site readiness for EHR-to-EDC automated data collection. *Contemp Clin Trials*. 2023 May;128:107144.
- 309) Lane K, Palm ME, Marion E, Kay MT, Thompson D, Stroud M, Boyle H, Hillery S, Nanni A, Hildreth M, Nelson S, Burr JS, Edwards T, Poole L, Waddy SP, Dunsmore SE, Harris P, Wilkins C, Bernard GR, Dean JM, Dwyer J, **Benjamin DK Jr**, Selker HP, Hanley DF, Ford DE. Approaches for enhancing the informativeness and quality of clinical trials: Innovations and principles for implementing multicenter trials from the Trial Innovation Network. *J Clin Transl Sci*. 2023 May 25;7(1):e131. PMC10308427.
- 310) Goldman JL, Kalu IC, Schuster JE, Erickson T, Mast DK, Zimmerman K, **Benjamin DK**, Kalb LG, Gurnett C, Newland JG, Sherby M, Godambe M, Shinde N, Watterson T, Walsh T, Foxe J, Zand M, Dewhurst S, Collier R, DeMuri GP, Archuleta S, Ko LK, Inkelas M, Manuel V, Lee R, Oh H, Murugan V, Kramer J, Okihiro M, Gwynn L, Pulgaron E, McCulloh R, Broadhurst J, McDaniels-Davidson C, Kiene S, Oren E, Wu Y, Wetter DW, Stump T, Brookhart MA, Fist A, Haroz E. Building School-Academic Partnerships to Implement COVID-19 Testing in Underserved Populations. *Pediatrics*. 2023 Jul 1;152(Suppl 1):e2022060352C.
- 311) Schuster JE, Erickson TR, Goldman JL, **Benjamin DK**, Brookhart MA, Dewhurst S, Fist A, Foxe J, Godambe M, Gwynn L, Kiene SM, Keener Mast D, McDaniels-Davidson C, Newland

- JG, Oren E, Selvarangan R, Shinde N, Walsh T, Watterson T, Zand M, Zimmerman KO, Kalu IC. Utilization and Impact of Symptomatic and Exposure SARS-CoV-2 Testing in K-12 Schools. *Pediatrics*. 2023 Jul 1;152(Suppl 1):e2022060352I.
- 312) Uthappa DM, Pak J, McGann KA, Brookhart MA, McKinzie K, Abdelbarr M, Cockrell J, Hickerson J, Armstrong S, D'Agostino EM, Weber DJ, Kalu IC, **Benjamin DK**, Zimmerman KO, Boutzoukas AE; ABC Science Collaborative. In-Person Instruction and Educational Outcomes of K-8 Students During the COVID-19 Pandemic. *Pediatrics*. 2023 Jul 1;152(Suppl 1):e2022060352L.
- 313) Uthappa DM, Mann TK, Goldman JL, Schuster JE, Newland JG, Anderson WB, Dozier A, Inkelas M, Foxe JJ, Gwynn L, Gurnett CA, McDaniels-Davidson C, Walsh T, Watterson T, Holden-Wiltse J, Potts JM, D'Agostino EM, Zandi K, Corbett A, Spallina S, DeMuri GP, Wu YP, Pulgaron ER, Kiene SM, Oren E, Allison-Burbank JD, Okihiro M, Lee RE, Johnson SB, Stump TK, Collier RJ, Mast DK, Haroz EE, Kemp S, **Benjamin DK**, Zimmerman KO. Common Data Element Collection in Underserved School Communities: Challenges and Recommendations. *Pediatrics*. 2023 Jul 1;152(Suppl 1):e2022060352N.
- 314) Zimmerman KO, **Benjamin DK**. Lessons Learned From the COVID-19 Pandemic in K-12 Education. *Pediatrics*. 2023 Jul 1;152(Suppl 1):e2023060352O.
- 315) O'Halloran JA, Ko ER, Anstrom KJ, Kedar E, McCarthy MW, Panettieri RA Jr, Maillo M, Nunez PS, Lachiewicz AM, Gonzalez C, Smith PB, de Tai SM, Khan A, Lora AJM, Salathe M, Capo G, Gonzalez DR, Patterson TF, Palma C, Ariza H, Lima MP, Blamoun J, Nannini EC, Sprinz E, Mykietiuk A, Alicic R, Rauseo AM, Wolfe CR, Witting B, Wang JP, Parra-Rodriguez L, Der T, Willsey K, Wen J, Silverstein A, O'Brien SM, Al-Khalidi HR, Maldonado MA, Melsheimer R, Ferguson WG, McNulty SE, Zakrofsky P, Halabi S, **Benjamin DK Jr**, Butler S, Atkinson JC, Adam SJ, Chang S, LaVange L, Proschan M, Bozzette SA, Powderly WG; ACTIV-1 IM Study Group Members. Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. *JAMA*. 2023 Jul 25;330(4):328-339.
- 316) Hanley DF Jr, Bernard GR, Wilkins CH, Selker HP, Dwyer JP, Dean JM, **Benjamin DK Jr**, Dunsmore SE, Waddy SP, Wiley KL Jr, Palm ME, Mould WA, Ford DF, Burr JS, Huvane J, Lane K, Poole L, Edwards TL, Kennedy N, Boone LR, Bell J, Serdoz E, Byrne LM, Harris PA Decentralized clinical trials in the trial innovation network: Value, strategies, and lessons learned. *J Clin Transl Sci*. 2023 Jul 25;7(1):e170. PMC10465321.
- 317) Harris PA, Dunsmore SE, Atkinson JC, **Benjamin DK Jr**, Bernard GR, Dean JM, Dwyer JP, Ford DF, Selker HP, Waddy SP, Wiley KL, Wilkins CH, Cook SK, Burr JS, Edwards TL, Huvane J, Kennedy N, Lane K, Majkowski R, Nelson S, Palm ME, Stroud M, Thompson DD, Busacca L, Elkind MSV, Kimberly RP, Reilly MP, Hanley DF; Trial Innovation Network. Leveraging the Expertise of the CTSA Program to Increase the Impact and Efficiency of Clinical Trials. *JAMA Netw Open*. 2023 Oct 2;6(10):e2336470. PMC10773966.
- 318) Sauder KA, Cohen CC, Mueller NT, Hockett CW, Switkowski KM, Maldonado LE, Lyall K, Kerver JM, Dabelea D, O'Connor TG, Glueck DH, Melough MM, Couzens GL, Catellier DJ; program collaborators for Environmental influences on Child Health Outcomes; ECHO Components—Coordinating Center; Smith PB, Newby KL, **Benjamin DK**; Data Analysis Center; ECHO Awardees and Cohorts. Identifying Foods That Optimize Intake of Key Micronutrients During Pregnancy. *J Nutr*. 2023 Oct;153(10):3012-3022.

- 319) Zimmerman KO, Westreich D, Funk MJ, **Benjamin DK Jr**, Turner D, Stürmer T. Comparative Effectiveness of Dual- Versus Mono-Sedative Therapy on Opioid Administration, Sedative Administration, and Sedation Level in Mechanically Ventilated, Critically Ill Children. *J Pediatr Pharmacol Ther.* 2023;28(5):409-416. Epub 2023 Oct 3. PMC10731925.
- 320) Palm ME, Edwards TL, Wieber C, Kay MT, Marion E, Boone L, Nanni A, Jones M, Pham E, Hildreth M, Lane K, McBee N, **Benjamin DK Jr**, Bernard GR, Dean JM, Dwyer JP, Ford DE, Hanley DF, Harris PA, Wilkins CH, Selker HP. Development, implementation, and dissemination of operational innovations across the trial innovation network. *J Clin Transl Sci.* 2023 Oct 20;7(1):e251. PMC10790103.
- 321) **Benjamin DK Jr**. Duke STAR Program. *J Pediatric Infect Dis Soc.* 2023 Dec 26;12(Suppl 2):S1-S2.
- 322) Moreda E, Al-Dhalimy H, Ha M, Nwanaji-Enwerem E, Nguyen A, Pieters K, Alan Brookhart M, Hickerson J, **Benjamin DK Jr**, Zimmerman KO, Boutzoukas AE. Leveraging School Infection Data to Address Community COVID-19 Data Gaps. *J Pediatric Infect Dis Soc.* 2023 Dec 26;12(Supplement_2):S3-S8. PMC10750306
- 323) Stark A, **Benjamin DK Jr**, Kajencki A, Mann K, Rodriguez N, Troan I, Hill L, Boutzoukas AE, Zimmerman KO. School Absenteeism as a Marker for Community COVID-19 Rates. *J Pediatric Infect Dis Soc.* 2023 Dec 26;12(Supplement_2):S9-S13.
- 324) Thakkar PV, Scott Z, Hoffman M, Delarosa J, Hickerson J, Boutzoukas AE, **Benjamin DK Jr**, Brookhart MA, Zimmerman KO, Moorthy GS. Impact of the COVID-19 Pandemic on Pediatric Preventive Health Care Among North Carolina Children Enrolled in Medicaid. *J Pediatric Infect Dis Soc.* 2023 Dec 26;12(Supplement_2):S14-S19. PMC10750309
- 325) Sielaty R, Boutzoukas AE, Zimmerman KO, Caison B, Charles CO, Coyne Smith T, Darden T, Overman RA, **Benjamin DK Jr**, Brookhart MA. Trends in Pediatric Emergency and Inpatient Healthcare Use for Mental and Behavioral Health Among North Carolinians During the Early COVID-19 Pandemic. *J Pediatric Infect Dis Soc.* 2023 Dec 26;12(Supplement_2):S20-S27. PMC10750307
- 326) Kumar KR, Shah SJ, Fayyad RM, Turla TM, O'Sullivan LM, Wallace B, Clark RH, **Benjamin DK Jr**, Greenberg RG, Hornik CP. Association Between Hypoglycemia and the Occurrence of Early Onset Sepsis in Premature Infants. *J Pediatric Infect Dis Soc.* 2023 Dec 26;12(Supplement_2):S28-S36.
- 327) Speier RL, Cotten CM, **Benjamin DK Jr**, Lewis K, Keeler K, Kidimbu G, Roberts W, Clark RH, Zimmerman KO, Stark A, Greenberg RG. Late-Onset Sepsis Evaluation and Empiric Therapy in Extremely Low Gestational Age Newborns. *J Pediatric Infect Dis Soc.* 2023 Dec 26;12(Supplement_2):S37-S43.
- 328) Lamb AE, Rent S, Brannon AJ, Greer JL, Ndey-Bongo NP, Cho SH, Greenberg RG, **Benjamin DK Jr**, Clark RH, Kumar KR. Diagnostic Utility of Cerebrospinal Fluid White Blood Cell Components for the Identification of Bacterial Meningitis in Infants. *J Pediatric Infect Dis Soc.* 2023 Dec 26;12(Supplement_2):S44-S52. PMC10750308
- 329) Olague S, Boyle H, Ahmed I, Buchh B, Truong GST, Reyburn B, DeLeon C, Lin GC, Ahmad KA, Carr B, Singhal M, Althouse M, Castro R, Rudine A, Rider E, Macomber-Estill ML, Doles

- B, Ferry JF, Pierantoni H, Sutherland S, Clark RH, Blackwell CK, Smith PB, **Benjamin DK Jr**, Greenberg RG. Direct-to-participant recruitment of mothers and infants: A strategic approach during challenging pandemic times. *Contemp Clin Trials Commun*. 2024 Jan 17;38:101261. PMC10825472.
- 330) Heyward EB, Clark RH, Smith PB, **Benjamin DK Jr**, Zimmerman KO, Ahmad KA, Blackwell CK, Won H, Ssengonzi R, Belbase A, Ndalama CO, An J, Nwaezeigwe O, Greenberg RG. Trends in COVID-19 diagnoses and outcomes in infants hospitalized in the neonatal intensive care unit. *J Perinatol*. 2024 Jan;44(1):35-39.
- 331) Thakkar PV, Sutton KF, Detwiler CB, Henegar JG, Narayan JR, Perez-Romero M, Strausser CM, Clark RH, **Benjamin DK Jr**, Zimmerman KO, Goldberg RN, Younge N, Tanaka D, Brian Smith P, Greenberg RG, Kilpatrick R. Risk factors and epidemiology of spontaneous intestinal perforation among infants born at 22-24 weeks' gestational age. *J Perinatol*. 2024 Jan;44(1):94-99.
- 332) Khan S, Kilpatrick R, **Benjamin DK**, Kolnik SE, Greenberg RG, Clark R, Zimmerman KO, Puia-Dumitrescu M. Morbidity and mortality of twins and triplets compared to singleton infants delivered between 26-34 weeks gestation in the United States. *J Perinatol*. 2024 Feb;44(2):231-238. Epub 2023 Nov 21.
- 333) Balevic SJ, **Benjamin DK Jr**, Powderly WG, Smith PB, Gonzalez D, McCarthy MW, Shaw LK, Lindsell CJ, Bozzette S, Williams D, Linas BP, Blamoun J, Javeri H, Hornik CP; ACTIV-1 IM Study Group. Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial. *JAMA Netw Open*. 2024 Apr 1;7(4):e247615. PMC11046337.
- 334) Foote HP, Thomassy H, Baquero L, Cayli M, Jacobs E, Paladugu A, Roy A, Heyward E, Clark RH, Hornik CP, Benjamin DK, **Benjamin DK Jr**, Greenberg RG. Acyclovir Dosing Practices Across a Multicenter Cohort of Neonatal Intensive Care Units. *Pediatr Infect Dis J*. 2024 Jun 26:10.1097. Online ahead of print. PMC11669730
- 335) Wade KC, Greenberg RG, **Benjamin DK Jr**, Chen LL, Vo B, Ang BL, Boutzoukas A, Zimmerman K, Clark RH, Cohen-Wolkowicz M, Le J; Administrative Core Committee of the Best Pharmaceuticals for Children Act – Pediatric Trials Network. Post discontinuation Antibiotic Exposure in Hospitalized Infants at Risk for Late-onset Sepsis in the Neonatal Intensive Care Unit. *Pediatr Infect Dis J*. 2024 Oct 1;43(10):991-996. Epub 2024 Jun 17. PMC11408093.
- 336) Roberts AG, Kilpatrick R, Diaz LD, Benjamin S, Espinoza Santiago AJ, Jallow B, Monteith MF, Rumsey S, Clark RH, Zimmerman K, **Benjamin DK Jr**, Greenberg RG. Trends in Gabapentin Use in Neonatal Intensive Care Units from 2005 to 2020. *Am J Perinatol*. 2025 Jun;42(8):1017-1023. doi: 10.1055/a-2451-9925. Epub 2024 Nov 25. PMID: 39586804
- 337) Aleem S, **Benjamin DK Jr**, Burns CM, Duncan J, Melaku K, Norbekov A, Graham B, Mantena S, Ladipo T, Jung A, Zimmerman KO, Clark RH, Greenberg RG. Epidemiology and outcomes of bacterial meningitis in the neonatal intensive care unit. *J Perinatol*. 2024 Dec;44(12):1822-1826. Epub 2024 Jul 26.

- 338) Chen N, Kilpatrick R, VerHage EJ, Smith PB, Bukhari A, Hornik CD, Tolia VN, **Benjamin DK Jr**, Greenberg RG. Epidemiology and treatment of herpes simplex virus in the neonatal intensive care unit. *J Perinatol*. 2025 Jan;45(1):116-121. Epub 2024 Oct 11.
- 339) Thakkar PV, Boutzoukas AE, Compton SN, Sivashankar O, Zimmerman KO, **Benjamin DK Jr**, Brookhart MA. Predictors of Potentially Inappropriate Stimulant Prescribing Among Adults. *Pharmacoepidemiol Drug Saf*. 2025 Jan;34(1):e70079. PMC11731891
- 340) Kumar KR, Ciociola EC, Skinner KR, Dixit GM, Alvarez S, Benjamin EK, Faulkner JC, Greenberg RG, Clark RH, **Benjamin DK Jr**, Hornik CP, Lee JH. Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants. *Cardiol Young*. 2025 Jan;35(1):93-101. doi: 10.1017/S1047951124025976. Epub 2024 Oct 16. PMID: 39410754
- 341) Ericson JE, Greenberg RG, Smith PB, Clark RH, **Benjamin DK Jr**, Kilpatrick R. Early Effective Antibiotic Therapy and Meningitis following a Bloodstream Infection in Hospitalized Infants: A Cohort Study. *Am J Perinatol*. 2025 Dec;42(16):2169-2175. doi: 10.1055/a-2568-7085. Epub 2025 Mar 28. PMID: 40154528
- 342) Jennings MR, Elhaisouni N, Colantuoni E, Prochaska EC, Johnson J, Xiao S, Clark RH, Greenberg RG, **Benjamin DK Jr**, Milstone AM. Epidemiology and Mortality of Invasive Staphylococcus aureus Infections in Hospitalized Infants. *JAMA Pediatr*. 2025 Apr 14;179(7):747-55. doi: 10.1001/jamapediatrics.2025.0429. Online ahead of print. PMID: 40227743
- 343) Greenberg RG, Lang J, Smith PB, Shekhawat P, Courtney SE, Hudak ML, Moya F, Iyengar A, Eldemerdash A, Bloom B, Go M, Hanna M, Rhein L, Aliaga S, Lewis T, Febre A, Kiefer AS, Bhatt-Mehta V, Khoury JA, Selewski D, Anand R, Martz K, Payne EH, Zimmerman KO, **Benjamin DK Jr**, Laughon M; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Furosemide Safety in Preterm Infants at Risk for Bronchopulmonary Dysplasia: A Randomized Clinical Trial. *J Pediatr*. 2025 Aug;283:114629. doi: 10.1016/j.jpeds.2025.114629. Epub 2025 Apr 28. PMID: 40306549 Clinical Trial.
- 344) Greenberg RG, Lang J, Smith PB, Shekhawat P, Courtney SE, Hudak ML, Moya F, Iyengar A, Eldemerdash A, Bloom B, Go M, Hanna M, Rhein L, Aliaga S, Lewis T, Febre A, Kiefer AS, Bhatt-Mehta V, Khoury JA, Selewski D, Anand R, Martz K, Payne EH, Zimmerman KO, **Benjamin DK Jr**, Laughon M; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Corrigendum to "Furosemide Safety in Preterm Infants at Risk for Bronchopulmonary Dysplasia: A Randomized Clinical Trial." *J Pediatr*. 2025 Oct;285:114734. doi: 10.1016/j.jpeds.2025.114734. Epub 2025 Aug 14. PMID: 40817023
- 345) Daniel KB, Olague S, Boyle H, Ahmed I, Buchh B, Truong GS, Reyburn B, DeLeon C, Lin G, Ahmad K, Carr B, Singhal M, Althouse M, Castro R, Rudine A, Rider E, Macomber-Estill M, Doles B, Ferry J, Pierantoni H, Sutherland S, Kelleher A, Clark R, Blackwell C, Smith PB, **Benjamin DK**, Greenberg R. Outcomes of Mothers and Infants Affected by COVID-19. *Am J Perinatol*. 2026 Jan;43(2):189-198. doi: 10.1055/a-2598-9547. Epub 2025 May 2. PMID: 40315886
- 346) Harris PA, Wilkins CH, Lane K, Bernard GR, Casey JD, Ford DE, Waddy SP, Wiley KL Jr, Edwards TL, McBee N, Thompson DD, Stroud M, Serdoz E, Kennedy N, Nelson SJ, Jones M, Eyzaguirre LM, Boone LR, Baird J, Lawrence C, Holthouse E, Cook SK, Tischbein M, Amrine N, Chen T, Cohen J, Deyampert L, Dilts N, Burts D, Baig A, Christodoulou J, Rodriguez M,

Miller ER 3rd, Casella JF, Mould WA, Dean JM, **Benjamin DK Jr**, Selker HP, Palm ME, Poole L, Burr JS, Hassani S, Nanni A, Hildreth M, Hanley DF. Enhancing Multicenter Trials With the Trial Innovation Network's Initial Consultation Process. *JAMA Netw Open*. 2025 May 1;8(5):e2512926. doi: 10.1001/jamanetworkopen.2025.12926. PMID: 40440017

- 347) Balevic SJ, Gonzalez D, Smith PB, Powderly WG, Schmid A, Kang A, McCarthy MW, Shaw LK, Lindsell CJ, Bozzette S, Hoetelmans RMW, Hornik CP, **Benjamin DK Jr.**, for the ACTIV-1 IM Study Group Members, Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID-19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV-1 IM), *Journal of Clinical Pharmacology*, 2025 Nov;65(11):1497-1505. doi: 10.1002/jcph.70057. Epub 2025 Jun 9. PMID: 40488513
- 348) Randell RL, Balevic SJ, Greenberg RG, Cohen-Wolkowicz M, Smith MJ, **Benjamin DK Jr**, Bendel C, Bliss JM, Chaaban H, Chhabra R, Dammann CEL, Downey LC, Hornik CD, Hussain N, Laughon MM, Lavery A, Moya F, Saxonhouse M, Sokol GM, Trembath A, Weitkamp J-H, Hornik CP; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Metronidazole exposure-response and safety in infants. *Antimicrob Agents Chemother*. 2025 Nov 5;69(11):e0037725. doi: 10.1128/aac.00377-25. Epub 2025 Sep 19. PMID: 40970766
- 349) Watt KM, Thompson EJ, Lam L, Zimmerman K, Hornik CP, Atz AM, Fernandez A, Hupp SR, Bhatt-Mehta V, **Benjamin DK Jr**, Anand R, Cohen-Wolkowicz M, Gonzalez D, Smith PB, Capparelli EV; Best Pharmaceuticals for Children Act — Pediatric Trials Network Steering Committee. Population Pharmacokinetics to Support Intravenous and Enteral Methadone Dosing in Children. *J Clin Pharmacol*. 2026 Jan;66(1):e70143. doi: 10.1002/jcph.70143. PMID: 41474167
- 350) Maglalang PD, Sinha J, Helfer VE, Edginton A, Zimmerman K, Hornik CD, Muller WJ, Rathore M, **Benjamin DK Jr**, Chen JY, Anand R, Gonzalez D; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity. *J Clin Pharmacol*. 2026 Feb;66(2):e70107. doi: 10.1002/jcph.70107. Epub 2025 Sep 29. PMID: 41020741
- 351) Lang JE, Gonzalez D, Hornik CD, Greenberg R, O'Shea M, **Benjamin DK Jr**, Chiswell K, Waymers S, Laughon M. Pharmacokinetics, safety and preliminary efficacy study of montelukast in critically ill infants with developing bronchopulmonary dysplasia (PRISM). *Contemp Clin Trials Commun*. 2026 Feb 9;49:101609. doi: 10.1016/j.conctc.2026.101609. eCollection 2026 Feb. PMID: 41716483
- 352) Boutzoukas AE, Le J, Kilpatrick R, Smith MJ, Laughon M, Gonzalez D, Wade KC, Greenberg RG, Babilonia-Rosa M, **Benjamin DK Jr**, Cohen-Wolkowicz M, Zimmerman KO. Evaluating the duration of post-discontinuation therapeutic ampicillin exposures in preterm infants. *J Perinatol*. 2026 Mar 13. doi: 10.1038/s41372-026-02600-5. Online ahead of print. PMID: 41826670
- 353) Randell RL, Maharaj A, Laughon M, Hornik CD, Greenberg RG, Lang JE, Cohen-Wolkowicz M, Hornik CP, Anand R, Martz K, Payne EH, Watt K, Muller WJ, Courtney SE, Atz A, Al-Uzri A, Sokol GM, Bloom BT, Iyengar A, Hanna M, **Benjamin DK Jr**, Balevic SJ; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Population

Publications not listed as co-author but Principal Investigator and/or member of the steering committee: (trainees underlined)

- 354) Trembath A, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M; Best Pharmaceuticals for Children Act—**Pediatric Trials Network**. Comparative effectiveness of surfactant preparations in premature infants. *J Pediatr.* 2013 Oct;163(4):955-60.e1. PMC3779477.
- 355) Abdel-Rahman SM, Paul IM, James LP, Lewandowski A; Best Pharmaceuticals for Children Act-**Pediatric Trials Network**. Evaluation of the Mercy TAPE: performance against the standard for pediatric weight estimation. *Ann Emerg Med.* 2013 Oct;62(4):332-339.e6. PMC4039210.
- 356) Samiee-Zafarghandy S, Raman SR, van den Anker JN, McHutchison K, Hornik CP, Clark RH, Brian Smith P; Best Pharmaceuticals for Children Act-**Pediatric Trials Network** Administrative Core Committee Safety of milrinone use in neonatal intensive care units. *Early Hum Dev.* 2015 Jan;91(1):31-5. PMC4302030.
- 357) Testoni D, Hornik CP, Neely ML, Yang Q, McMahon AW, Clark RH, Smith PB; Best Pharmaceuticals for Children Act — **Pediatric Trials Network** Administrative Core Committee. Safety of octreotide in hospitalized infants. *Early Hum Dev.* 2015 Jul;91(7):387-92. PMC4450124.
- 358) Trachtman H, Frymoyer A, Lewandowski A, Greenbaum LA, Feig DI, Gipson DS, Warady BA, Goebel JW, Schwartz GJ, Lewis K, Anand R, Patel UD; Best Pharmaceuticals for Children Act-**Pediatric Trials Network** Administrative Core Committee. Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection. *Clin Pharmacol Ther.* 2015 Jul;98(1):25-33. PMC4536255.
- 359) Samiee-Zafarghandy S, van den Anker JN, Laughon MM, Clark RH, Smith PB, Hornik CP; Best Pharmaceuticals for Children Act – **Pediatric Trials Network** Administrative Core Committee. Sildenafil and retinopathy of prematurity risk in very low birth weight infants. *J Perinatol.* 2016 Feb;36(2):137-40. PMC4731250.
- 360) Estep JH, Melloni C, Thornburg CD, Wiczling P, Rogers Z, Rothman JA, Green NS, Liem R, Brandow AM, Crary SE, Howard TH, Morris MH, Lewandowski A, Garg U, Jusko WJ, Neville KA; Best Pharmaceuticals for Children Act - **Pediatric Trials Network** Administrative Core Committee. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. *J Clin Pharmacol.* 2016 Mar;56(3):298-306. PMC4892120.
- 361) England A, Wade K, Smith PB, Berezny K, Laughon M; Best Pharmaceuticals for Children Act — **Pediatric Trials Network** Administrative Core Committee. Optimizing operational efficiencies in early phase trials: The Pediatric Trials Network experience. *Contemp Clin Trials.* 2016 Mar;47:376-82. PMC4997801.
- 362) Gonzalez D, Chamberlain JM, Guptill JT, Cohen-Wolkowicz M, Harper B, Zhao J, Capparelli EV; Best Pharmaceuticals for Children Act – **Pediatric Trials Network** Steering Committee.

Population Pharmacokinetics and Exploratory Pharmacodynamics of Lorazepam in Pediatric Status Epilepticus. *Clin Pharmacokinet*. 2017 Aug;56(8):941-951. PMC5466505.

- 363) Shakhnovich V, Smith PB, Guptill JT, James LP, Collier DN, Wu H, Livingston CE, Zhao J, Kearns GL. Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures, *J Pediatr*, February 2018; 193, 102-108 e1. PMC5806153
- 364) Gulack BC, Greenberg R, Clark RH, Miranda ML, Blakely ML, Rice HE, Adibe OO, Tracy ET, and Smith PB. A Multi-Institution Analysis of Predictors of Timing of Inguinal Hernia Repair among Premature Infants. *J Pediatr Surg*. 2018 Apr;53(4):784-788. PMID: 29055488.
- 365) Thompson EJ, Greenberg RG, Kumar K, Laughon M, Smith PB, Clark RH, Crowell A, Shaw L, Harrison L, Scales G, Bell N, Hornik CP. Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight. *J Pediatr*. 2018 Aug;199:231-236. PMC6063759
- 366) Shakhnovich V, Smith PB, Guptill JT, James LP, Collier DN, Wu H, Livingston CE, Zhao J, Kearns GL, Cohen-Wolkowicz M, Best Pharmaceuticals for Children Act—**Pediatric Trials Network**. A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents. *Paediatr Drugs*. 2018 Oct;20(5):483-495. PMC6178956
- 367) Ku LC, Hornik CP, Beechinor RJ, Chamberlain JM, Guptill JT, Harper B, Capparelli EV, Martz K, Anand R, Cohen-Wolkowicz M, Gonzalez D. Best Pharmaceuticals for Children Act - **Pediatric Trials Network** Steering Committee. Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus. *CPT Pharmacometrics Syst Pharmacol*. 2018 Nov;7(11):718-727. PMC6263663.
- 368) Dumitrescu MP, Bretzius OM, Brown N, Fitz-Henley JA, Ssengonzi R, Wechsler CS, Gray KD, Benjamin DK Sr, Smith PB, Clark RH, Gonzalez D, Hornik CP. Evaluation of Gentamicin Exposure in the Neonatal Intensive Care unit and Hearing Function at Discharge. *J Pediatr*, 2018 Dec;203:131-136. PMC6361629.
- 369) Thompson EJ, Perez K, Hornik CP, Smith PB, Clark RH, Laughon M, Best Pharmaceuticals for Children Act—**Pediatric Trials Network** Steering Committee. Sildenafil Exposure in the Neonatal Intensive Care Unit. *Am J Perinatol*. 2019 Feb;36(3):262-267. PMC6996478.
- 370) Hornik CP, Atz AM, Bendel C, Chan F, Downes K, Grundmeier R, Fogel B, Gipson D, Laughon M, Miller M, Smith M, Livingston C, Kluchar C, Heath A, Jarrett C, McKerlie B, Patel H, Hunter C; Best Pharmaceuticals for Children Act—**Pediatric Trials Network**. Creation of a Multicenter Pediatric Inpatient Data Repository Derived from Electronic Health Records. *Appl Clin Inform*. 2019 Mar;10(2):307-315. PMC6506334.
- 371) Taylor G, Jackson W, Hornik CP, Chan A, Koss A, Mantena S, Hornsley K, Gattis B, Kudumu-Clavell M, Clark R, Smith PB, Laughon MM. Surfactant Administration in Premature Infants: Drug Development Opportunities. *J Pediatr*. 2019 May;208:163-168. PMC6486873.
- 372) Padula AM, Monk C, Brennan PA, Borders A, Barrett ES, McEvoy CT, Foss S, Desai P, Alshawabkeh A, Wurth R, Salafia C, Fichorova R, Varshavsky J, Kress A, Woodruff TJ, Morello-Frosch R; program collaborators for **Environmental influences on Child**

Health Outcomes. A review of maternal prenatal exposures to environmental chemicals and psychological stressors-implications for research on perinatal outcomes in the ECHO Program. *J Perinatol.* 2020 Jan;40(1):10-24. PMC6957228.

- 373) Drolet BA, Boakye-Agyeman F, Harper B, Holland K, Lewandowski A, Stefanko N, Melloni C; **Pediatric Trials Network** Steering Committee (See Acknowledgments for a listing of committee members.). Systemic timolol exposure following topical application to infantile hemangiomas. *J Am Acad Dermatol.* 2020 Mar;82(3):733-736.
- 374) Ge S, Mendley SR, Gerhart JG, Melloni C, Hornik CP, Sullivan JE, Atz A, Delmore P, Tremoulet A, Harper B, Payne E, Lin S, Erinjeri J, Cohen-Wolkowicz M, Gonzalez D; Best Pharmaceuticals for Children Act - **Pediatric Trials Network** Steering Committee. Population Pharmacokinetics of Metoclopramide in Infants, Children, and Adolescents. *Clin Transl Sci.* 2020 Apr 23. [Epub ahead of print].
- 375) Salerno SN, Edginton A, Gerhart JG, Laughon MM, Ambalavanan N, Sokol GM, Hornik CD, Stewart D, Mills M, Martz K, Gonzalez D, Pharmaceuticals for Children Act - **Pediatric Trials Network** Steering Committee. Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants. *Clin Pharmacol Ther.* 2020 Jul 21. doi: 10.1002/cpt.1990. Online ahead of print.
- 376) Lyall K, Hosseini M, Ladd-Acosta C, Ning X, Catellier D, Constantino JN, Croen LA, Kaat AJ, Botteron K, Bush NR, Dager SR, Duarte CS, Fallin MD, Hazlett H, Hertz-Picciotto I, Joseph RM, Karagas MR, Korrick S, Landa R, Messinger D, Oken E, Ozonoff S, Piven J, Pandey J, Sathyanarayana S, Schultz RT, St John T, Schmidt R, Volk H, Newschaffer CJ; program collaborators for **Environmental influences on Child Health Outcomes**. Distributional Properties and Criterion Validity of a Shortened Version of the Social Responsiveness Scale: Results from the ECHO Program and Implications for Social Communication Research. *J Autism Dev Disord.* 2020 Sep 17. doi: 10.1007/s10803-020-04667-1. Online ahead of print. PMC7965796.
- 377) Polcwiartek LB, Smith PB, Benjamin DK, Zimmerman K, Love A, Tiu L, Murray S, Kang P, Ebbesen F, Hagstrøm S, Clark RH, Greenberg RG. Early-onset sepsis in term infants admitted to neonatal intensive care units (2011-2016). *J Perinatol.* 2020 Oct 17;1-7. PMC7568457 (**R25 publication**).
- 378) Aleem S, Robbins C, Murphy B, Elliott S, Akinyemi C, Paredes N, Tolia VN, Zimmerman KO, Goldberg RN, Benjamin DK, Greenberg RG. The use of supplemental hydrocortisone in the management of persistent pulmonary hypertension of the newborn. *J Perinatol.* 2021 Apr;41(4):794-800. (**R25 publication**). PMC8052278.
- 379) Rachel L Randell, Lindsay Singler, Anthony Cunningham, Laura E Schanberg, Michael Cohen-Wolkowicz, Christoph P Hornik, Stephen J Balevic, with the CARRA Registry investigators. Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial. *Lupus Sci Med.* 2021 May;8(1):e000494. (**GPCTN publication**).
- 380) Aaron J Donoghue, Maybelle Kou, Grace L Good, Carmel Eiger, Mark Nash, Fred M Henretig, Helen Stacks, Adam Kochman, Julie Debski, Jia-Yuh Chen, Gaurav Sharma, Christoph P Hornik, Leigh Gosnell, David Siegel, Steven Krug, Mark D Adler, Best Pharmaceuticals for Children Act – **Pediatric Trials Network**. Impact of Personal Protective

Equipment on Pediatric Cardiopulmonary Resuscitation Performance: A Controlled Trial. *Pediatr Emerg Care*. 2020 Jun;36(6):267-273. PMC7274141.

- 381) Ganguly S, Edginton AN, Gerhart JG, Cohen-Wolkowicz M, Greenberg RG, Gonzalez D; Best Pharmaceuticals for Children Act—**Pediatric Trials Network Steering Committee**. Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants. *Clin Pharmacokinet*. 2021 Jun 22. doi: 10.1007/s40262-021-01046-6. Online ahead of print.
- 382) Lane MD, Kishnani S, Udemadu O, Danquah SE, Treadway RM 3rd, Langman A, Balevic S, Jackson WM, Laughon M, Hornik CP, Greenberg RG, Clark RH, Zimmerman KO. Comparative efficacy and safety of late surfactant preparations: a retrospective study. *J Perinatol*. 2021 Jul 20:1-6. doi: 10.1038/s41372-021-01142-2. Online ahead of print. PMC8290378. (**R25 publication**).
- 383) Bekelman TA, Dabelea D, Ganiban JM, Law A, McGovern Reilly A, Althoff KN, Mueller N, Camargo CA Jr, Duarte CS, Dunlop AL, Elliott AJ, Ferrara A, Gold DR, Hertz-Picciotto I, Hartert T, Hipwell AE, Huddleston K, Johnson CC, Karagas MR, Karr CJ, Hershey GKK, Leve L, Mahabir S, McEvoy CT, Neiderhiser J, Oken E, Rundle A, Sathyanarayana S, Turley C, Tylavsky FA, Watson SE, Wright R, Zhang M, Zoratti E; Program collaborators for **Environmental influences on Child Health Outcomes (ECHO)**. Regional and sociodemographic differences in average BMI among US children in the ECHO program. *Obesity (Silver Spring)*. 2021 Aug 31. doi: 10.1002/oby.23235. Online ahead of print.
- 384) Sauder KA, Harte RN, Ringham BM, Guenther PM, Bailey RL, Alshawabkeh A, Cordero JF, Dunlop AL, Ferranti EP, Elliott AJ, Mitchell DC, Hedderson MM, Avalos LA, Zhu Y, Breton CV, Chatzi L, Ran J, Hertz-Picciotto I, Karagas MR, Sayarath V, Hoover J, MacKenzie D, Lyall K, Schmidt RJ, O'Connor TG, Barrett ES, Switkowski KM, Comstock SS, Kerver JM, Trasande L, Tylavsky FA, Wright RJ, Kannan S, Mueller NT, Catellier DJ, Glueck DH, Dabelea D; **Program Collaborators for Environmental influences on Child Health Outcomes (ECHO)**. Disparities in Risks of Inadequate and Excessive Intake of Micronutrients during Pregnancy. *J Nutr*. 2021 Sep 7:nxab273. doi: 10.1093/jn/nxab273. Online ahead of print.
- 385) Gerhart JG, Carreño FO, Edginton AN, Sinha J, Perrin EM, Kumar KR, Rikhi A, Hornik CP, Harris V, Ganguly S, Cohen-Wolkowicz M, Gonzalez D; Best Pharmaceuticals for Children Act—**Pediatric Trials Network Steering Committee**. Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling. *Clin Pharmacokinet*. 2021 Oct 7. doi: 10.1007/s40262-021-01072-4. Online ahead of print.
- 386) Cernich AN, Lee S, Bianchi DW. Building the Evidence for Safe Return to School During the COVID-19 Pandemic. *Pediatrics*. 2022 Feb 1;149(12 Suppl 2):e2021054268B.
- 387) D'Agostino EM, Haroz EE, Linde S, Layer M, Green M, Ko LK. School-Academic Partnerships in Support of Safe Return to Schools During the COVID-19 Pandemic. *Pediatrics*. 2022 Feb 1;149(12 Suppl 2):e2021054268C.
- 388) Ko LK, Tingey L, Ramirez M, Pablo E, Grass R, Larzelere F, Cisneros O, Chu HY, D'Agostino EM. Mobilizing Established School Partnerships to Reach Underserved Children During a Global Pandemic. *Pediatrics*. 2022 Feb 1;149(12 Suppl 2):e2021054268F.

- 389) Haroz EE, Kalb LG, Newland JG, Goldman JL, Mast DK, Ko LK, Grass R, Shah P, Walsh T, Schuster JE. Implementation of School-Based COVID-19 Testing Programs in Underserved Populations. *Pediatrics*. 2022 Feb 1;149(12 Suppl 2):e2021054268G.
- 390) Sherby MR, Kalb LG, Collier RJ, DeMuri GP, Butteris S, Foxe JJ, Zand MS, Freedman EG, Dewhurst S, Newland JG, Gurnett CA. Supporting COVID-19 School Safety for Children With Disabilities and Medical Complexity. *Pediatrics*. 2022 Feb 1;149(12 Suppl 2):e2021054268H.
- 391) Goldman JL, Schuster JE, Maier VF, Anand R, Hill EE, Butteris SM, DeMuri GP, Omidfar SA, Brookhart MA, Pak J, Benjamin DK, Zimmerman KO. Urban Classification, Not COVID-19 Community Rates, Was Associated With Modes of Learning in US K-12 Schools? *Pediatrics*. 2022 Feb 1;149(12 Suppl 2):e2021054268M.
- 392) Gerhart JG, Carreño FO, Loop MS, Lee CR, Edginton AN, Sinha J, Kumar KR, Kirkpatrick CM, Hornik CP, Gonzalez D; Best Pharmaceuticals for Children Act - **Pediatric Trials Network Steering Committee**. Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children with Obesity. *Clin Pharmacol Ther*. 2022 Apr 22. doi: 10.1002/cpt.2618. Online ahead of print.
- 393) Gerhart JG, Carreño FO, Ford JL, Edginton AN, Perrin EM, Watt KM, Muller WJ, Atz AM, Al-Uzri A, Delmore P, Gonzalez D; Best Pharmaceuticals for Children Act-**Pediatric Trials Network Steering Committee**. Use of physiologically-based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity. *CPT Pharmacometrics Syst Pharmacol*. 2022 Jun;11(6):778-791. PMC9197535
- 394) Sauder KA, Cohen CC, Mueller NT, Hockett CW, Switkowski KM, Maldonado LE, Lyall K, Kerver JM, Dabelea D, O'Connor TG, Glueck DH, Melough MM, Couzens GL, Catellier DJ; program collaborators for Environmental influences on Child Health Outcomes. ECHO Components—Coordinating Center; Data Analysis Center; **ECHO Awardees and Cohorts**. Identifying foods that optimize intake of key micronutrients during pregnancy. *J Nutr*. 2023 Aug 19:S0022-3166(23)72536-4. PMID37604382
- 395) Maglalang PD, Sinha J, Zimmerman K, McCann S, Edginton A, Hornik CP, Hornik CD, Muller WJ, Al-Uzri A, Meyer M, Chen JY, Anand R, Perrin EM, Gonzalez D; Best Pharmaceuticals for Children Act—**Pediatric Trials Network Steering Committee**. Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population. *Clin Pharmacokinet*. 2024 Jun;63(6):885-899. Epub 2024 May 30. PMC11225543.
- 396) Carreño FO, Gerhart JG, Helfer VE, Sinha J, Kumar KR, Kirkpatrick C, Hornik CP, Gonzalez D; Best Pharmaceuticals for Children Act—**Pediatric Trials Network Steering Committee**. Characterizing Enoxaparin's Population Pharmacokinetics to Guide Dose Individualization in the Pediatric Population. *Clin Pharmacokinet*. 2024 Jul;63(7):999-1014. Epub 2024 Jul 2. PMC11288483
- 397) Wen J, McCann S, Balevic SJ, Muller WJ, Hornik CD, Autmizguine J, Anderson SG, Payne EH, Turdalieva S, Gonzalez D; Best Pharmaceuticals for Children Act – **Pediatric Trials Network Steering Committee**. Pharmacokinetics of Dexamethasone in Children and Adolescents with Obesity. *J Clin Pharmacol*. 2024 Dec;64(12):1491-1504. Epub 2024 Aug 9. PMC11598673

- 398) Sinha J, Zimmerman K, Balevic SJ, Hornik C, Muller WJ, Rathore M, Meyer M, Finkelstein Y, Al-Uzri A, Lakhotia A, Goldstein S, Chen JY, Anand R, Gonzalez D; **Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee**. Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity. *Clin Pharmacokinet*. 2026 Feb;65(2):329-344. doi: 10.1007/s40262-025-01579-0. Epub 2025 Nov 17. PMID: 41247430
- 399) Sinha J, Zimmerman K, Balevic SJ, Hornik C, Muller WJ, Rathore M, Meyer M, Finkelstein Y, Al-Uzri A, Lakhotia A, Goldstein S, Chen JY, Anand R, Gonzalez D; **Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee**. Correction: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity. *Clin Pharmacokinet*. 2026 Feb;65(2):345. doi: 10.1007/s40262-025-01613-1. PMID: 41493701

Peer-Reviewed Invited Review Articles and Editorials: (trainees underlined)

- 400) **Benjamin DK Jr.** Fluconazole prophylaxis in the nursery. *Pediatric Infections Forum*. 2005; 7(2).
- 401) **Benjamin DK Jr.**, Garges HP, Steinbach WJ. *Candida* bloodstream infections in neonates. *Semin Perinatol*. 2003;27:375–383. PMID14626501.
- 402) Smith PB, Steinbach WJ, **Benjamin DK Jr.** Neonatal candidiasis: treatment and prophylaxis. *Infect Dis Clin North Am*. 2005;19:603–615. PMID16102651.
- 403) Smith PB, Steinbach WJ, **Benjamin DK Jr.** Invasive *Candida* infections in the neonate. *Drug Resist Updat*. 2005;8:147–162. PMID16002326.
- 404) Zaoutis TE, and **Benjamin DK Jr.**, Steinbach WJ. Antifungal treatment in pediatric patients. *Drug Resist Updat* 2005;8:235-245 PMID16054422.
- 405) Steinbach WJ, **Benjamin DK Jr.** New antifungal agents under development in children and neonates. *Curr Opin Infect Dis*. 2005;18:484–489. PMID16258320.
- 406) **Benjamin DK Jr.**, Stoll BJ. Infection in later preterm infants. *Clin Perinatol*. 2006;33:871–882. PMID17148010.
- 407) Tiffany KF, Smith PB, **Benjamin DK Jr.** Neonatal candidiasis: prophylaxis and treatment. *Expert Opin Pharmacother*. 2005;6:1647–1655. PMID16086651.
- 408) Cohen-Wolkowicz M, **Benjamin DK Jr.**, Steinbach WJ, Smith PB. Anidulafungin: a new echinocandin for the treatment of fungal infections. *Drugs Today*. 2006;42:533–544. PMID16969430.
- 409) Li JS, Smith PB, Califf RM, **Benjamin DK Jr.** Is pediatric exclusivity working? *Ped Health*. 2007;1:43–49.
- 410) **Benjamin DK Jr.** First, do no harm. *Pediatrics*. 2008;121:831–832. PMC2727631.
- 411) Cohen-Wolkowicz M, **Benjamin DK Jr.** Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. *Curr Opin Pediatr*. 2009;21:177–181. Review. PMC3319032.

- 412) Cohen-Wolkowicz M, Moran C, Benjamin DK Jr., Smith PB. Pediatric antifungal agents. *Curr Opin Infect Dis*. 2009;22:553–558. Review. PMC2776826.
- 413) Moran C, Smith PB, Cohen-Wolkowicz M, Benjamin DK Jr. Clinical trial design in neonatal pharmacology: effect of center differences with lessons from the Pediatric Oncology Cooperative Research experience. *Clin Pharmacol Ther*. 2009;86:589–591. PMC2782890.
- 414) Downey LC, Smith PB, Benjamin DK Jr. Risk factors and prevention of late-onset sepsis in premature infants. *Early Hum Dev*. 2010;86 Suppl 1:7–12. Review. PMC2889164.
- 415) Downey LC, Smith PB, Benjamin DK Jr., Cohen-Wolkowicz M. Recent advances in the detection of neonatal candidiasis. *Curr Fungal Infect Rep*. 2010;4:17–22. PMC2864036.
- 416) Smith PB, Benjamin DK Jr. Choosing the right empirical antibiotics for neonates. *Arch Dis Child Fetal Neonatal Ed*. 2011;96:F2–3. PMC2941568.
- 417) Watt K, Li JS, Benjamin DK Jr., Cohen-Wolkowicz M. Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation. *J Cardiovasc Pharmacol*. 2011;58:126–132. PMC3155009.
- 418) Watt K, Benjamin DK Jr., Cohen-Wolkowicz M. Pharmacokinetics of antifungal agents in children. *Early Hum Dev*. 2011;87 Suppl 1:S61–65. PMC3418808.
- 419) Testoni D, Smith PB, Benjamin DK Jr. The use of antifungal therapy in neonatal intensive care. *Clin Perinatol*. 2012;39:83–98. PMC3285432.
- 420) Cohen-Wolkowicz M, Benjamin DK Jr. Fluconazole therapeutic drug monitoring in children with cancer-not today. *Clin Infect Dis*. 2014 Dec 1;59(11):1534-6.
- 421) Greenberg RG, Benjamin DK Jr. Neonatal candidiasis: Diagnosis, prevention, and treatment. *J Infect*. 2014 Nov;69 Suppl 1:S19-22. PMC4252884.
- 422) Offringa M, Davis JM, Turner MA, Ward R, Bax R, Maldonado S, Sinha V, McCune SK, Zajicek A, Benjamin DK Jr, Bucci-Rechtweg C, Nelson RM; Applying Regulatory Science to Develop Safe and Effective Medicines for Neonates: Report of the US Food and Drug Administration First Annual Neonatal Scientific Workshop, October 28-29, 2014; *Special Section on Pediatrics: Analytical Report*

Peer-Reviewed Case Reports and Letters: (trainees underlined)

- 423) Dixon TC, Steinbach WJ, Benjamin DK Jr., Williams LW, Myers LA. Disseminated *Candida tropicalis* in a patient with chronic mucocutaneous candidiasis: a brief report. *South Med J*. 2004;97:788–790. PMID15352680.
- 424) Chu V, Cabell CH, Benjamin DK Jr., Kuniholm EF, Fowler VG Jr., Engemann J, Sexton DJ, Corey GR, Wang A. Early predictors of in-hospital mortality in infective endocarditis. Infective endocarditis: should diabetic patients be treated more aggressively? *Circulation*. 2004;110:e72. PMID15313963.

- 425) Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, **Benjamin DK Jr.**, et al. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. *Clin Infect Dis*. 2006;43:1031–1039. PMID16983616.
- 426) Santos RP, Sanchez PJ, Mejias A, **Benjamin DK Jr.**, Walsh TJ, Patel S, Jafri HS. Successful medical treatment of cutaneous *Aspergillo*sis in a premature infant using liposomal amphotericin B, voriconazole, and micafungin. *Pediatr Infect Dis J*. 2007;26:364–366. PMID17414408.
- 427) Berezny K, Smith PB, **Benjamin DK Jr.** Future of the NICHD Pediatric Trial Network. *e-Journal of Neonatology Research*. 2011;1(2).

Peer-Reviewed Electronic Publications Not Retrievable by Medline Search: (trainees underlined)

- 428) Wratney A, **Benjamin DK Jr.**, Cheifetz I. Critical appraisal of: De Bast Y, De Backer D, Moraine JJ et al. The cuff leak test to predict failure of tracheal extubation for laryngeal edema. *Intensive Care Med*. 2002;28:1267–1272. In *The PedsCCM Evidence-Based Journal Club*, 2004. Available: http://PedsCCM.wustl.edu/EBJ/THERAPY/Smulders-drain_VAP.html.
- 429) Wratney AT, **Benjamin DK Jr.**, Cheifetz IM. Critical appraisal of: Farias JA, Alía I, Retta A, et al. An evaluation of extubation failure predictors in mechanically ventilated infants and children. *Intensive Care Med*. 2002;28:752–757. In *The PedsCCM Evidence-Based Journal Club*, 2005. Available from: <http://PedsCCM.wustl.edu/EBJ>.

Non-Peer Reviewed Publications: (trainees underlined)

- 430) Ko ER, Anstrom KJ, Panettieri RA, Lachiewicz AM, Maillo M, O'Halloran JA, Boucher C, Smith PB, McCarthy MW, Segura Nunez P, Mendivil Tuchia de Tai S, Khan A, Mena Lora AJ, Salathe M, Kedar E, Capo G, Rodríguez Gonzalez D, Patterson TF, Palma C, Ariza H, Patelli Lima M, Blamoun J, Nannini EC, Sprinz E, Mykietiuk A, Wang JP, Parra-Rodriguez L, Der T, Willsey K, **Benjamin DK**, Wen J, Zakrotsky P, Halabi S, Silverstein A, McNulty SE, O'Brien SM, Al-Khalidi HR, Butler S, Atkinson J, Adam SJ, Chang S, Maldonado MA, Proscham M, LaVange L, Bozzette SA, Powderly WG; ACTIV-1 IM study group members. Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19. medRxiv. 2022 Sep 26:2022.09.22.22280247. doi: 10.1101/2022.09.22.22280247. Preprint. PMC9536071
- 431) O'Halloran J, Kedar E, Anstrom KJ, McCarthy MW, Ko ER, Segura Nunez P, Boucher C, Smith PB, Panettieri RA, Mendivil Tuchia de Tai S, Maillo M, Khan A, Mena Lora AJ, Salathe M, Capo G, Rodriguez Gonzalez D, Patterson TF, Palma C, Ariza H, Patelli Lima M, Lachiewicz AM, Blamoun J, Nannini E, Sprinz E, Mykietiuk A, Alicic R, Rauseo AM, Wolfe CR, Wittig B, **Benjamin DK**, McNulty SE, Zakrotsky P, Halabi S, Butler S, Atkinson J, Adam SJ, Melsheimer R, Chang S, LaVange L, Proscham M, Bozzette SA, Powderly WG. Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19. medRxiv. 2022 Sep 26:2022.09.22.22280245. doi: 10.1101/2022.09.22.22280245. Preprint. PMC9516856

Book Chapters: (trainees underlined)

- 432) **Benjamin DK Jr.** Pediatrics chapter. In: *Emergency Medicine Recall*. Lippincott Williams and Wilkins; 2000.

- 433) Cotten M, **Benjamin DK Jr.** Clinical approach to the infected neonate. In: *Pediatric Infectious Disease*. 2008.
- 434) Cotten M, **Benjamin DK Jr.** Necrotizing enterocolitis. In: *Pediatric Infectious Disease*. 2008.
- 435) Li JS, **Benjamin DK Jr.**, Severin T, Portman RJ. Paediatric anti-hypertensive clinical trials and various factors influencing trial success or failure. In: *Guide to Paediatric Drug Development and Clinical Research*. 2010.
- 436) **Benjamin DK Jr.** Principles of antifungal therapy. In: *Nelson Textbook of Pediatrics*, 19th edition, online. 2011.
- 437) Smith PB, **Benjamin DK Jr.** Clinical approach to the infected neonate. In: *Infectious Diseases of the Fetus and Newborn Infants*. Remington & Klein; 2011.
- 438) Cohen-Wolkowicz M, Steinbach WJ, **Benjamin DK Jr.** Antifungal agents. In: *Neonatal and Pediatric Pharmacology*. 2011.
- 439) Smith PB, **Benjamin DK Jr.** Neonatal-Perinatal Infections: An Update. *Clinics in Perinatology*. 2015.
- 440) Ericson JE, **Benjamin DK Jr.** Clinical Approach to the Infected Neonate. *Principles and Practice of Pediatric Infectious Diseases*. 2016
- 441) Ericson JE, **Benjamin DK Jr.** Candida. *Nelson Textbook of Pediatrics*. 2019
- 442) Greenberg RG, **Benjamin DK Jr.** Infants: Yeasts are beasts early in life. *Antifungal Therapy*, 2nd edition. 2019.
- 443) Ericson JE, **Benjamin DK Jr.** Candida. *Nelson Textbook of Pediatrics*. 2023

Selected Abstracts: (trainees underlined)

- 444) **Benjamin DK Jr.**, Ross K, Benjamin DK, McKinney RE Jr., Auten R, Fisher RG. When to suspect fungal infections in neonates: a clinical comparison of *Candida albicans* and *Candida parapsilosis* fungemia with coagulase-negative staphylococcal bacteremia (IDSA 1999).
- 445) **Benjamin DK Jr.**, Miller W, Garges H, Benjamin DK, McKinney RE Jr, Cotten M, Fisher RG, Alexander K. Bacteremia, central catheters, and neonates: when to pull the line (IDSA 2000).
- 446) Calland JF, Guerlain S, **Benjamin DK Jr.**, Foley S, Owen S, Adams RB. Opinions of Virginia surgeons and primary care physicians toward issues of patient safety (Southeastern Surgical Congress, 2001).
- 447) Steinbach WJ, Sectish TC, **Benjamin, DK Jr.**, Chang KW, Messner A. Pediatric residents' clinical diagnostic accuracy of otitis media and a proposal for improved resident education and competency (American Academy of Pediatrics 2001).

- 448) Dyke C, **Benjamin DK Jr.**, Nelson C, Oshea C, Cantor W, Newby K, Tcheng J. Elevated troponin following elective percutaneous coronary intervention predicts long term outcomes: Results from the ESPRIT Trial (AHA 2001).
- 449) Calland JF, **Benjamin DK Jr.**, Seward C, Adams RB. Standardization of family history data collection by surgeons in an academic medical center (The Association of Academic Surgeons Poster Session, 2011).
- 450) **Benjamin DK Jr.** Clinical predictive model for neonatal candidemia (Focus on Fungal Infections 12, 2002).
- 451) Chu V, **Benjamin DK Jr.**, Cabell C, et al. Early predictors of mortality in patients with endocarditis: the importance of severity of illness (American College of Cardiology, 2002).
- 452) **Benjamin DK Jr.**, DeLong ER, Steinbach WJ, Cotten CM, Clark R. Clinical predictive modeling in children (Focus on Fungal Infections 13, 2003).
- 453) Steinbach WJ, Perfect JR, Corey GR, Li JS, **Benjamin DK Jr.** Medical management with combination antifungal therapy for *Candida* endocarditis (Focus on Fungal Infections 13, 2003).
- 454) Drew RH, Duane RD, Palmer SM, **Benjamin DK Jr.**, Perfect JR. Comparative safety of aerosolized treatments of amphotericin B lipid complex and amphotericin B deoxycholate as antifungal prophylaxis in lung transplant recipients: a randomized, double-blind study (Focus on Fungal Infections 13, 2003).
- 455) **Benjamin DK Jr.**, DeLong ER PhD, Steinbach WJ, Cotten CM, Walsh TJ, and Clark R. Empirical Therapy for Neonatal Candidemia in Very Low Birth Weight Infants (Society for Pediatric Research, 2003)
- 456) **Benjamin DK Jr.**, Miller WC, Benjamin DK, Ryder RW, Weber DJ, Walter E, McKinney RE Jr. A comparison of height and weight velocity to predict laboratory and clinical progression in pediatric HIV (Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003).
- 457) **Benjamin DK Jr.**, DeLong ER, CM Cotten, Clark RH. Mortality in premature infants with gram-negative rod bacteremia (Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003).
- 458) Miller JL, Schell WA, Wills E, Toffaletti D, Boyce M, Bartroli J, **Benjamin DK Jr.**, Perfect JR. In vitro and in vivo efficacy of the new triazole albaconazole (UR-9825) against *Cryptococcus neoformans* (Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003).
- 459) Steinbach WJ, **Benjamin DK Jr.**, Perfect JR, Kontoyiannis DA, Lutsar I, Marr KA, Jafri H, Walsh TJ. Treatment and outcomes of invasive *Aspergillus terreus*: review of in vitro analyses, animal models, clinical case reports, and 87 retrospective multi-center cases (Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003).
- 460) Cunnion KM, **Benjamin DK Jr.**, Hester CG, Frank MM. Complement receptor 1 (CD35) and C3 influence murine survival of *Staphylococcus aureus* bacteremia (IDSA, 2003).

- 461) Weintrob AC, Hamilton JD, Hahn C, Klinzman D, Moyo G, Zdunek D, Hess G, **Benjamin DK Jr.**, Stapleton JT. Active or prior GB virus C infection does not protect against vertical transmission of HIV in co-infected women from Tanzania (IDSA, 2003).
- 462) **Benjamin DK Jr.**, DeLong ER, Cotten MC, Garges HP, Clark RH. Increased mortality in premature infants with gram-negative rod bacteremia and candidemia (Pediatric Research Supplement, April 2004, publication number 2291).
- 463) Tiffany K, **Benjamin DK Jr.**, O'Donnell K, Gutman L. Improved neuro-developmental outcomes following long-term suppressive oral acyclovir in infants with disseminated/encephalitic herpes simplex disease (Pediatric Academic Society, 2004).
- 464) El-Ahdab F, **Benjamin DK Jr.**, Wang W, Corey GR, Sexton DJ, Cabell CH, Reller LB, Fowler VG. The risk of prosthetic valve endocarditis (PVE) in patients with *Staphylococcus aureus* bacteremia (American College of Cardiology, 2004).
- 465) **Benjamin DK Jr.**, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins R, Duara S, Poole K, Laptook A, Goldberg R. Neonatal candidiasis among infants < 1000 g birth weight: risk factors, mortality, and neuro-developmental outcomes at 18–22 months (Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004).
- 466) **Benjamin DK Jr.**, Driscoll T, Siebel NL, Gonzalez CE, Roden MM, Dowell JA, Schranz J, Walsh TJ. Safety and pharmacokinetics of anidulafungin in pediatric patients with neutropenia. (Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004).
- 467) Fowler VG Jr., Justice A, Moore C, **Benjamin DK Jr.**, Woods CW, Reller LB, Corey RG, Day NPJ, Peacock SJ. Risk factors for hematogenous complications of intravascular catheter-associated *Staphylococcus aureus* bacteremia (Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004).
- 468) Murdoch D, Chambers S, Marco F, Woods C, Wray D, Cecchi E, Bouza E, Pappas P, Hannan M, Vinogradova T, Corey R, Harkness J, Maria CG, **Benjamin DK Jr.**, Cabell C, for the ICE Investigators: Epidemiology, clinical presentation and in-hospital outcome of patients with infective endocarditis caused by HACEK group bacteria (International Society of Cardiovascular Infectious Diseases, 2005).
- 469) **Benjamin DK Jr.**, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins R, Duara S, Poole K, Laptook A, Goldberg R. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality, and neuro-developmental outcomes (Society for Pediatric Research, 2005).
- 470) **Benjamin DK Jr.**, Schelonka R, White R, Holley P, Bifano E, Cummings J, LeBlanc M, Kaufman D, White J, Cotten CM. A blinded, randomized, multicenter study to assess the safety of an intravenous *Staphylococcus aureus* immune globulin (human) [altastaph] in very-low-birth-weight neonates (Society for Pediatric Research, 2005).
- 471) **Benjamin DK Jr.**, Driscoll T, Siebel NL, Gonzalez CE, Roden MM, Dowell JA, Schranz J, Walsh TJ. Safety and pharmacokinetics of anidulafungin in pediatrics (Society for Pediatric Research, 2005).

- 472) Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, **Benjamin DK Jr.** Center differences in candidemia among extremely low birth weight (ELBW) infants: influence of antibiotic practices (Society for Pediatric Research, 2005).
- 473) Garges HP, Reller LB, Cotten CM, **Benjamin DK Jr.** Neonatal ventilator-associated pneumonia: are respiratory cultures useful? (Society for Pediatric Research, 2005).
- 474) Garges HP, Moody MA, Cotten CM, Smith PB, Tiffany K, Lenfestey R, Li J, **Benjamin DK Jr.** Diagnosis of neonatal meningitis: the lumbar puncture, the blood culture, and CSF parameters (Society for Pediatric Research, 2005).
- 475) Stryjewski M, Szczech L, **Benjamin DK Jr.**, Inrig J, Kanafani Z, Engemann J, Chu V, Reller L, Corey R, Fowler V. Clinical outcomes in hemodialysis-dependent patients with methicillin-susceptible *Staphylococcus aureus* (MSSA) bacteremia treated with vancomycin or first generation cephalosporins (ICAAC, 2005).
- 476) Kanafani ZA, Chu VH, Stryjewski ME, Pappas PA, Drew LA, **Benjamin DK Jr.**, Reller LB, Corey GR, Lee BA, Fowler VG Jr. Risk factors for healthcare-associated bacteremia among febrile patients undergoing blood cultures (ICAAC, 2005).
- 477) Smith PB, **Benjamin DK Jr.**, Alexander BA, Johnson MD, Steinbach WJ. 1→3 Beta-D glucan levels in healthy pediatric patients (Society for Pediatric Research, 2006).
- 478) Smith PB, Benjamin DK, Morgan J, Fridkin SK, Sanza LT, Harrison LH, Sofair AN, Huie-White S, **Benjamin DK Jr.** Increased costs associated with candidiasis in neonates (Society for Pediatric Research, 2006).
- 479) Smith PB, Schell WA, Johnson MD, Alexander BD, **Benjamin DK Jr.**, Perfect JR, Mitchell TG. Detection of *Candida albicans* and *Candida parapsilosis* DNA in blood by real-time PCR (American Society for Microbiology, 2006).
- 480) Johnson OO, **Benjamin DK Jr.**, Schimana W, Benjamin DK, Landman KZ Tillekeratne LG, Crump JA, Kinabo GD, Swai ME, Mmbaga BT, Msuya LJ, Cunningham CK. Absolute lymphocyte count and WHO pediatric clinical stage as markers to assess need to initiate antiretroviral therapy among HIV-infected children in Northern Tanzania (Abstract MoPe0100, XVI International AIDS Conference, Toronto, Canada, August 13–18, 2006).
- 481) Sánchez PJ, Cotten CM, Taylor S, Salhab WA, Heyne RJ, Goldberg RN, Stoll BJ, **Benjamin DK Jr.** Antimicrobial therapy for necrotizing enterocolitis (NEC): practice variations and clinical outcome (Society for Pediatric Research, 2006).
- 482) Smith PB, Garges HP, Cotten CM, Walsh TJ, Clark RH, **Benjamin DK Jr.** Meningitis in preterm neonates: importance of cerebrospinal fluid parameters (Society for Pediatric Research, 2007).
- 483) Cotten CM, Taylor S, Stoll B, Sanchez P, Ambalavanan N, Goldberg RN, Hansen N, Poole K, **Benjamin DK Jr.** for the NICHD Neonatal Research Network. Duration of initial antibiotic course in extremely low birth weight infants: association with necrotizing enterocolitis and death (Society for Pediatric Research, 2007).

- 484) Schultz ED, Smith PB, Dang CN, Wilfret DA, Kaye K, **Benjamin DK Jr.**, Goldberg RN. Use of mupirocin and chlorhexidine in the treatment of methicillin-resistant *Staphylococcus aureus* colonization in the neonatal intensive care unit (Society for Pediatric Research, 2007).
- 485) Ansong AK, Smith PB, Benjamin DK, Clark RH, Li JS, Cotten MC, Mangum B, Garges HP, **Benjamin DK Jr.** Group B streptococcal meningitis: cerebrospinal fluid parameters in the era of intrapartum antibiotic prophylaxis (Society for Pediatric Research, 2007).
- 486) Nowell L, Smith PB, Seed P, Alexander BD, Cotten CM, **Benjamin DK Jr.** Renal imaging following urinary tract infections among hospitalized infants (Society for Pediatric Research, 2007).
- 487) Smith PB, Walsh TJ, Hope W, Sawamoto T, Kearns GL, Kaufman D, Keirns JJ, Buell DN, **Benjamin DK Jr.** Pharmacokinetics of micafungin in premature neonates (ICAAC, 2007).
- 488) **Benjamin DK Jr.**, Stoll BJ, Goldberg R, Walsh TJ for the NICHD Neonatal Research Network. Neonatal candidiasis: epidemiology, clinical judgment, and outcomes (Society for Pediatric Research, 2008).
- 489) Greenberg R, Smith PB, Clark R, **Benjamin DK Jr.** Traumatic lumbar punctures in young infants: test performance of CSF parameters (Society for Pediatric Research, 2008).
- 490) Schultz ED, Tanaka DT, Goldberg RN, **Benjamin DK Jr.**, Smith PB. Methicillin-resistant *Staphylococcus aureus* colonization increases total hospital costs and prevents new admissions to the neonatal intensive care unit (Society for Pediatric Research, 2008).
- 491) Cohen-Wolkowicz M, Smith PB, Benjamin DK, Cotten CM, Clark RH, **Benjamin DK Jr.** Early onset sepsis in premature and term infants (Society for Pediatric Research, 2008).
- 492) Smith PB, Cohen-Wolkowicz M, Benjamin DK, Cotten CM, Clark RH, **Benjamin DK Jr.** Late onset sepsis in the neonatal intensive care unit (Society for Pediatric Research, 2008).
- 493) Wade KC, Wu D, Kaufman DA, Ward RM, **Benjamin DK Jr.**, Hoppu K, Adamson PI, Gastonguay M, Barrett JS, on behalf of the NICHD Pediatric Pharmacology Research Unit Network. Population pharmacokinetics of fluconazole in young Infants (Society for Pediatric Research, 2008).
- 494) Wade K, **Benjamin DK Jr.**, on behalf of the NICHD Pediatric Pharmacology Research Unit Network. Novel opportunistic trial design to facilitate phase 1 pharmacokinetic drug studies in neonates (Society for Pediatric Research, 2008).
- 495) Petraitiene R, Petraitis V, Hope WW, Mickiene D, Kelaher AM, Murray HA, Mya-San C, Hughes JE, Cotten MC, Bacher J, **Benjamin DK Jr.**, Walsh TJ. (1→3)- β -D-glucan in cerebrospinal fluid is a surrogate marker for detection and therapeutic response of hematogenous *Candida* meningoenzephalitis. (Immunocompromised Host Society Meeting, 2008).
- 496) **Benjamin DK Jr.**, Smith PB, Arrieta A, Castro L, Sanchez P, Kaufman D, Arnold L, Kovanda L, Sawamoto T, Buell DN, Hope WW, Walsh TJ. Safety and pharmacokinetics (PK) of repeat-dose micafungin (MICA) in neonates (ICAAC, 2008).

- 497) Grussemeyer CA, Moran C, Spalding JR, **Benjamin DK Jr.**, Reed SD. Bloodstream infection with *C. Albicans* and non-*albicans* associated with high economic and mortality burden among children and adults (ICAAC, 2008).
- 498) Piper L, Smith PB, Cotten CM, Clark RH, Cohen-Wolkowicz M, **Benjamin DK Jr.** Blood stream infections in young infants with congenital heart disease (Society for Pediatric Research, 2009).
- 499) Greenberg RG, Moran C, Ulshen M, Smith PB, **Benjamin DK Jr.**, Cohen-Wolkowicz M. Outcomes of catheter-associated infections in pediatric patients with short bowel syndrome (Society for Pediatric Research, 2009).
- 500) **Benjamin DK Jr.**, Smith PB, Arrieta A, Castro L, Sanchez PJ, Kaufman D, Arnold LJ, Kovanda LL, Sawamoto T, Buell DN, Hope WW, Walsh TJ. Safety and pharmacokinetics of repeat-dose micafungin in neonates and young infants (Society for Pediatric Research, 2009).
- 501) Smith PB, Capparelli EV, Castro LM, Valencia G, Bidegain M, Schelonka R, Finer N, van den Anker J, MacKendrick W, Arrieta A, Ward R, Bhatt-Mehta V, Cohen-Wolkowicz M, Wade KC, Blumer JL, Hope W, Kearns GL, **Benjamin DK Jr.** on behalf of the Meropenem Study Team. Pharmacokinetics and safety of meropenem in young infants with intra-abdominal infections (Society for Pediatric Research, 2009).
- 502) Valdez JM, Petraitiene R, Lizak MJ, Klaunberg B, Ikonomidou V, Greene L, Aghamolla T, Pyrgos V, Stergiopoulou T, **Benjamin DK Jr.**, Walsh TJ, Petraitis V. Enhanced detection of experimental hematogenous *Candida* meningoenophalitis (HCME) by magnetic resonance imaging (MRI) (ICAAC, 2009).
- 503) Pyrgos V, Petraitis V, Petraitiene R, Mickiene D, Cotten M, Greene L, Aghamolla T, Valdez J, Mocanu M, Brundant N, Donoghue M, **Benjamin DK Jr.**, Hardwick M, Shoham S, Walsh TJ. Permeability of the blood brain barrier (BBB) to amphotericin B (AMB) is focally increased in experimental hematogenous *Candida* meningoenophalitis (ICAAC, 2009).
- 504) Cohen-Wolkowicz M, Smith PB, Piper L, Moran C, Liu P, Kashuba A, Capparelli E, Walsh TJ, Hope WW, **Benjamin DK Jr.** Safety and pharmacokinetics of multiple-dose anidulafungin in infants (ICAAC, 2009).
- 505) Hope WW, Smith PB, Buell DN, Roy M, Walsh TJ, Cohen-Wolkowicz M, **Benjamin DK Jr.** Population pharmacokinetics of micafungin in neonates and young infants (ICAAC, 2009).
- 506) Yanni SB, Augustijns P, **Benjamin DK Jr.**, Thakker DR, Annaert PP. In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats. (International Society for the Study of Xenobiotics, 2009, Baltimore, MD).
- 507) Adams-Chapman I, Bann CM, Stoll BJ, Walsh M, Sanchez P, Higgins R, Shankaran S, Watterburg K, Goldberg RN, **Benjamin DK Jr.** for the NICHD Neonatal Research Network. Neurodevelopmental outcome of ELBW infants with *Candida* infection. (Society for Pediatric Research, Vancouver, 2010).
- 508) Greenberg RG, Gantz M, Smith PB, Cotten CM, **Benjamin DK Jr.**, on behalf of the *Candida* Subcommittee for the NICHD Neonatal Research Network. Outcomes of empirical antifungal

therapy in extremely low birth weight infants (Society for Pediatric Research, Vancouver, 2010).

- 509) Jean-Baptiste N, Cohen-Wolkowicz M, Smith PB, Clark RH, **Benjamin DK Jr.** Coagulase negative *Staphylococcus* sepsis in the neonatal intensive care unit (Society for Pediatric Research, Vancouver, 2010).
- 510) Joseph M, Bliss JM, Wong AY, Bhak G, Laforce-Nesbitt SS, Taylor S, **Benjamin DK Jr.** on behalf of the *Candida* subcommittee for the NICHD Neonatal Research Network. *Candida parapsilosis* virulence properties and adverse clinical outcomes in neonatal candidiasis (Society for Pediatric Research, Vancouver, 2010).
- 511) Piper L, Smith PB, Hornik CP, Cheifetz IM, Barret JS, Moorthy G, Wade KC, **Benjamin DK Jr.** Fluconazole loading dose pharmacokinetics and safety in infants (Society for Pediatric Research, Vancouver, 2010).
- 512) Downey LC, **Benjamin DK Jr.**, Clark RH, Cohen-Wolkowicz M, Smith PB. Urinary tract infection concordance with blood and cerebrospinal fluid cultures in the neonatal intensive care unit (Society for Pediatric Research, Vancouver, 2010).
- 513) Bauserman MS, Laughon MM, Smith PB, **Benjamin DK Jr.**, Clark RH, Engmann C, Cohen-Wolkowicz M. Epidemiology of group B *Streptococcus* and *Escherichia coli* infections in infants in the era of intrapartum antibiotic prophylaxis (Society for Pediatric Research, Vancouver, 2010).
- 514) Wynn JL, **Benjamin DK Jr.**, Cohen-Wolkowicz M, Piper L, Moran C, Clark RH, Smith PB. Very late onset bacteremia in the neonatal intensive care unit (Society for Pediatric Research, Vancouver, 2010).
- 515) Smith PB, Capparelli EV, Castro LM, Poindexter B, Valencia G, Bidegain M, Schelonka R, Weitkamp JH, van den Anker J, Ward R, Walsh M, Burchfield D, Arrieta A, Bhatt-Mehta V, Cohen-Wolkowicz M, Wade KC, Blumer JL, Kearns GL, **Benjamin DK Jr.** on behalf of the Meropenem Study Team. Pharmacokinetics and safety of meropenem in young infants with intra-abdominal infections (Society for Pediatric Research, Vancouver, 2010).
- 516) Moran C, Cohen-Wolkowicz M, Smith PB, Lott KL, Downey LC, Piper L, **Benjamin DK Jr.**, Grant GA. Ventricular fluid pharmacokinetics of vancomycin and validation of CSF scavenge sampling techniques in children (50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 2010).
- 517) Cohen-Wolkowicz M, **Benjamin DK Jr.**, Piper L, Moran C, Liu P, Aram J, Kashuba A, Capparelli E, Walsh TJ, Hope WW, Smith PB. Safety and pharmacokinetics (PK) of multiple-dose anidulafungin in neonates (50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 2010).
- 518) Wynn JL, Tan S, **Benjamin DK Jr.**, and the Neonatal Research Network (NRN) *Candida* Subcommittee. Outcomes following candiduria in extremely low birth weight infants (2011 Pediatric Academic Societies' & Asian Society for Pediatric Research Joint Meeting, April 30–May 3, 2011, Denver, CO).

- 519) Sood BG, Shankaran S, Schelonka RL, Saha S, Benjamin DK Jr, Sánchez PJ, Adams-Chapman I, Stoll BJ, Thorsen P, Skogstrand K, Ehrenkranz RA, Hougaard DM, Goldberg RN, Tyson JE, Das A, Higgins RD, Carlo WA. Cytokine profiles of preterm neonates with fungal and bacterial sepsis (2011 Pediatric Academic Societies' & Asian Society for Pediatric Research Joint Meeting, April 30–May 3, 2011, Denver, CO).
- 520) Doby, B, **Benjamin DK Jr.**, Blaschke AJ, Ward RM, Pavia AT, Cohen-Wolkowicz M, Moran C. Voriconazole pharmacokinetics in children less than 3 years of age (2011 Pediatric Academic Societies' & Asian Society for Pediatric Research Joint Meeting, April 30–May 3, 2011, Denver, CO).
- 521) Aliaga S, Smith PB, Clark R, Cohen-Wolkowicz M, Wade K, Massie SE, Tolleson-Rinehart, **Benjamin DK Jr.**, Laughon M. Assessment of off-label prescribing practices of meropenem in young infants (Society for Pediatric Research, Denver, CO, 2011).
- 522) Smith PB, Cohen-Wolkowicz M, Watt K, **Benjamin DK Jr.** Pharmacokinetics and safety of daptomycin in young infants (Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011).
- 523) Watt KM, **Benjamin DK Jr.**, Cheifetz IM, Moorthy G, Wade KC, Smith PB, Kashuba A, Brouwer K, Capparelli E, Cohen-Wolkowicz M. Pharmacokinetics (PK) of fluconazole in infants supported with extracorporeal membrane oxygenation (ECMO) (Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011)
- 524) Hornik CP, Benjamin DK, Becker KC, **Benjamin DK Jr.**, Li J, Clark RH, Cohen-Wolkowicz M, Smith PB. Diagnosis of early-onset neonatal sepsis using the complete blood cell count (2012 Pediatric Academic Societies' Annual Meeting, Boston, MA).
- 525) Perez KM, Chantala K, Herring AH, Smith PB, Clark RH, **Benjamin DK Jr.**, Cohen-Wolkowicz M, Laughon M. Sildenafil exposure in the neonatal intensive care unit (2012 Pediatric Academic Societies' Annual Meeting, Boston, MA).
- 526) Ascher SB, **Benjamin DK Jr.**, Cotten CM, Hornik CP, Cohen-Wolkowicz M, Clark RH, Smith PB. Safety of acyclovir in hospitalized infants (2012 Pediatric Academic Societies' Annual Meeting, Boston, MA).
- 527) Aliaga S, Clark RH, Laughon M, Benjamin DK, **Benjamin DK Jr.**, Smith PB. Decreasing incidence of neonatal invasive candidiasis (2012 Pediatric Academic Societies' Annual Meeting, Boston, MA).
- 528) Camelo Castillo W, Boggess K, Tils Sturmer T, Brookhart A, **Benjamin DK Jr**, Jonsson-Funk M Glyburide Versus Insulin for Treatment of Gestational Diabetes (GDM): Neonatal Outcomes with Practical Experience in a Large Cohort, 34th Annual Society of Maternal-Fetal Medicine Meeting 2014, New Orleans, LA
- 529) Gonzalez D, Melloni C, Yogev R, Watt KM, Poindexter B, Mendley S, Delmore P, Autmizguine J, Lewandowski A, Harper B, Capparelli EV, **Benjamin DK Jr**, Cohen-Wolkowicz M, Best Pharmaceuticals for Children Act-Pediatric Trials Network. Developmental pharmacokinetics of clindamycin from premature infants to adolescents. *Clin Pharmacol Ther*, Late-Breaking Abstract ID #743 (American Society for Clinical Pharmacology and Therapeutics 2014 Annual Meeting, Atlanta, GA).

- 530) Hornik CP, **Benjamin DK Jr**, Clark RH, Capparelli EV, Le J, Tremoulet A, Cohen-Wolkowicz M, and Smith PB, Ampicillin Exposure and Odds of Seizures in a Large Cohort of Hospitalized Neonates, Society for Pediatric Research, Vancouver, Canada, May 2014.
- 531) Gostelow M, Tripathi N, **Benjamin DK Jr**, Hornik C, Cohen-Wolkowicz M, Clark RH, Laughon MM, and Smith PB, Evaluation of the Best Pharmaceuticals for Children Act Priority List: Are Drug Priorities Reflective of Clinical Need in Premature Infants?, Society for Pediatric Research, Vancouver, Canada, May 2014. (accepted as platform).
- 532) Gonzalez D, Palazzi D, Bhattacharya-Mithal L, Al-Uzri A, James L, Bradley J, Neu N, Jasion T, Hornik C, Smith PB, **Benjamin DK Jr.**, Rosiak C, Oh R, Keedy K, Fernandes P, Cohen-Wolkowicz M. Solithromycin concentrations measured in dried blood spots collected from adolescents. Accepted for poster presentation at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting, Clin Pharmacol Ther., Late-Breaking Abstract ID #963, New Orleans, LA.
- 533) Ericson JE, Popoola VO, Smith PB, Benjamin DK, **Benjamin DK Jr**, Clark RH, Milstone AM. Methicillin sensitive *Staphylococcus aureus* is more common in infants than methicillin resistant *Staphylococcus aureus*. Poster Session, *St Jude/Pediatric Infectious Disease Society Research Conference*. Memphis, Tennessee. 2015 February 20.
- 534) Gonzalez D, Palazzi D, Bhattacharya-Mithal L, Al-Uzri A, James L, Bradley J, Neu N, Jasion T, **Benjamin DK Jr.**, Rosiak C, Oh R, Keedy K, Fernandes P, Cohen-Wolkowicz M. Pharmacokinetics and Safety of Solithromycin in Adolescents with Suspected or Confirmed Bacterial Infection. Accepted for poster presentation at the Pediatric Academic Societies 2015 Annual Meeting, Publication # 1545.340, San Diego, CA, April 2015.
- 535) Ericson JE, Gostelow M, Autmizguine J, Clark RH, **Benjamin DK Jr**, Hornik CP, and Smith PB on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee, Safety of Acyclovir in Infants with HSV in the Era of High-dose Therapy, Pediatric Academic Societies, San Diego, CA, April 2015.
- 536) Momper JD, Capparelli EV, Wade KC, Natarajan G, Gao J, Laughon M, Smith PB, **Benjamin DK Jr**, Population Pharmacokinetics of Fluconazole in Extremely Low Birth Weight Infants, Pediatric Academic Societies, San Diego, CA, April 2015.
- 537) Kelly MS, Wynn J, Benjamin DK, Clark RH, **Benjamin DK Jr.**, and Smith PB, Timing of cardiorespiratory deterioration preceding death among infants with sepsis, Pediatric Academic Societies, San Diego, CA, April 2015.
- 538) **Benjamin DK, Jr.**, WW Hope, D Kaufman, PB Smith, A Arietta, P Manzoni, C Lademacher, L Kovanda, C. Wu, B Isaacson, D Jednachowski, T Walsh, Micafungin (MICA) versus Conventional Amphotericin B (CAB) in the Treatment of Invasive Candidiasis (IC) in Infants. The American Society for Microbiology (ASM) and the International Society of Chemotherapy (ISC) for the joint ICAAC/ICC Meeting, San Diego, CA, September 2015.
- 539) England M, Greenberg RG, Clark RH, Laughon M, Cohen-Wolkowicz M, **Benjamin DK Jr**, Smith PB; on behalf of the Administrative Core Committee of the Best Pharmaceuticals for Children Act – Pediatric Trials Network, Dosing of Antimicrobials in the Neonatal Intensive Care Unit: Does Clinical Practice Reflect Published Recommendations? Pediatric Academic Societies, Baltimore, MD, May 2016.

- 540) Greenberg RG, Wu H, Laughon M, Capparelli E, **Benjamin DK Jr**, Smith PB, Cohen-Wolkowicz M, Population Pharmacokinetics (PK) of Dexmedetomidine in Infants, Pediatric Academic Societies, Baltimore, MD, May 2016.
- 541) Bradley J, **Benjamin DK Jr**, Corneli A, Gamel B, Noel G, Thaden J and Roberts JN, Pediatric Trials in Antibacterial Drug Development: Findings from the Clinical Trials Transformation Project, Pediatric Academic Societies, Baltimore, MD, May 2016.
- 542) Dallefeld SH, Smith PB, Crenshaw EG, Daniel KR, Gilleskie ML, Smith DS, Greenberg RG, Chu V, Clark RH, Hornik CP, Zimmerman KO, Safety of chloral hydrate in hospitalized infants, Pediatric Academic Societies, San Francisco, CA, May 2017.
- 543) Dumitrescu MP, Smith PB, **Benjamin DK Jr.**, Greenberg R, Abuzaid N, Andrews W, Chellani K, Gupta A, Price D, Williams C, Clark R, Zimmerman K, Impact of gastrostomy tube placement on weight gain in hospitalized premature infants, Pediatric Academic Societies, San Francisco, CA, May 2017.
- 544) Liken H, Weitkamp JH, Cantey J, Wade K, Sanchez PJ, Smith PB, **Benjamin DK Jr**, Ericson J, Kaufman D. Antifungal Prophylaxis in the NICU: A Survey of Prophylaxis Use and Influencing Factors, Pediatric Academic Societies, San Francisco, CA, May 2017.
- 545) Jafri H, Noel G, **Benjamin DK**, Bradley J, Smith PB, Farley J, Nambiar S New Recommendations to Enhance Pediatric Trials in Antibacterial Drug Development from the Clinical Trials Transformation Initiative (CTTI), 35th Annual Meeting of European Society for Pediatric Infectious Diseases (ESPID 2017), Madrid, Spain, May 2017.
- 546) Hwang MF, Beechinor RJ, Wade KC, **Benjamin DK Jr.**, Smith PB, Hornik CP, Duara S, Kennedy KA, Cohen-Wolkowicz M, and Gonzalez D. External Validation of Two Fluconazole Infant Population Pharmacokinetic Models. 2017 American College of Clinical Pharmacology Annual Meeting, San Diego, CA, September, 2017.
- 547) Smith PB, Bloom D, Bradley J, Gamel B, Greenberg R, Noel G, Tiernan R, Wheeler C, **Benjamin DK Jr.** Obstacles to Pediatric Clinical Trial Enrollment: Why Parents Refuse; Findings from the Clinical Trials Transformation Initiative. September 2017 (accepted as a platform).
- 548) Gerhart JG, Watt KM, Edginton A, Wade KC, **Benjamin DK Jr.**, Smith PB, Hornik CP, Cohen-Wolkowicz M, Duara S, Ross AS, Shattuck K, Stewart DL, Neu N, Gonzalez D. Physiologically-based pharmacokinetic (PBPK) modeling of fluconazole using plasma and cerebrospinal fluid (CSF) samples collected from preterm and term infants. Accepted for poster presentation at the 2018 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting in Orlando, Florida on March 21, 2018.
- 549) Smith M, Autmizguine J, Hudak ML, Zinkhan EK, Bloom B, Heresi G, Lavery A, Courtney SE, Sokol G, Cotten CM, Bliss JM, Mendley S, Bendel CM, Damman C, Weitkamp JH, Saxonhouse MA, Mundakel G, Debski J, Lewandowski A, Erinjeri J, Gao J, **Benjamin D**, Hornik CP, Smith PB, Cohen-Wolkowicz M. Antibiotic Safety and Efficacy in Infants with Complicated Intra-Abdominal Infections (cIAls). Accepted into the "Top Abstracts in Pediatric Infectious Diseases" oral abstract session on May 7, 2018.
- 550) Smith M, Autmizguine J, Hudak ML, Zinkhan EK, Bloom B, Heresi G, Lavery A, Courtney SE, Sokol G, Cotten CM, Bliss JM, Mendley S, Bendel CM, Damman C, Weitkamp JH,

Saxonhouse MA, Mundakel G, Debski J, Lewandowski A, Erinjeri J, Gao J, **Benjamin D**, Hornik CP, Smith PB, Cohen-Wolkowicz M. Antibiotic Safety and Efficacy in Infants with Complicated Intra-Abdominal Infections (cIAIs). Accepted into the “Top Abstracts in Pediatric Infectious Diseases” oral abstract session on May 7, 2018 (accepted as a platform).

- 551) Ericson JE, **Benjamin DK Jr**, Boakye-Agyeman F, Adler-Shohet FC, Laughon M, Poindexter B, Zhao J, Payne EH, Kaneshige K, Martinez B, Smith PB on behalf of the Pediatric Trials Network. Dosing-Safety Relationship for Acyclovir in the Treatment of Neonatal Herpes Simplex Virus Disease. Accepted for poster presentation at the 2018 Pediatric Academic Societies meeting in May 2018.
- 552) Ericson JE, Bradley JS, McGuire J, Michaels MG, Schwarz A, Frenck R, Deville JG, Agarwal S, Bressler A, Gao J, Spears T, **Benjamin DK Jr**, Smith PB on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network and the Clinical Trials Transformation Initiative. Hospital Associated and Ventilator Acquired Bacterial Pneumonia in Infants and Children. Accepted for poster presentation at the 2018 Pediatric Academic Societies meeting in May 2018.
- 553) Dorismond C, Hunter S, McNaull P, Zimmerman KO, **Benjamin DK Jr**, Greenberg RG, Laughon M, Jackson W. Wide Variability in Perioperative Drugs Used in Inguinal Hernia Repairs. Accepted for poster presentation at the 2019 Pediatric Academic Societies meetings in April 2019.
- 554) Hunter S, Dorismond C, McNaull P, Zimmerman KO, **Benjamin DK Jr**, Greenberg RG, Laughon M, Jackson W. Perioperative doses of anesthetic drugs and neurodevelopmental Impairment in premature infants. Accepted for poster presentation at the 2019 Pediatric Academic Societies meetings in April 2019.
- 555) Stark A, England M, Clark R, Laughon M, Cohen-Wolkowicz M, Childers J, **Benjamin DK Jr**, Smith PB, Greenberg RG. Dosing of Antimicrobials in the Neonatal Intensive Care Unit: Does Clinical practice Reflect Published Recommendations? An Update. Accepted for poster presentation at the 2019 Pediatric Academic Societies meetings in April 2019.
- 556) Smith M, Laughon M, Hudak M, Zinkhan E, Bloom B, Heresi G, Lavery A, Courtney SE, Sokol G, Hornik CD, Gowan E, Chaaban H, Downey L, Dammann C, Weitkamp H, Gao J, **Benjamin DK Jr**, Hornik C, Smith PB, Cohen-Wolkowicz M. Neurodevelopmental Outcomes of Premature Infants with Complicated Intra-abdominal Infections. Accepted for poster presentation at the 2019 Pediatric Academic Societies meetings in April 2019.
- 557) Gelfand A, Kessel S, Pezzuto T, Szperka C, Hornik C, Cohen-Wolkowicz M, Hammett A, **Benjamin DK Jr**. Creation of a National Real-World Data Pediatric Migraine Registry: Proof of Principle. Accepted for poster presentation at the American Academy of Neurology Annual Meeting, April 2020 in Toronto, ON, Canada.
- 558) Kaplan S, Braverman D, Robinson C, Ramirez Campos V, Krasenbaum LJ, Rainville C, Benjamin DK, Design Of A Prospective, Observational Migraine pregnancy Registry Assessing Adverse Maternal, Fetal, And Infant outcomes In Women Exposed To Medications For Migraine, Including fremanezumab, American Headache Society (AHS) February 2022 in Denver, Colorado.

- 559) Greenberg RG, Lang J, Smith PB, Cicio K, Shekhawat P, Courtney Sherry, Hudak M, Moya Fernando, Iyengar A, Eldermerdash A, Bloom B. Go M, Hanna M, Rhein L, Aliaga S, Lewis T, Febre A, Kiefer A, Bhatt-Mehta V, El Khoury J, Martz K, Anand R, Zimmerman KO, **Benjamin DK**, Laughon M, Safety of Furosemide in Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Randomized Controlled Trial. Pediatric Academic Societies (PAS), April 2022 in Denver, Colorado.
- 560) Hayward EB, Clark RH, Smith PB, **Benjamin DK**, Kaashif A Ahmad, Blackwell CK, Greenberg RG. Trends in COVID-19 Diagnoses and Outcomes in Hospitalized Infants, Pediatric Academic Societies (PAS), April 2022 in Denver, Colorado.
- 561) Yoon H, Stark A, **Benjamin DK**, Greenberg RG, Clark RH, Laughon M. Poster presentation. Pharmacoepidemiology of Ganciclovir and Valganciclovir as Treatment for Congenital Cytomegalovirus in Neonates. Pediatric Academic Societies (PAS) Annual Meeting 2023, Washington, DC, April 2023.
- 562) Stark A, Faulkner J, Hou A, Rockwell R, Quiett V, Roberts T, Benjamin R, Clark RH, Greenberg RG, Zimmerman KO, **Benjamin DK**, Boutzoukas AE. Duration of Therapy for Escherichia coli Bacteremia Without CSF Evaluation in the NICU: is shorter better? Platform presentation: Pediatric Academic Societies (PAS) Annual Meeting 2024, Toronto, Ontario, Canada, May 2024.
- 563) Stark A, Faulkner J, Hou A, Rockwell R, Quiett V, Roberts T, Benjamin R, Clark RH, Greenberg RG, Zimmerman KO, **Benjamin DK**, Boutzoukas AE. Duration of Therapy for Escherichia coli Bacteremia Without Meningitis in the NICU: is shorter better? Platform presentation: Pediatric Academic Societies (PAS) Annual Meeting 2024, Toronto, Ontario, Canada, May 2024.

I have held an **investigator-held IND (Investigational New Drug) Application** for over 50 molecules. These are trials that have usually been supported by NIH funding for which I am the Principal Investigator.

¹Many of the molecules are clustered under the same IND number because they are part of a platform trial.² Over the past 20 years, FDA has expanded/reorganized/renamed the number of Divisions and Offices; the Division name listed was at the time of most grant funding. And thus, the listed office/division may not exist today.

Drug Names ¹	IND number	Network/Funding Source	FDA Division ²	Effective Date
Abatacept	151802	NCATS, BARDA, ACTIV-2	Rheumatology	10/1/2020
Alfentanil	114531	NICHD-Pediatric Trials Network	Anesthesiology	3/3/2012
Amikacin	113645	NICHD-Pediatric Trials Network	Anti-infectives	11/11/2011
Amiodarone	114892	NICHD-Pediatric Trials Network	Cardio-Renal	4/7/2012
Amphetamine	163156	NICHD-Pediatric Trials Network	Psychiatry	8/19/2022
Ampicillin	125250	NICHD-Pediatric Trials Network	Anti-infectives	1/30/2015
Aripiprazole	132329	NICHD-Pediatric Trials Network	Psychiatry	10/24/2017
Bumetanide	118358	NICHD-Pediatric Trials Network	Pulmonary	5/15/2013
Cefepime	113645	NICHD-Pediatric Trials Network	Anti-infectives	11/11/2011
Cenicriviroc	151802	NCATS, BARDA, ACTIV-3	Rheumatology	10/1/2020
Ciprofloxacin	113645	NICHD-Pediatric Trials Network	Anti-infectives	11/11/2011
Clindamycin	113645	NICHD-Pediatric Trials Network	Anti-infectives	11/11/2011
Clobazam	149364	NICHD-Pediatric Trials Network	Neurology	4/27/2020
Dexmedetomidine	114531	NICHD-Pediatric Trials Network	Anesthesiology	3/3/2012
Dextroamphetamine	163156	NICHD-Pediatric Trials Network	Psychiatry	8/19/2022
Doxycycline	113951	NICHD-Pediatric Trials Network	Anti-infectives	1/25/2017
Epinephrine	114892	NICHD-Pediatric Trials Network	Cardio-Renal	4/7/2012
Ertapenem	111727	NICHD-U01	Anti-infectives	4/4/2011
Etomidate	114531	NICHD-Pediatric Trials Network	Anesthesiology	3/3/2012
Fentanyl	114531	NICHD-Pediatric Trials Network	Anesthesiology	3/3/2012
Fluconazole (ECMO)	108314	Thrasher Research Fund	Anti-infectives	4/14/2009
Fluconazole	76813	FDA Orphan Drug; NICHD R01	Anti-infectives	1/9/2007
Fosfomycin	113645	NICHD-Pediatric Trials Network	Anti-infectives	11/11/2011
Furosemide	118358	NICHD-Pediatric Trials Network	Pulmonary	5/15/2013
Granisetron	114369	NICHD-Pediatric Trials Network	Gastroenterology	2/10/2012
Griseofulvin	115226	NICHD-Pediatric Trials Network	Dermatology	6/7/2012
Griseofulvin ultramicrosize	115226	Private Foundation	Anti-infectives	5/11/2012
Guanfacine hydrochloride	163156	NICHD-Pediatric Trials Network	Psychiatry	8/19/2022
Hydrochlorothiazide	114892	NICHD-Pediatric Trials Network	Cardio-Renal	4/7/2012
Hydromorphone	114531	NICHD-Pediatric Trials Network	Anesthesiology	3/3/2012
Hydroxocobalamin	114531	NICHD-Pediatric Trials Network	Anesthesiology	3/3/2012
Infliximab	151802	NCATS, BARDA, ACTIV-1	Rheumatology	10/1/2020
Ketamine	114531	NICHD-Pediatric Trials Network	Anesthesiology	3/3/2012
Meropenem	113645	NICHD-Pediatric Trials Network	Anti-infectives	11/11/2011
Methadone	114531	NICHD-Pediatric Trials Network	Anesthesiology	3/3/2012
Methylprednisolone	118358	NICHD-Pediatric Trials Network	Pulmonary	5/15/2013
Metoclopramide	114369	NICHD-Pediatric Trials Network	Gastroenterology	2/10/2012
Metozolov	114369	NICHD-Pediatric Trials Network	Gastroenterology	2/10/2012

Midazolam	114531	NICHHD-Pediatric Trials Network	Anesthesiology	3/3/2012
Nafcillin	113645	NICHHD-Pediatric Trials Network	Anti-infectives	11/11/2011
Nalbuphine	114531	NICHHD-Pediatric Trials Network	Anesthesiology	3/3/2012
Ondansetron	114369	NICHHD-Pediatric Trials Network	Gastroenterology	2/10/2012
Ondansetron	135559	NICHHD-Pediatric Trials Network	Gastroenterology	6/25/2017
Oxycodone	114531	NICHHD-Pediatric Trials Network	Anesthesiology	3/3/2012
Pentobarbital	114531	NICHHD-Pediatric Trials Network	Anesthesiology	3/3/2012
Piperacillin tazobactam	104988	NCATS	Anti-infectives	6/14/2009
Pocapavir	164628	Emergency IND, Patient Access	Antivirals	11/4/2022
Pravastatin	118329	NICHHD-Pediatric Trials Network	Lipid Disorder Obesity	5/15/2013
Rocuronium	114531	NICHHD-Pediatric Trials Network	Anesthesiology	3/3/2012
Simvastatin	118329	NICHHD-Pediatric Trials Network	Lipid Disorder Obesity	5/15/2013
Terbutaline sulfate	118358	NICHHD-Pediatric Trials Network	Pulmonary	5/15/2013
Tobramycin	113645	NICHHD-Pediatric Trials Network	Anti-infectives	11/11/2011
Trimethoprim-sulfa	134436	NICHHD-Pediatric Trials Network	Anti-infectives	3/23/2017
Vancomycin	113645	NICHHD-Pediatric Trials Network	Anti-infectives	11/11/2011
Vecuronium	114531	NICHHD-Pediatric Trials Network	Anesthesiology	3/3/2012

LABEL CHANGES: The Pediatric Trials Network, under my leadership, has led studies that have resulted in 26 labeling changes to the US FDA label. A complete list is available on pediatrictrials.org; below are the changes which have been led by mentees or have had significant contributions by mentees

IND or NDA	Date (year)	Molecule	Indication studied
NDA 019949/0072	2024	fluconazole	Invasive candidiasis
NDA 207958	2023	levetiracetam	Partial-onset seizures
NDA 215212	2023	meropenem	Intra-abdominal infection
ANDA 214745	2023	diazepam	Partial-onset seizures
NDA 050420/0089	2023	rifampin	Infection
NDA 208083/0008	2022	clindamycin	Other
ANDA 072370	2021	diazepam	Partial-onset seizures
NDA 017376/0063	2020	bactrim	Other
NDA 208253/0003	2020	doxycycline hyclate	Other
NDA 020793/0019	2020	caffeine citrate	Apnea in neonates
NDA 018603/0030	2019	acyclovir sodium	Herpes simplex virus
	2019	Mercy BabyTAPE	Weight estimation newborns
NDA 018421/0031	2018	lithium	Bipolar disorder, mania
ANDA 999907 - Original 1	2018	ampicillin	meningitis bacteremia
NDA 018140/0040	2016	lorazepam	N/A
	2015	Mercy TAPE	Weight estimation ages 2-16
ANDA 071961 - Original 1	2013	sodium nitroprusside	N/A

CONSULTANT APPOINTMENTS AND REVIEW RESPONSIBILITIES

NIH Leadership Positions

- 1) **NIH** Risk Group 2 Member for the Bacteriology and Mycoses Study Group 2003–2005
- 2) **NICHD** Committee Vice Chair, Clinical Research Committee for NICHD-sponsored Pediatric Pharmacology Research Unit (PPRU), 2003–2005
- 3) **NICHD-FDA** Newborn Drug Development Initiative, Apnea Committee Member for the Best Pharmaceuticals for Children Act, 2004
- 4) **NICHD** Committee Chair, Newborn and Infant Drug Development for the PPRU, 2004
- 5) **NICHD-FDA** Newborn Drug Development Initiative, Drug Prioritization Committee Member for the Best Pharmaceuticals for Children Act, 2004–2019
- 6) **NICHD** Protocol Chair, Early Diagnosis of Neonatal Candidiasis for the Neonatal Research Network, 2003–2008
- 7) **NICHD** Subcommittee Chair, Candidiasis Subcommittee for the Neonatal Research Network, 2003–2010
- 8) **NICHD** Committee Member, Protocol Review Committee for the PPRU, 2003–2008
- 9) **NICHD** Committee Member, Executive Committee for the PPRU, 2005–2010
- 10) **NICHD** Committee Chair, Antimicrobial Therapy for the PPRU, 2005–2010
- 11) **NICHD-FDA** Committee Member, Pediatric Infectious Disease, Best Pharmaceuticals for Children Act, 2006–2010
- 12) **NICHD-FDA** Committee Member, Cough and Cold, Best Pharmaceuticals for Children Act, 2009–2010
- 13) **NICHD** Chair, Pediatric Trials Network, 2010–present
- 14) **NICHD-NIGMS** Committee Member, Pediatric Clinical Pharmacology Training Program, 2011–present
- 15) **NIH** Panelist, Advisory Committee to the NIH Director Precision Medicine Initiative (PMI) Working Group, May 28, 2015
- 16) **NIH Office of the Director** Chair, Coordinating Center for the Environmental influences on Child Health Origins (ECHO) Program, 2016-2021
- 17) **NAMHC** Drug Development workgroup, 2020
- 18) **NICHD** Mentorship of Junior Faculty (K12) 2023-present

Food and Drug Administration (FDA) Leadership

- 1) **Office of Pediatric Therapeutics**: Special Advisor to the Office of the Commissioner, Food and Drug Administration—jointly employed by Duke and the FDA under an Inter-Agency Personnel Agreement in the Office of Pediatric Therapeutics. Special Advisor to guide the analysis of pediatric clinical trials performed under FDA guidance.
- 2) **Office of Antimicrobials***: Use of non-inferiority and trial design for otitis media trials, 2006
- 3) **Office of Antimicrobials**: Animal models for the investigation of neonatal candidiasis, 2006
- 4) **Office of Pediatric Therapeutics** Adverse events in the placebo arm of randomized pediatric drug trials, 2006–2008
- 5) **Office of Pediatric Therapeutics** Risks, cost, and benefits of Pediatric Exclusivity trials, 2007
- 6) **Office of Clinical Pharmacology** Anti-hypertensive trial design in children, 2007–2008
- 7) **Office of Antimicrobials** Extrapolation of infectious disease indications in neonates

*formerly Division of Anti-Infective and Ophthalmology Products

Global Leadership Positions

- 1) National Institute of Child Health and Human Development, Food and Drug Administration, and European Medicines Agency (EMA) Pediatric Drug Development Collaboration 2007–2009
- 2) International Alliance for Better Medicines for Children, 2007
- 3) Critical Path Initiative Neonatal Drug Development 2014-2025

- 4) Critical Path Initiative Neonatal Clinical Pharmacology 2015-2025
- 5) Critical Path Initiative Pediatric Clinical Trials 2015-2025

Scientific Advisory Boards and Leadership Positions in Professional Societies

- 1) Thrasher Research Foundation, Scientific Advisory Board Member, 2006–2013
- 2) Infectious Disease Society of America, Author of Guidelines for the Treatment of Invasive Candidiasis, Sections on Neonatal Candidiasis and Pediatric Pharmacology
- 3) National Institute of Health, Author of Guidelines for the Treatment of Candidiasis in Children with HIV
- 4) Infectious Disease Society of America, Antimicrobial Task Force, 2010–2012
- 5) Pediatric CABP-ABSSSI Sub-team Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, 2012–2020
- 6) Infectious Disease Society of America, Antimicrobial Resistance Committee (ARC), 2012-2020
- 7) Thrasher Research Fund, Executive Committee Member 2013-present
- 8) Women and Children’s Health Research Institute (WCHRI), Canada Scientific Advisory Committee member, 2017-2021

Other Consultancy Positions: all industry consultancies resigned during my FDA appointment (2005–2007)

- 1) Ligocyte Pharmaceuticals, Senior Pediatric Consultant, Neonatal Candidiasis, 2002–2005
- 2) AstraZeneca, Pediatric and Neonatal Protocol Consultant, 2003–2004
- 3) Vicuron, Pediatric and Neonatal Consultant, 2002–2005
- 4) Fujisawa Inc., Consultant for Neonatal Candidiasis, 2003–2005
- 5) MedImmune Inc., Neonatal and Infant RSV, 2002–2005
- 6) Enzon Pharmaceuticals, Neonatal and Pediatric Invasive Candidiasis, 2003–2005
- 7) NABI Biopharmaceuticals, Consultant for Protocol Design and Neonatal Nosocomial Infections, 2002–2005
- 8) Biosynexus, Neonatal Staphylococcal Infections, 2008–2011
- 9) Astellas, Neonatal Candidiasis, 2008-2012
- 10) Pfizer, Pediatric Scientific Advisor, 2009-2012
- 11) Cerexa, Scientific Advisory Board Member, 2010-2012
- 12) GlaxoSmithKline, Pediatric Scientific Advisory Board Member, 2010-2012
- 13) Johnson & Johnson, Neonatal Meningitis, 2010–2013
- 14) Cubist, Neonatal Bacteremia, 2011-2012
- 15) The Medicines Company, 2011-2015
- 16) Durata Pharmaceutical Company, bacteremia, 2012-2015
- 17) Cempra Pharmaceutical Company Community Acquired Pneumonia, 2012-2015
- 18) Trius Pharmaceutical Company Intra-abdominal infections, 2013-2015
- 19) Astra-Zeneca Complicated Urinary Tract Infections, 2013-2015
- 20) Kowa therapeutics related to lipid and triglyceride management, 2014-2015
- 21) UCB Bioscience Inc. Scientific Advisory Board Maternal-Fetal safety, 2014-2019
- 22) Shionogi neonatal therapeutics, 2014-2019
- 23) Life science therapeutics for the management of inflammation post-lung transplant, 2015
- 24) AbbVie, Inc., current
- 25) PPD, Inc., current
- 26) Syneos Health, current

REVIEW RESPONSIBILITIES

Grant and Contract Reviewer National Institute of Health

- 1) National Institute of Neurological Disorders & Stroke, NeuroNext, 2011
- 2) National Institute of Child Health and Human Development Scientific Review, ZHD1 DSR-Z, 2009
- 3) National Institute of Child Health and Human Development Scientific Review, 2009
- 4) National Institute of Allergy and Infectious Disease, 2007
- 5) National Institutes of Health (NINDS) Clinical Trials Network, 2011
- 6) National Institutes of Health Special Emphasis Panel/Scientific Review, ZHD1 DSR-Y (56), 2011
- 7) National Institutes of Health, Bethesda, MD, Loan Repayment Program 2012/08 ZAI1 RWM-M (S1) 1, 2012
- 8) NIAID Clinical Trial Planning Grants (R34) and Implementation Grants and Cooperative Agreements (R01, U01), 2012
- 9) NIAID Loan Repayment Program Review ZAI1-MM-I-S1, 2013
- 10) NICHD T32 Institutional Training Grant ZHD1 DRG-D (90) 2011-2015
- 11) NIAID Extramural Loan Repayment Program for Clinical Researchers NOT-OD-14-105, 2015
- 12) NIAID Extramural Loan Repayment Program for Pediatric Research NOT-OD-14-107, 2015
- 13) NIH Center for Scientific Review, reviewer for R01 applications from across study sections for a pilot study for the Center for Scientific Review, 2015
- 14) NIH Safe and Effective Instruments and Devices for Use in Neonatal and Pediatric Care Settings (R41/R42), PAR-13-091, 2015
- 15) NIH Non- or Minimally-Invasive Methods to Measure Biochemical Substances for Neonatal and Perinatal Clinical Care and Research (R41), RFA-HD-16-028, 2015
- 16) NIH ZRG1 DKUS C 52 R01 in response to PAR 13-306 (Developmental Pharmacology and Toxicology: Role of Ontogeny), 2013-2015
- 17) 2016/05 XNDA Xenobiotic and Nutrient Disposition and Action Study Section, 2016
- 18) NIAID Extramural Loan Repayment Program for Clinical Research (LRP-CR) NOT-OD-15-121, 2016
- 19) NIAID Extramural Loan Repayment Program for Clinical Research (LRP-PR) NOT-OD-15-122, 2016
- 20) NIAID Extramural Loan Repayment Program for Clinical Research and Pediatric Research ZAI-EC-M-S1, 2017
- 21) National Institute of Dental and Craniofacial Research ZDE1 GZ (07) DPBRN ARC, 2018
- 22) NIDA Program Project Review (PAR-18-425)2019/05 ZRG1 DKUS-L (40) P, 2019
- 23) NIH Loan Repayment Meeting, 2019/08 ZHD1 DSR-K (90) 1, 2019
- 24) Chair 2020/01 ZRG1 SBIB-N PAR-17-169: Biomarkers: Bridging Pediatric and Adult Therapeutics, 2019
- 25) NIH 2020/05 ZMH1 ERB-D (04) S: Early Phase Clinical Trials – Pharma/Device, 2020
- 26) NICHD 2020/08 ZHD1 DSR-K (90) 1: Loan Repayment Review, 2020
- 27) NIH 2020/08 ZRG1 IFCN-U (50) Special Emphasis Panel/Scientific Review Group, 2020

Grant and Contract Reviewer Foundations and Outside the USA

- 1) Thrasher Research Fund, United States of America, 2005–present
- 2) Raine Medical Research Society, Australia, 2007
- 3) European Union FP-7, Seventh Research Framework Programme, 2009

Editorial Board and Contributing Editor

Yearbook of Neonatal and Perinatal Medicine, 2008
Pediatric Infectious Disease Journal, 2009–2020
Brazilian Journal of Internal Medicine, 2009–2020
Generics & Biosimilars Initiative Journal, 2011–2020
Journal of Pediatric Infectious Diseases Society - 2012-2017

Reviewer for Professional Society Statements

Institute of Medicine Reviewer, 2011 Best Pharmaceuticals for Children Act
Council of Canadian Academies, Improving Medicines for Children in Canada, 2014

Journal Reviewer

- 1) American Heart Journal
- 2) American Journal of Perinatology
- 3) Journal of American Medical Association (JAMA)
- 4) Journal of Pediatrics
- 5) Journal of Perinatology
- 6) New England Journal of Medicine (NEJM)
- 7) Pediatrics
- 8) Pediatric Infectious Disease Journal

DATA AND SAFETY MONITORING BOARD (DSMB) EXPERIENCE

DSMB Charter Author

- 1) Randomized Blinded Phase II Trial of a Polyclonal Antibody to Prevent *Staphylococcus aureus*
Sponsor: NABI Biopharmaceuticals
Brief Description: This was a randomized trial conducted in over 20 neonatal intensive care nurseries and enrolled 200 premature infants.
Role: I wrote the charter and recruited the members.
- 2) Randomized Blinded Phase III Trial of Anidulafungin vs. Fluconazole for the Treatment of Invasive Candidiasis
Sponsor: Vicuron
Brief Description: This was a randomized, pivotal multi-national trial conducted in over 60 centers and enrolled 225 patients with invasive candidiasis.
Role: I wrote the charter and recruited the members

DSMB Chair

- 3) Open Label PK and Safety trial of Dalbavancin
Sponsor: Durata
Brief Description: Elucidate dosing and safety of a novel antibiotic in children and infants
Role: Chair
- 4) Randomized Safety and Efficacy trial of Dalbavancin for the treatment of osteomyelitis
Sponsor: Durata
Brief Description: Elucidate efficacy and safety of a novel antibiotic in children and infants with bone and joint infections
Role: Chair
- 5) Treatment of Invasive Fungal Infections
Sponsor: Pfizer
Brief Description: Study of new antifungal agents in children to treat *Aspergillois*
Role: Chair
- 6) Treatment of Invasive Candidiasis
Sponsor: Pfizer
Brief Description: Study of new antifungal in children to treat invasive fungal infection.
Role: Statistician and Chair
- 7) Treatment of Osteomyelitis in Children with Dalbavancin vs. Standard of Care
Sponsor: Durata
Brief Description: Randomized pivotal study of a new antibiotic to treat osteomyelitis
Role: Chair
- 8) Treatment of Complicated Skin and Soft Tissue Infections in Children with Dalbavancin
Sponsor: Durata
Brief Description: Randomized study of a new antibiotic to treat soft tissue infections
Role: Chair

- 9) Pharmacokinetic and Safety Study of Oritavancin
Sponsor: The Medicines Company
Brief Description: Open label study of a new antibiotic in children
Role: Chair
- 10) Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infections
Sponsor: Durata Therapeutics International B.V. (an Allergan Affiliate)
Brief Description: A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infections
Role: Chair
- 11) Hydroxychloroquine vs. Azithromycin for Outpatients with Confirmed COVID-19
Sponsor: NIH/NCATS
Brief Description: Randomized, pivotal, direct to family trial powered for efficacy and comparing HCQ to Azithromycin in adults with mild COVID-19 disease
Role: Chair
- 12) Hydroxychloroquine for Outpatients with Confirmed COVID-19
Sponsor: NIH/NCATS
Brief Description: Randomized, pragmatic, potentially dose-ranging blinded study of HCQ compared to placebo in adults with moderate COVID-19 disease
Role: Chair
- 13) Vabomere (Meropenem-Vaborbactam) in Children with Complicated UTI, Phase II
Sponsor: Melinta Therapeutics
Role: Chair
2023-2024

DSMB Presenting (Non-voting) Statistician

- 14) Randomized Blinded Phase III Trial of Anidulafungin vs. Fluconazole for the Treatment of Invasive Candidiasis
Sponsor: Vicuron
Brief Description: This was a randomized, pivotal multi-national trial.
Role: I conducted the primary analyses for each of the open and closed reports and presented the data to the voting members of the DSMB.

DSMB Voting Member

- 15) Randomized Blinded trial for the Treatment of Patent Ductus Arteriosus 'Beat PDA'
Sponsor: Investigator-initiated trial
Brief Description: Randomized for treatment of PDA; trial stopped early for lack of enrollment.
Role: Member
- 16) Randomized Blinded Trial for the Treatment of Multiple Sclerosis
Sponsor: Berlex
Brief Description: Medical intervention for multiple sclerosis; stopped early for futility.
Role: Member

- 17) Assessment of Massage Therapy in Premature Infants
Sponsor: National Institutes of Health
Brief Description: Pilot study in which enrolled infants are randomized to receive either massage or sham massage; endpoints include immunologic markers, infections, and mortality.
Role: Member
- 18) Sponsor: BioCryst Pharmaceuticals
Role: Member
2023
- 19) Sponsor: Syneos Health
Role: Member
2023
- 20) RESOLVE/KALPAS Randomized Trial of Ketamine for Chronic Post-Mastectomy Pain
Sponsor: John Hopkins University
Brief Description: Multicenter, randomized, double-blind, placebo-controlled Phase III trial evaluating perioperative ketamine strategies to prevent chronic post-mastectomy pain and reduce opioid-related risks.
Role: Member
2023-2024
- 21) REMPEX 507
Sponsor: Melinta Therapeutics (began as TMC)
Role: DSMB Committee Chair
2016 – 2020
- 22) Teva Migraine Pregnancy Registry
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
CRO: Syneos Health, LLC
Role: Registry Advisory Committee Member
2021 – 2025
- 23) HORIZON: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Efficacy and Safety Study of Tezepelumab in Children 5 to <12 Years Old With Severe Uncontrolled Asthma
Sponsor: AstraZeneca
Brief description: Evaluate the efficacy and safety of Tezepelumab compared with placebo in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) plus at least one additional controller medication, with or without oral corticosteroids.
Role: Member
2023-present
- 24) ORKIDS
Sponsor: Melinta Therapeutics
Role: DSMB Committee Chair
2024 – present

25) ML-ORI-201

Sponsor: Melinta Therapeutics
Role: DSMB Committee Chair
2024 – 2025

26) ML-VAB-201-3248-2

Sponsor: Melinta Therapeutics
Role: DSMB Committee Chair
2024 – present

PROFESSIONAL AWARDS

Teaching/Mentor Awards:

- 1) University of Virginia Resident Teaching Award Department of Pediatrics, 1997
Awarded annually to one pediatric resident noted to be an outstanding teacher (of ~30 pediatric residents in the Department)
- 2) University of Virginia School of Medicine Teaching Award, 1998
Awarded annually to the 10 residents across the medical system noted to be outstanding teachers (of ~600 residents total in 1998)
- 3) University of Virginia Graduate Student Teaching Award, 1998
Awarded annually to the one graduate education teacher of the ~7,000 professional students, post-doctoral students, residents and fellows at the University of Virginia. I was the first medical school recipient of the award.
- 4) Duke University Department of Pediatrics Fellow Teaching Award, 1999
Awarded to the subspecialty fellow most instrumental in pediatric house staff education (of ~60 subspecialty fellows in the Department)
- 5) Duke University Teaching Award for Resident Education Department of Pediatrics, 2003
Awarded to the faculty member dedicated to resident education (~200 faculty)
- 6) Duke University Duke Clinical Research Institute RM Califf Mentorship Award, 2007
Awarded to the faculty member most instrumental in the mentorship of post-doctoral fellows; I was the inaugural recipient of the award
- 7) Duke University Clinical Science Research Mentoring Award, 2013
- 8) Duke University School of Medicine Faculty Mentor Award, 2019
- 9) Duke University Department of Pediatrics Outstanding Research Mentor, 2019
- 10) Society for Pediatric Research, Maureen Andrew Mentor Award, 2026

Citizenship Awards:

- 1) Society of the Cincinnati Citizen Scholar Award, 1995: Awarded for outstanding citizenship and leadership to a member of the graduating medical school class

Research Awards:

- 1) National Institutes of Health Pediatric Loan Repayment Program:
2002–2004
2004–2005
2005–2006
2006–2007
- 2) Pediatric Infectious Disease Society: Young Investigator Award, 2006
- 3) Elected member, American Society Clinical Investigation (ASCI), 2010
- 4) Duke University Ruth and A. Morris Williams Jr. Faculty Research Prize, 2012
- 5) Elected member, Associations of American Physicians, 2023

RESEARCH SUPPORT

Summary of Awards as PI or MPI from Industry, Private Foundations, and Federal Sources by Year.

For industry sponsored projects, the company typically held the IND/IDE (except as noted in description) for sponsored clinical trials; and for federal projects, I (or one of my mentees) typically held the IND/IDE.

My career-long extramural funding includes over \$700,000,000 as either PI or MPI, summarized in the table below and outlined in detail in the subsequent pages.

Sponsor	Title	Role	Year	Total Award	Description
MedImmune	RSV	PI	2002	\$85,000	North Carolina epidemiology
NIH	R03 HD42940-02	PI	2002	\$154,000	Pediatric HIV
Pfizer	Pediatric Fungal	MPI	2003	\$50,000	Clinical risk factors
Vicuron Inc	PK of anidulafungin	PI	2003	\$277,100	Protocol chair for labeling
NABI Inc	Neonatal altastaph	PI	2003	\$611,000	Protocol chair for labeling
Vicuron Inc	DSMB	PI	2003	\$40,000	Analyst
Rockeby Inc	Neonatal candidiasis	PI	2004	\$500,000	Diagnostic testing
Cape Cod Inc	Neonatal candidiasis	PI	2004	\$750,000	Diagnostic testing
Astra Zeneca	Fellowship training	PI	2005	\$250,000	Training award as mentor
NIH	K23 HD-044799-01	PI	2005	\$657,380	K23 neonatal candidiasis
J&J	Minority Fellowship	PI	2006	\$240,000	Training award as mentor
Astellas	PK of micafungin	PI	2006	\$40,000	Neonatal trial (IND holder)
Astellas	PK of micafungin	PI	2006	\$75,000	Premature infant trial (IND holder)
NIH	1U10-HD45963	PI	2006	\$986,476	PPRU
NIH	HHSN267200700051C	PI	2007	\$5,196,786	Neonatal meropenem
Pfizer	PK of voriconazole	PI	2008	\$34,000	Protocol Chair PK of infants
NIH	HHSN2672007000051C	PI	2008	\$486,667	Neonatal meningitis
Thrasher Fndn.	Neonatal candidiasis	PI	2008	\$197,000	Diagnostic testing
FDA	4R01 FD003519	PI	2008	\$1,600,000	Neurodevelopment
NIH	5R01 HD057956	PI	2008	\$2,500,000	Prophylaxis neonatal candidiasis
Pfizer	PK of anidulafungin	PI	2009	\$100,000	Neonatal trial (IND holder)
NIH	3 UL1 RR024128-04S5	PI	2009	\$499,116	Neonatal PK
Thrasher Fndn.	Neonatal candidiasis	PI	2009	\$451,000	Neurodevelopment
NIH	5K24 HD058735	PI	2009	\$650,445	K24 to train junior faculty
NIH	HHSN-27500001	PI	2010	\$95,000,000	Pediatric Trials Network
UCB Inc	Neurology fellowship	PI	2011	\$160,330	Training award as mentor
NIH	5T32 GM086330	PI	2011	\$1,652,000	Director for T32
BARDA	Pneumonia	MPI	2013	\$2,414,668	Solithromycin
NIH	5K24 HD058736	PI	2013	\$650,000	K24 competitive renewal
NIH	2R25 HD076475	PI	2013	\$481,193	Summer research for students
NIH	5U2 COD023375	MPI	2016	\$119,200,227	ECHO Coordinating Center
NIH	5U24 TR001608	PI	2016	\$19,115,847	Trial Innovation Network
NIH	5T32 HD043029	PI	2017	\$285,452	Director for T32
FDA	5U18 FD006298	PI	2017	\$5,000,000	Global Pediatric Network
NIH	2R25 HD076476	PI	2018	\$500,000	R25 competitive renewal
NIH	HHSN27500001	PI	2018	\$98,000,000	PTN competitive renewal
NIH	3U24-TR001608-06S1	PI	2019	\$19,601,765	HEAL Coordinating Center

BARDA	HHSO100201400002I	PI	2020	\$42,667,161	ACTIV-1 Global Randomized Trial
NIH	1OT 2HD107559-01	MPI	2021	\$5,000,000	ABC COVID in Schools
NIH	5U24-TR001608-05S4	PI	2021	\$38,494,599	ACTIV-6
NIH	3U24-TR001608-06S1	PI	2021	\$77,049,200	ACTIV-6
NC DHHS	EP5064792	PI	2021	\$500,000	COVID-19 Prevention in Schools
NIH	1OT2HD107559-01	MPI	2021	\$3,004,526	COVID-19 Screening and Testing
NIH	3U24TR004314-06S1	PI	2021	\$3,623,708	Trial Innovation Network
NIH	3U24-TR001608-06S1	PI	2021	\$20,600,000	ACTIV-6
NIH	3OT2HD107559-01S1	MPI	2022	\$1,995,475	COVID-19 Screening and Testing
NIH	3U24TR004314-06S1	PI	2022	\$1,534,497	Trial Innovation Network
NIH	7K12HD113189	MPI	2023	\$1,470,720	K12 Ped Clin-Pharmacology
NIH	3U24TR004314-07S1	PI	2023	\$2,330,569	Trial Innovation Network
NIH	275201800003I-0-759402300004-1	PI	2023	\$3,669,861	Trial Designs+Assay Development
NIH	275201800003I-P00003-759402000002-1	PI	2023	\$300,001	Breast Milk Pharmacology
NIH	5U24TR004314	PI	2023	\$2,475,031	HEAL PAIN ERN
NIH	1U24HD116261	MPI	2024	\$4,061,732	HEAL KIDS Pain Resource
NIH	HHSN 75N94025D00003	PI	2025	\$149,600,000	PTN competitive renewal
Total			23 yrs	\$736,869,532	

Awards as Mentor/Co-Mentor of Duke Faculty or Mentor-to-the-Mentor (K12, K23, K24 awards)

Sponsor	Title	PI	Project Yrs	Description
NIH	1K23HD060040-01	Smith, Brian	2009-2012	PK of Antimicrobials in High Risk Infants
NIH	1K23HD064814-01	Cohen-Wolkowicz, M.	2010-2013	PK/PD Antibiotics in Premature Infants
NIH	1K23HD075891-01A1	Watt, Kevin	2014-2018	PK in Critically Ill Children
NIH	1K23HD083465-01	Gonzalez, Daniel	2015-2019	PK/PD Models to Streamline Drug Approvals
NIH	1K24HD058735-01A1	Benjamin, Daniel	2009-2019	Mentorship of early-career pediatricians in quantitative and therapeutic methods
NIH	1K23HD090239-01	Hornik, Christoph	2017-2020	PK/PD Methylprednisolone in Neonates on Bypass
NIH	1K23HD091398-01	Zimmerman, Kanecia	2017-2020	Polypharmacy adverse events in critically ill children
NIH	1K24AI143971-01	Cohen-Wolkowicz, M.	2019-2024	Mentoring in Clinical Pharmacology and Early Phase Trials
NIH	1K23DK117061-03	Syed, Sana	2019-2024	Computational Characterization of Environmental Enteropathy
NIH	1K23AR075874-01A1	Balevic, Stephen	2020-2025	Dosing Biologics in Obese Patients with Arthritis
NIH	1K12HD113189-01	Gonzalez, Daniel	2023-2028	National Career Development Program for Researchers in Pediatric Clinical Pharmacology
NIH	1K23AR084424-01	Randell, Rachel	2024-2029	Hydroxychloroquine in adolescents w lupus
NIH	1K24HL173596-01	Hornik, Christoph	2024-2029	Mentoring in Pediatric Cardiovascular Pharmacology and Early Phase Trials
NIH	1K23HD116971-01	Thompson, Elizabeth	2025-2029	PK/PD Drug Dosing in Critically Ill Children
NIH	1K23-HD113839-01A1	Boutzoukas, A.	2025-2029	Short-course ampicillin in neonates

NIH	1K24AI192996-01	Syed, Sana	2025-2030	Mentoring in Data Science for Big Data and omics in Immunologic Diseases
NIH	1K24AI196322-01	Gonzalez, Daniel	2026-2031	Mentoring in Anti-Infective Clinical Pharmacology and Pharmacometrics

GRANTS AND EXTRAMURAL RESEARCH AWARDS

Present Extramural Research:

HHSN 75N94025D00003 75N94025F-00001 TO1 (PD/PI: Benjamin)

Sponsor: NIH

Total Base Award Amount: \$17,268,194

Dates: 06/4/2025-06/3/2032

Title: Best Pharmaceuticals for Children Act: Pediatric Trials Network

Major Goals: To conduct research to better understand the effects and effectiveness of pharmaceuticals on maternal and child health.

HHSN 75N94025D00003 75N94025F-00002 TO2 (PD/PI: Greenberg, R./ Benjamin, D)

Sponsor: NICHD

Dates: 9/20/2025 - 9/19/2030

Total Base Award Amount: \$14,810,162

Title: PTN 3.0 Task Order #2

Major Goals: To conduct research to better understand the effects and effectiveness of pharmaceuticals on maternal and child health.

5U24-HD116261-02 (PI: Greenberg)

Sponsor NIH

Total Award Amount (including Indirect Costs): \$4,061,732

Dates: 9/4/2024-8/31/2030

Title: Duke-Utah HEAL KIDS Pain Resource and Data Center.

Major Goals: The Duke-Utah RDC will harmonize the distinct APCT trials in an integrated program with shared objectives, procedures, and tools to maximize knowledge gained in pediatric pain. I am a co-Investigator.

4U2C-OD023375-09 (PI: Smith)

Sponsor: NIH, Office of the Director

Total Award Amount (including Indirect Costs): \$8,427,639

Dates: 6/01/2025–5/31/2030

Title: Environmental influences on Child Health Outcomes (ECHO) Coordinating Center.

Major Goals: ECHO CC administrative core will provide the internal administrative structure for the ECHO CC and will manage the ECHO CC awards and contracts. I am the co-Investigator.

5K23-HD113839-02 (PI: Boutzoukas)

Sponsor: NICHD

Total Annual Amount (including Indirect Costs): \$154,862

Project Dates: 1/3/2025 - 12/31/2029

Title: Short-course ampicillin in preterm neonates to promote antimicrobial stewardship

Major Goals: The major goals of the project are to establish the pharmacokinetic profile and safety of short course ampicillin in preterm infants, to develop a novel clinical trial outcome to be used in future antimicrobial stewardship trials, and to provide the training and mentorship needed for Dr. Angelique Boutzoukas to attain research independence.

HHSN275201-800003I 75N94024F00001-TO18

(PI: Benjamin)

Sponsor: NICHD

Total Award Amount (including Indirect Costs): \$2,910,569

Project Dates: 9/23/2024 - 9/22/2028

Title: NICHD Pediatric and Maternal Resource Center: Bridging Pharmacology and the Real World

Major Goals: 1. Conduct clinical trials that align with the priorities of the BPCA program, including therapeutic areas that need further study. 2. Provide laboratory methods and expertise that support pharmacology research throughout the PTN network with the ability to expand such support to other NIH networks. 3. Provide and coordinate opportunities that can lead to active participation in therapeutics research across NIH networks, collaborating with programs and centers that may have limited expertise in regulatory rigorous clinical trials. 4. Provide mentorship and training resources (such as didactic and/or experiential products) to academic, community, or primary care centers and sites that have clinical research programs that could benefit from learning how to conduct clinical trials under regulatory rigor.

5K12HD113189-04

(PI: Gonzalez, MPI: Benjamin)

Sponsor: NICHD

Total Award Amount (including Indirect Costs): \$1,470,720

Project Dates: 1/23/2024 - 7/31/2028

Title: National Career Development Program for Researchers in Pediatric Clinical Pharmacology

Major Goals: This career development program will enable scholars to generate the publication record, preliminary data, and skill set that is necessary to be competitive for independent research grants. Following completion of the program, all scholars will be exceptionally well-positioned to pursue impactful careers focused on promoting the safe and effective use of medications in children.

HHSN275201-800003I -75N94023F00004-TO17

(PI: Benjamin)

Sponsor: NICHD

Total Award Amount (including Indirect Costs): \$8,783,682

Project Dates: 9/28/2023 - 9/27/2027

Title: BPCA Innovative Trial Designs and Assay Developments in Pediatric Therapeutics

Major Goals: To perform innovative trial designs, with clinically relevant outcomes such as endpoints, biomarkers, and epidemiology data included as part of every protocol, to obtain comprehensive and comparative analysis of the data for the advance of the science and knowledge gaps in the dosing, effectiveness and safety of therapeutics used in the pediatric populations.

5U24-TR004314-04

(PI: Benjamin)

Sponsor: NIH

Total Award Amount (including Indirect Costs): \$8,002,669

Dates: 09/23/2022 – 08/31/2027

Title: HEAL Clinical Coordinating Resource Center for the Pain Management Effectiveness Research Network

Major Goals: In support of the HEAL Pain Management ERN the Duke/Vanderbilt Trial Innovation Center will: Specific Aim 1. Provide clinical trial leadership and expertise, assistance in study and protocol design, study implementation, and management, in collaboration with the other HEAL ERN Resource Centers, for existing and new HEAL ERN trials. Specific Aim 2. Serve as the clinical coordinating resource center (CCRC) for existing and new HEAL ERN trials. Specific Aim 3. Provide single IRB support for HEAL ERN trials for existing and new HEAL ERN trials. Through completion of these specific aims, we will harmonize the HEAL studies to achieve major innovations in trial design and execution, including combination and reuse of valuable data, efficiencies of implementation,

shared pain expertise among investigative teams, and the integration of three TICs as a cohesive unit, poised for future trial implementation.

Sponsor: Treehouse Family Foundation (PI: Benjamin)

Total Award Amount (including Indirect Costs): \$409,396

Dates: 9/1/2024 - 8/31/2027

Title: K-12 Continuum of Care Program.

Major Goals: This project will assist schools in developing, implementing, and sustaining trauma-informed multi-tiered systems of support that foster student achievement, resilience, and well-being. Duke Clinical Research Institute will collect, curate, and analyze data at regular intervals throughout the duration of this research project.

HHSN275201-800003I -75N94023F00004-TO17 (PI: Benjamin)

Sponsor: NICHD

Total Award Amount (including Indirect Costs): \$3,699,861

Dates: 9/28/2023–9/27/2026

Title: BPCA Innovative Trial Designs and Assay Developments in Pediatric Therapeutics.

Major Goals: To perform innovative trial designs, with clinically relevant outcomes such as endpoints, biomarkers, and epidemiology data included as part of every protocol, to obtain comprehensive and comparative analysis of the data for the advance of the science and knowledge gaps in the dosing, effectiveness and safety of therapeutics used in the pediatric populations. I am the principal investigator.

HHSN275201-800003I- 75N94022F00002-TO13 (PI: Greenberg)

Sponsor: NIH

Total Award Amount (including Indirect Costs): \$5,759,708

Dates: 9/28/2022–9/27/2026

Title: PTN 2.0 TO13 Improving Off-label Medication Use in Children.

Major Goals: The goal of the new task order will be to identify remaining gaps in off-label use in children and to design clinical research (systematic literature reviews, epidemiology studies, population PK modeling studies, and innovative safety and effectiveness studies) on the identified off-label drugs that have been prioritized as a part of the BPCA prioritization process. I am the co-Investigator.

HHSN-275201000003I TO #6 PARENT (PI: Benjamin)

Sponsor: NICHD

Total Award Amount: \$19,225,600 (Total Award \$96,000,000 since 9/28/2010)

Dates: 9/12/2019–7/31/26

Title: Best Pharmaceuticals for Children Act: Pediatric Trials Network

Major Goals: To increase the availability of pediatric safety and appropriate dosing data for therapeutics and devices in children. I am the principal investigator.

Completed Research Support:

2U2C-OD023375-08 (PI: Smith)

Sponsor: NIH, Office of the Director

Total Award Amount (including Indirect Costs): \$8,427,639

Dates: 9/01/2023–5/31/2025

Title: Environmental influences on Child Health Outcomes (ECHO) Coordinating Center.

Major Goals: ECHO CC administrative core will provide the internal administrative structure for the ECHO CC and will manage the ECHO CC awards and contracts. I am the co-Investigator.

OPT1-HHSN 275201800003I -TO15

(PI:Kumar)

Sponsor: NICHD

Total Award Amount (including Indirect Costs): \$1,109,274

Dates: 9/20/2023 - 9/19/2025

Title: BPCA Concept Development, Investigator Development and Clinical Trial Readiness Support.

Major Goals: The goal of this task order is to provide a platform for clinical trial hypothesis generation as well as support clinical trial readiness for the development of regulatory compliant studies that can be conducted or supported within the BPCA Clinical Program.

5K12HD113189-03

(PI: Gonzalez)

Sponsor: NIH

Total Annual Amount (including Indirect Costs): \$292,194

Budget Dates: 1/23/24-7/31/25

Title: National Career Development Program for Researchers in Pediatric Clinical Pharmacology.

Major Goals: This career development program will enable scholars to generate the publication record, preliminary data, and skill set that is necessary to be competitive for independent research grants. Following completion of the program, all scholars will be exceptionally well-positioned to pursue impactful careers focused on promoting the safe and effective use of medications in children. I am a co-Investigator.

3U24-TR001608-06S1

(PD/PI: Benjamin, D./Hernandez A.)

Sponsor: NCATS

Total Award Amount (including Indirect Costs): \$77,049,200

Dates: 04/17/2021-06/30/2025

Title: ACTIV 6

Major Goals: Establish and Coordinate ACTIV-6 to support a multi-site, multi-network, master clinical trial protocol with an adaptive design for evidence generation of repurposed medications in the treatment of COVID-19 outpatient.

3U24-TR001608-07S1

(PI: Benjamin)

Sponsor: NIH

Total Award Amount (including Indirect Costs): \$21,469,057

Dates: 04/17/2021– 06/30/2025

Title: ACTIV -6.

Major Goals: Establish and coordinate ACTIV-6 to support a multi-site, multi-network, master clinical trial protocol with an adaptive design for evidence generation of repurposed medications in the treatment of COVID-19 outpatient.

HHSN 275201800003I TO6

(PI: Greenberg)

Sponsor: NICHD

Total Award Amount (including Indirect Costs): \$6,798,777

Dates: 9/12/2019 - 6/30/2025

Title: Clinical Pharmacokinetics and Safety Trials in Individuals with Down Syndrome

Major Goals: The purpose of this task order is to leverage the infrastructure of the PTN to provide an additional platform for the inclusion of individuals with Down Syndrome into pharmacology-based clinical trials conducted under the BPCA Clinical Program.

5U24-TR001608-07

(PI: Benjamin)

Sponsor: NCATS

Total Award Amount (including Indirect Costs): \$39,945,859

Dates: 7/1/2016 - 6/30/2025

Title: Center for Innovative TRIals in ChilDrEN and AdulTs (TRIDENT)

Major Goals: Well-designed studies and innovative solutions are urgently needed to overcome the barriers to successfully complete multicenter trials in order to improve public health. This proposal represents a partnership between Duke and Vanderbilt Universities and takes advantage of our complementary strengths that will enable us to establish the required infrastructure to reduce the time needed to initiate and efficiently conduct multicenter clinical trials by the CTSA.

75N94023-F00001-TO14 Opt1

(PI: Benjamin)

Sponsor: NIH

Total Award Amount (including Indirect Costs): \$3,385,60

Dates: 6/04/2023–6/3/2025

Title: Core Function Activities 2.0.

Major Goals: As the work and output of PTN have grown there is an increased need for scientific management of the network in order to accomplish the network goals. This translated to additional faculty effort to oversee and manage the scientific needs of the network and subcommittees that are involved in the development of protocols and FDA submissions. With the growth of PTN, we also have a greater need for administrative oversight, which involves staffing effort around program management, financial management, and process development. I am the principal investigator.

Duke STAR Program

(PI: Benjamin)

2R25HD076475-10

Current Annual Directs: \$99,800

Dates: 05/01/2013 – 4/30/2024 – Year 10

Title, scope, and role: NIH Duke Summer Training in Academic Research Program (R25) –Program director and PI for this training program comprising a partnership between Duke, North Carolina Central University (the nation's first liberal arts college for African Americans), and North Carolina public schools. Undergraduates, high school students, and high school teachers are exposed to clinical research concepts and methods through interaction with the DCRI's Pediatric Clinical Pharmacology and Therapeutics faculty. Dr. Benjamin provides oversight for all aspects of the program, chairs the senior mentorship team, provides mentorship for junior mentors, promotes efforts to link this program with other DCRI education efforts, and works to ensure minority recruitment and responsible conduct of research.

5U24-TR004314-02

(PI: Benjamin)

Sponsor: NIH

Current Annual Directs: \$1,599,232

Dates: 09/23/2022 – 08/31/2024

Title: HEAL Clinical Coordinating Resource Center for the Pain Management Effectiveness Research Network

Scope: In support of the HEAL Pain Management ERN the Duke/Vanderbilt Trial Innovation Center will: Specific Aim 1. Provide clinical trial leadership and expertise, assistance in study and protocol design, study implementation, and management, in collaboration with the other HEAL ERN Resource Centers, for existing and new HEAL ERN trials. Specific Aim 2. Serve as the clinical coordinating resource center (CCRC) for existing and new HEAL ERN trials. Specific Aim 3. Provide single IRB support for HEAL ERN trials for existing and new HEAL ERN trials. Through completion of these specific aims, we will harmonize the HEAL studies to achieve major innovations in trial design and execution, including: combination and reuse of valuable data, efficiencies of implementation, shared

pain expertise among investigative teams, and the integration of three TICs as a cohesive unit, poised for future trial implementation.

3U24-TR004314-02S1

(PI: Benjamin)

Sponsor: NIH

Current Annual Directs: \$953,104

Dates: 09/23/2022 – 08/31/2024

Title: HEAL Clinical Coordinating Resource Center for the Pain Management Effectiveness Research Network

Scope: Specific Aim 1. Provide clinical trial leadership and expertise, assistance in study and protocol design, study implementation, and management, in collaboration with the other HEAL ERN Resource Centers, for existing and new HEAL ERN trials. Specific Aim 2. Serve as the clinical coordinating resource center (CCRC) for existing and new HEAL ERN trials.

1OT2HD107559-02

(PD/PI: Zimmerman K./Benjamin, D.)

Sponsor: NIH

Current Annual Directs: \$1,261,741

Dates: 04/15/2021-03/31/2024

Title: SARS-CoV-2 Screening and Diagnostic testing for return to K-12 schools

Scope: Our goals are to ensure the safe and equitable return of K-12 school children to US public schools, maximize access to in-person learning, and limit the spread of SARS-CoV-2 in Black and Latino communities.

SA-D401-02/HHSO100201400002I

(PI: Benjamin)

Sponsor: Technical Resources International/BARDA

Total Awards: \$37,146,795

Dates: 08/17/2020 - 12/31/2023

Title: ACTIV-1

The ACTIV-1 master protocol will test promising immune modulator compounds, a class of drugs that help minimize the deleterious effects of an overactive immune response to SARS-CoV-2 infection. This Phase 3 trial will enroll hospitalized adults with moderate to severe COVID-19 disease. It will evaluate the safety and efficacy of at least three immune modulators when given as an add-on therapy to remdesivir, an antiviral approved for treatment of COVID-19, and the standard of care in use at local clinics. The different treatments will be assessed with respect to illness severity, recovery speed, mortality and hospital resource utilization.

5U2COD023375-06

(PI: Smith and Benjamin)

Sponsor: NIH

Current Annual Directs: \$1,148,831

Dates: 09/21/2016 – 08/31/2023

Title: ECHO Coordinating Center

Scope: The Environmental Influences on Child Health Outcomes (ECHO) program promises to leverage extant pediatric cohorts to test new hypotheses of how environmental exposures impact pediatric health. The Duke Clinical Research Institute (DCRI) will serve as the ECHO Coordinating Center (ECHO CC) to provide the organizational framework for the management, direction, and overall coordination of all common ECHO activities. I am the co-investigator.

5U2-COD023375-05

(PI: Smith/Newby/Benjamin)

Sponsor: NIH

Total Awards: \$1,837,200

Dates: 09/21/2016 - 08/31/2023

Title: ECHO Steering Committee Support and Communications Component

In order to coordinate all functions of the ECHO Leadership Team; develop and implement ECHO operating policies and procedures; develop targeted communication strategies for ECHO stakeholders; and develop and maintain the ECHO Web Portal, the DCRI will establish the ECHO CC Steering Committee Support and Communications Component (SC Component). The ECHO SC Component will focus on supporting communication between all ECHO components, investigators, and the public.

3U24-TR001608-05S3

(PI: Benjamin)

Sponsor: NCATS

Current Annual Directs: \$2,493,950

Dates: 09/26/19-06/30/23

Title: Duke/VUMC TIC Supplement for HEAL PAIN Studies

Scope: The Helping to End Addiction Long-term (HEAL) initiative was developed to identify scientific solutions to the national opioid public health crisis as quickly as possible. As part of this initiative, the NIH HEAL Pain Management Effectiveness Research Network (HEAL Pain ERN), will use the infrastructure of the NCATS Trial Innovation Network to provide scientific guidance and coordination of the HEAL Pain ERN Trials. Specifically, the three Trial Innovation Centers (TICs) at Duke/Vanderbilt, University of Utah and Johns Hopkins/Tufts will provide integrated functions for the clinical coordinating center (CCC), data coordinating center (DCC), and biostatistics core for the HEAL Pain ERN.

3U24-TR001608-05S2

(PI: Benjamin)

Sponsor: NCATS

Current Annual Directs: 549,882

Dates: 07/16/2016-06/30/2023

Title: COVID-19 Supplement - Center for Innovative TRIals in ChilDrEN and AdulTs (TRIDENT)

Scope: Evaluate the frequency of transmission and outcomes of infants and their mothers affected by COVID-19.

EP5064792

(PI: Benjamin)

Sponsor: NC Department of Public Instruction

Current Annual Directs: \$500,000

Dates: 03/26/2021-05/31/2022

Title: ABCs of North Carolina Plan A

In March 2021, the North Carolina General Assembly directed NCDPI to contract with Duke for the ABC Science Collaborative of the Duke School of Medicine (ABC Collaborative) to provide data collation, analysis, and interpretation of COVID-19 related metrics of student, teacher, and staff safety for local school administrative units providing in-person instruction under Plan A for middle and high school students.

1OT2HD107559-01

(PD/PI: Zimmerman K./Benjamin, D.)

Sponsor: NIH

Current Annual Directs: \$1,866,166

Dates: 04/15/2021-03/31/2022

Title: SARS-CoV-2 Screening and Diagnostic testing for return to K-12 schools

To determine appropriate testing approaches (surveillance, screening, and/or diagnostic testing); testing frequency; barriers to testing; perceptions of testing among the key stakeholders in school-based settings; timely return of test results to the child and/or their parent or guardian; determine appropriate approaches to implement strategies to mitigate transmission of SARS-CoV-2.

5U18FD006298-04

(PI: Benjamin and Cohen-Wolkowicz)

Sponsor: FDA

Total Awards: \$1,000,000

Dates: 09/25/2017 – 08/31/2022

Title: Global Pediatric Clinical Trials Network

The goal of the collaborative G-PCTN is to establish the infrastructure to efficiently conduct scientifically sound global pediatric clinical trials that will be leveraged by sponsors to generate regulatory-grade quality data in support of pediatric product development and to improve pediatric public health.

HHSN275201800003I - TO1 OP2

(PI: Benjamin)

Sponsor: NICHD

Current Annual Directs: \$603,278

Dates: 06/04/2021 - 06/03/2022

Title: Pediatric Trials Network 2.0_ Task Order 1_ Core Function Activities Option 3

The purpose of this Task Order is to establish and maintain centralized teams of experts who will develop protocols and informed consent forms and oversee, monitor and support all scientific and clinical aspects of research activities under the BPCA-PTN IDIQ contract.

NIH Contract: HHSN-275201000003I TO1-OPT 4

(PI: Benjamin)

Sponsor: NICHD

Current Annual Directs: \$973,488

Dates: 6/04/202 – 6/03/2023

Title, scope, and role: The purpose of this Task Order is to establish and maintain centralized teams of experts who will develop protocols and informed consent forms and oversee, monitor and support all scientific and clinical aspects of research activities under the BPCA-PTN IDIQ contract.

HHSN275201800003I - TO1 OP3

(PI: Benjamin)

Sponsor: NICHD

Current Annual Directs: \$223,547

Dates: 06/04/2021 - 06/03/2022

Title: Pediatric Trials Network 2.0_ Task Order 1_ Core Function Activities Option 3.1

NIH Contract: HHSN275201800003I / HHSN27500001

(PI: Benjamin)

Sponsor: NICHD

Direct Costs: \$1,014,917 (Base Period) Option Periods 1 – 4 total \$3,389,372

Dates: 06/04/2018 – 06/03/2020 (Base Period) Option Periods 1 – 4 end date of 06/03/2023

Title, scope, and role: Pediatric Trials Network Core Function Activities

PTN 2.0 Task Order #2_ Master Protocol

(PI: Benjamin and Zimmerman)

Sponsor: NICHD

Total Awards: \$1,745,389.00

Dates: 03/20/2020

Title: Mstr Prot - COVID-19 Supplement - Award Period #1

NIH Contract: HHSN275201800003I / HHSN27500045

(PI: Benjamin)

Sponsor: NICHD

Direct Costs: \$7,397,526

Dates: 09/28/16-08/16/21

Title, scope, and role: Pediatric Trials Network #45 Anti-Psychotic Treatment

The LAP01 study is a prospective, multi-site, Phase 4, longitudinal observational study designed to systematically collect robust longitudinal post-marketing safety and quality of life data about multi-year pediatric treatment with risperidone or aripiprazole. The primary objective is to evaluate the long term pathologic weight changes associated with multi-year risperidone or aripiprazole therapy over a period of 24 months in children ages 3 - <18 years.

NIH Contract: HHSN275201800003I TO6

(PI: Becker/Benjamin)

Sponsor: NICHD

Direct Costs: \$2,077,194

Dates: 09/12/19-09/11/22

Title, scope, and role: Clinical Pharmacokinetics and Safety Trials in Individuals with Down Syndrome
The goal of the study is to characterize the PK and PD of drugs commonly prescribed to children with Down syndrome.

5K24HD058735-10

(PI: Benjamin)

Direct Costs: \$130,089

Dates: 4/1/2009–12/31/2019

Title & Scope: Mentorship of early-career pediatricians in quantitative methods and therapeutic. This is a grant to provide me protected time to mentor junior physicians at Duke University.

5T32GM086330-08

(Co-Investigator: Benjamin)

Sponsor: NIGMS and NICHD

Direct Costs: \$ 330,500

Dates: 07/01/2011–6/30/2021

Title, scope, and role: UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program.

This is a postdoctoral training program in clinical pharmacology, multi-institutional training collaboration between the University of North Carolina (UNC), Duke University, and the Hamner Institute for Drug Safety Sciences.

5T32HD043029-15

(PI/Project Director: Benjamin)

Direct Cost: \$285,452

Dates Budget Period: 05/01/2017 – 04/30/2018

Title: Duke Research Training Program for Pediatricians

Scope: The Institutional Research Training Grant supports fellowship training in the Department of Pediatrics at Duke University Medical Center. The long-term objective of the training program is to foster the growth and development of pediatric investigators who are prepared to pursue independent academic careers examining important issues relevant to the health and well-being of children. The program will generally provide funding for two years of investigation and will emphasize the application of cell and molecular biologic approaches and rigorous clinical and epidemiologic methods to improve our understanding of the processes that underlie pediatric diseases and to develop new and effective therapies for children.

5UL1-TR001117-02

(PI: Boulware, Li, McNamara)

Direct Cost: \$\$5,781,766

Dates: 9/26/2013 -4/30/2018

NCATS

Title: Duke CTSA

Scope: The Duke Clinical and Translational Science Award (CTSA) provides infrastructure support to investigators conducting research along the translational spectrum. The CTSA offers resources based upon common needs among researchers, including education, biostatistics, biobanking, regulatory

expertise, ethics, pilot funding and recruitment assistance. The program also includes tailored resources for specialized needs across research communities that include early translation, proof of concept, site-based research and population based research, which includes multi-site trials, outcomes, health services, implementation science and community engaged research. The Duke CTSA fosters the translational research process, ensuring that new discoveries are developed and evaluated more quickly and that clinical research is done with high quality, efficiency, safety and cost-effectiveness.

Role: Director, Education Component

Cempra Pharmaceuticals, Inc.: HHSO100201300009C

(PI: Cohen-Wolkowicz)

Direct Annual Cost: \$2,414,668

Dates: 05/24/13 – 11/30/2016

SOLI - Solithromycin Pediatric Development Program (Phase 1A)

SOLI - Solithromycin Pediatric Development Program (CLIN Period 1 Phase IB)

SOLI – Solithromycin Pediatric Development Program Phase II/III Year 1

The main purpose of the study is to evaluate the pharmacokinetics of Solithromycin in children 0-17 years of age with community acquired bacterial pneumonia. I provide mentorship to the PI and have broad oversight related to operations, project management, and collaborate with the PI on scientific thought leadership.

Fluconazole prophylaxis for the prevention of candidiasis in neonates <750 grams birth weight

(PI: Benjamin)

02828-2

Thrasher Research Foundation

Direct Costs: \$451,000

Dates: 07/01/2009–06/30/2013

Title, scope, and role: Prevention of invasive candidiasis and neurodevelopmental follow-up.

Prevention of invasive candidiasis: PK, safety, and neurodevelopmental outcomes

(PI: Benjamin)

5R01HD057956-05

Direct Annual Costs: \$500,000

Dates: 6/28/2008–5/31/2013

I am the PI for a multi-center randomized trial of the safety and efficacy of fluconazole to prevent invasive candidiasis in premature infants.

Prevention of Invasive Candidiasis: PK, Safety, and Neurodevelopmental Outcomes

(PI: Benjamin)

4R01FD003519-04

Direct Annual Costs: \$400,000

Dates: 9/20/2008–7/31/2012

This was a co-funding application for the grant through NICHD (5R01HD057956-01) outlined above. This mechanism was through the Orphan Drug Program; the goals and my role were as per above.

Thrasher Research Foundation

(PI: Benjamin)

Sponsor: Thrasher Research Fund

Direct Annual Costs: \$197,000

Effort: 0.5 months

Dates: 03/01/2004–01/31/2012

Title, scope, and role: "Early Diagnosis of Neonatal Candidiasis.": The project evaluated new diagnostic assays for neonatal candidiasis.

Neurodevelopmental follow-up and prevention of invasive candidiasis

(PI: Benjamin)

Thrasher Research Fund

Direct Annual Costs: \$220,000

Dates: 1/1/2009–1/1/2012

Title, scope, and role: Evaluate the risks of antifungal therapy in 2 year neurodevelopmental follow-up.

1UL 1RR024128-01

(PI: Califf)

Sponsor: NCRR

Direct Annual Cost: \$6,320,676.00

Effort: 0.5 months

Dates: 9/30/06–9/29/11

Role: Co-Investigator

Duke CTSI (DTMI)

To support infrastructure in the development of the Duke Clinical and Translational Science Institute. This new institute will link with other key programs, including the Duke Comprehensive Cancer Center, the Duke University School of Nursing, and the Duke Institute for Genome Sciences and Policy, to create a comprehensive home for clinical and translational researchers. My role was to provide analytic thought leadership to the pediatric group within the DTMI.

Grant Number: 3 UL1 RR024128-04S5

(PI: Benjamin)

Sponsor NCRR/NICHD

Direct Annual Costs: \$499,116

Dates: 9/30/09–9/30/10

Title, scope, and role: The proposed research developed an algorithm to improve PK trial testing in premature infants. This was a supplement to the main CTSA grant.

Government Contract HHSN2672007000051C

(PI: Benjamin)

Sponsor: NIDDK/NICHD

Direct Costs: \$485,667

Dates: 09/30/2008–09/30/2010

Title, scope, and role: These funds were used to prospectively test scavenge sampling as a viable method of estimating PK in FDA compliant trials, to evaluate the CSF penetration of meropenem, and to investigate the tissue of meropenem; I was the PI, but two trainees (P. Brian Smith and Michael Cohen-Wolkowicz) led the research.

Government Contract HHSN2672007000051C

(PI: Benjamin)

Sponsor: NIDDK/NICHD

Direct Costs: \$5,196,786

Dates: 09/30/2007–09/30/2010

Title, scope, and role: "BPCA: Use of Meropenem in Infants." The scope of this project was to: 1) study meropenem PK, safety, and tolerability in young (<91 days old) infants with suspected or early intra-abdominal infections; and 2) determine the feasibility of a study comparing safety and efficacy of meropenem in 600 infants with complicated intra-abdominal infections. I was the protocol chair and principal investigator.

1U10-HD45962-06

(PI: Benjamin)

Sponsor: NICHD

Direct Annual Costs: \$246,619

Effort 1 month

Dates: 01/01/04–12/31/09

Title, scope, and role: The North Carolina Collaborative PPRU Network increased the availability of pediatric pharmacokinetic data in children. I was the principal investigator.

K23 HD-044799-01 (PI: Benjamin)
Sponsor: NICHD
Direct Annual Costs: \$131,476
Effort 6 months
Dates: 1/1/2005–12/31/2008
Title, scope, and role: “Early Diagnosis of Neonatal Candidiasis.” The project evaluated new diagnostic assays and described risk factors for neonatal candidiasis. I was the PI.

Pharmacokinetics of Micafungin (PI: Smith; Faculty Sponsor: Benjamin)
Co-Sponsorship: Astellas and NICHD
Direct Annual Costs: \$75,000
Dates: 7/2006–7/2008
I arranged financial support for a multi-center pharmacokinetic study to be completed in neonates, and arranged for one of the fellows that I mentored to be the principal investigator. Dr. Smith was the PI for the project and the first author of the paper.

Pharmacokinetics of Micafungin (PI: Benjamin)
Sponsor: Astellas
Direct Annual Costs: \$40,000
Effort 0.25 months
Dates: 7/2006–7/2008
Title, scope, and role: I was the protocol chair and steering committee member for two pharmacokinetic studies to be completed in neonates, infants, and children. These projects evaluated the safety and pharmacokinetics of micafungin in three different patient populations.

Treatment of neonatal candidiasis (PI: Benjamin)
Sponsor: Astellas
Direct Annual Costs: \$100,000
Effort: 0.25 months
Dates: 1/2006–7/2008
Title, scope, and role: The project was to test the efficacy of micafungin for the treatment of neonatal candidiasis.

U01 AI66590-02 (PI: Mitchell)
Sponsor NIAID
Effort: 10%
Dates: 7/1/2005–6/30/2007
Title, scope, and role: The project developed a platform for new diagnostic tools in invasive infections. My role was to lead the efforts in the development of PCR as a diagnostic tool for neonatal candidiasis, and to lead the analysis and interpretation of the data.

Gerber Grant (PI: Malcolm)
Sponsor: Gerber Foundation
Effort: 3%
Dates: 07/2004–06/2006
Title, scope, and role: The project described risk of infection and other outcomes in premature infants under a variety of feeding regimens. I was the statistician for the project.

Industry-sponsored data and safety monitoring board #2472 (PI: Benjamin)
Sponsor: Vicuron Pharmaceuticals

Direct Costs: \$40,000

Effort: 12%

Dates: 01/2003–12/2004

Title, scope, and role: Data and safety monitoring board: protect the well-being of patients enrolled in a pivotal multi-national study for the efficacy of a new antifungal agent. I was the lead statistician

Muscular Dystrophy Association

(PI: Koeberl)

Sponsor: Muscular Dystrophy Association

Effort: 4.6%

Direct Costs: \$99,927

Dates: 10/2002–09/2004

Title, scope, and role: Preclinical Studies for Development of Gene Therapy in Glycogen Storage Disease II with AAV Vectors. Observational study. I was the statistician.

Pediatric Fungal Network

(PI: Benjamin)

Sponsor: Pfizer

Direct Costs: \$50,000

Effort: 1%

Dates: 7/1/03–7/1/04

Title, scope, and role: Described risk factors for invasive fungal infections in children and neonates.

Industry-sponsored clinical trial: #2337

(PI: Benjamin)

Sponsor: NABI Pharmaceuticals

Direct Costs: \$611,000

Effort: 20%

Dates: 03/2003–05/2004

Title, scope, and role: Neonatal Altastaph: Randomized trial to determine the pharmacokinetic and safety of a new product to prevent bacteremia in premature infants.

R03 HD42940-02

(PI: Benjamin)

Sponsor: NICHD

Direct Costs: \$154,000

Effort: 40%

Dates: 07/19/2002–06/30/2004

Title, scope, and role: "Prediction of Antiretroviral Failure." The project outlined clinical parameters to predict outcomes and therapy failure.

Industry-sponsored clinical trial: #2312

(PI: Benjamin)

Sponsor: Vicuron Pharmaceuticals

Direct Costs: \$277,100

Effort: 15%

Dates: 01/2003–05/2004

Title, scope, and role: Pediatric PK study. First use of a new antifungal agent in the pediatric population; described the pharmacokinetics of the anidulafungin in children.

HIV Fellowship Training Grant

(PI: Hamilton)

Sponsor: NIAID

Direct Annual Costs: \$42,000

Effort: 100%

Dates: 4/99–4/01

Title, scope, and role: Training grant. I was a post-doctoral fellow supported by the grant.

NIH Contract: HHSN-27500001 Pediatric Trials Network Task Order #1 (PI: Benjamin)
Sponsor: NICHD
Direct Cost: \$585,875.00
Dates: 9/30/10–8/02/2015
Title, scope, and role: Pediatric Trials Network program management support.

NIH Contract: HHSN-27500002 Pediatric Trials Network Task Order #2 (PI: Benjamin)
Sponsor: NICHD
Direct Annual Costs: \$366,863.00
Dates: 09/30/2010 – 06/30/2013
Title, scope, and role: Pediatric Trials Network Hypertension Protocol Development Team.

NIH Contract HHSN27500003 Pediatric Trials Network Task Order #3 (PI: Benjamin)
Sponsor: NICHD
Total Costs: \$250,806
Dates 12/6/2010–3/5/2013
Title, scope, and role: This trial will investigate the kinetics and safety of metronidazole in premature infants. One of my mentees (Dr. Michael Cohen-Wolkowicz) is the PI for this award, and I serve a mentoring role in accordance with my role as Chair of the Pediatric Trials Network and my K24 award.

NIH Contract: HHSN-27550003 Pediatric Network Trials Task Order #4 (PI: Benjamin)
Sponsor: NICHD
Direct Costs:\$1,416,841.00
Dates: 5/25/2010–5/31/2014
Title, scope, and role: “Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients with Sickle Cell Anemia.” We will characterize the disposition and evaluate the relative bioavailability of liquid HU formulation PK parameters. One of my mentees (Dr. Chiara Melloni) leads this award, and I serve a mentoring role in accordance with my role as Chair of the Pediatric Trials Network and my K24 award.

NIH Contract: HHSN-27550005 Pediatric Trials Network Task Order #5 (PI: Benjamin)
Sponsor: NICHD
Direct Costs: \$752,268.00
Dates: 6/20/2011–10/19/2015
Title, scope, and role: “Acyclovir.” We will be investigating pharmacokinetic, dosing, tolerability, and safety parameters for acyclovir in preterm and full term infants.

NIH Contract: HHSN-27550006 Pediatric Trials Network Task Order #6 (PI: Benjamin)
Sponsor: NICHD
Direct Costs: \$4,458,276.00
Dates: 8/15/2011–8/14/2016
Title, scope, and role: “Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care.” One of my mentees (Dr. Chiara Melloni) is the PI for this award, and I serve a mentoring role in accordance with my role as Chair of the Pediatric Trials Network and my K24 award.

NIH Contract: HHSN-27550007 Pediatric Trials Network Task Order #7 (PI: Benjamin)
Sponsor: NICHD
Direct Costs: \$1,399.882.00

Dates: 8/22/2011–8/31/2015

Title, scope, and role: “Safety and Pharmacokinetics of Lisinopril in Pediatric Kidney Transplant Recipients.” I am the co-investigator.

NIH Contract: HHSN-27550008 Pediatric Trials Network Task Order #8 (PI: Benjamin)

Sponsor: NICHD

Direct Annual Costs: \$482,923.00

Dates: 9/15/2011–9/14/2013

Title, scope, and role: “Efficacy of the Mercy Tape in Predicting the Actual Weight of Children.”

NIH Contract: HHSN-27550009 Pediatric Trials Network Task Order #9 (PI: Benjamin)

Sponsor: NICHD

Direct Costs: \$539,784

Dates: 9/15/2011–9/15/2016

Title, scope, and role: “Midazolam.” We will determine if the efficacy IM midazolam is not inferior to IV lorazepam and assess the rapidity of both medications comparing intervals for termination of clinical evident seizures.

NIH Contract: HHSN-275500010 Pediatric Trials Network Task Order #10 (PI: Benjamin)

Sponsor: NICHD

Direct Annual Costs: \$249,099.00

Dates: 9/26/2011–6/25/2013

Title, scope, and role: “Ampicillin.” This study will obtain specific pharmacokinetic & pharmacodynamics parameters and assess the safety & tolerability of ampicillin monotherapy or in combination with other antibiotics for the treatment of sepsis and/or meningitis in neonates.

NIH Contract: HHSN-275500011 Pediatric Trials Network Task Order #11 (PI: Benjamin)

Sponsor: NICHD

Direct Annual Costs: \$509,277.00

Dates: 9/26/2011–3/25/2013

Title, scope, and role: “Obesity Informatics Database.” We will develop a pediatric drug database that provides accurate dosing recommendations and identify the molecular characteristics that may offer a predictor of adipose based pharmacokinetic variance in children.

NIH Contract: HHSN-27500012 Pediatric Trials Network Task Order #12 (PI: Benjamin)

Sponsor: NICHD

Direct Annual Cost: \$441,265

Dates: 8/24/2012–8/23/2014

Title, scope, and role: Pediatric Trials Network Protocol Development: Oversee PTN protocol development and start-up activities.

NIH Contract: HHSN-27500013 Pediatric Trials Network Task Order #13 (PI: Benjamin)

Sponsor: NICHD

Direct Cost: \$939,124

Dates: 8/27/2012–2/26/2017

Title, scope, and role: “Pharmacokinetics of Antistaphylococcal Antibiotics in Infants.” The purpose of this task order is to study the pharmacokinetics of rifampin, ticarcillin-clavulanate, and clindamycin in infants.

NIH Contract: HHSN-27500014 Pediatric Trials Network Task Order #14 (PI: Benjamin)

Sponsor: NICHD

Direct Cost: \$1,156,356.00

Dates: 8/27/2012–6/30/2017

Title, scope, and role: "Sildenafil Study." The purpose of this study is to assess the pharmacokinetics (PK) of sildenafil administered either intravenously or enterally as per standard of care in premature infants ≤ 28 weeks of gestational age with pulmonary hypertension.

NIH Contract: HHSN-27500015 Pediatric Trials Network Task Order #15

(PI: Benjamin)

Sponsor: NICHD

Direct Annual Cost: \$289,630

Dates: 9/25/2012–9/24/2015

Title, scope, and role: "Fluconazole Safety Trials." The purpose of this study is to evaluate the safety of prophylactic fluconazole in premature infants.

NIH Contract: HHSN-27500016 Pediatric Trials Network Task Order #16

(PI: Benjamin)

Sponsor: NICHD

Direct Cost: \$350,013

Dates: 9/25/2012–9/24/2015

Title, scope, and role: "Pediatrix Safety Study." The purpose of this study is to characterize the safety of drugs used in hospitalized infants.

NIH Contract: HHSN-27500017 Pediatric Trials Network Task Order #17

(PI: Benjamin)

Sponsor: NICHD

Direct Cost: \$1,420,601

Dates: 9/25/2012–12/08/2015

Title, scope, and role: "Bioanalytical Analysis: POPS1, Fluconazole, Meropenem." The purpose of this study is to establish a laboratory to develop and validate a bioanalytical method for quantifying fluconazole and meropenem in plasma and cerebrospinal fluid. One of my mentees (Dr. Michael Cohen-Wolkowicz) is the PI for this award, and I serve a mentoring role in accordance with my role as Chair of the Pediatric Trials Network and my K24 award.

NIH Contract: HHSN-27500018 Pediatric Trials Network Task Order #18

(PI: Benjamin)

Sponsor: NICHD

Direct Cost: \$1,044,435.00

Dates: 9/25/2012–9/27/2014

Title, scope, and role: "Safety and Pharmacokinetics of Multiple Dose Intravenous and Oral Clindamycin in Pediatric Subjects with BMI $\geq 85^{\text{th}}$ Percentile." The purpose of this study is to determine the PK of IV clindamycin in overweight and obese children and adolescents. One of my mentees (Dr. Kevin Watt) is the PI for this award, and I serve a mentoring role in accordance with my role as Chair of the Pediatric Trials Network and my K24 award.

NIH Contract: HHSN-27500019 Pediatric Trials Network Task Order #19

(PI: Benjamin)

Sponsor: NICHD

Direct Cost: \$984,140

Dates: 9/28/2012–9/27/2016

Title, scope, and role: "Sedation, Status Epilepticus Lab Reanalysis." The purpose of this study is to develop and validate new assays for lorazepam, diazepam, and midazolam as well as alcohol, propylene glycol, and polyethylene glycol concentration in plasma. One of my mentees (Dr. Kevin Watt) is the PI for this award, and I serve a mentoring role in accordance with my role as Chair of the Pediatric Trials Network and my K24 award.

NIH Contract: HHSN-27500020 Pediatric Trials Network Task Order #20

(PI: Benjamin)

Sponsor: NICHD

Direct Cost: \$2,839,326.00

Dates: 9/28/2012–6/25/2016

Title, scope, and role: “Pharmacokinetics of understudied drugs administered to children per standard of care (POPS) II.” The purpose of this study is to characterize the pharmacokinetics (PK) of understudied therapeutics administered to children per standard of care as prescribed by their treating caregiver. One of my mentees (Dr. Michael Cohen-Wolkowicz) is the PI for this award, and I serve a mentoring role in accordance with my role as Chair of the Pediatric Trials Network and my K24 award.

NIH Contract: HHSN-27500021 Pediatric Trials Network Task Order #21

(PI: Benjamin)

Direct Cost: 752,096.00

Dates: 7/22/2013 – 7/21/2016

Title: Pharmacokinetics of Multiple Dose Methadone in Children

Title, scope, and role: Purpose of this study is to determine the PK of enteral methadone in children treated for opiate withdrawal. I am the co-investigator.

NIH Contract: HHSN-27500022 Pediatric Trials Network Task Order #22

(PI: Benjamin)

Sponsor: NICHD

Direct Cost: \$246,123

Dates 7/22/2013-7/21/2015

Title scope and role: BPD Diuretics in the NICU The goal of this study is to describe the safety of diuretics used for prevention of BPD in premature infants. I am the co-investigator.

NIH Contract: HHSN-27500023 Pediatric Trials Network Task Order #23

(PI: Benjamin)

Sponsor: NICHD

Direct Cost: \$1,128,910

Dates 7/29/13-1/28/2018

Title scope and role: PK of Pantoprazole in Obese Children The goal of this study is to describe the PK and safety of pantoprazole in obese children. I am the co-investigator.

NIH Contract: HHSN-27500024 Pediatric Trials Network Task Order #24

(PI: Benjamin)

Sponsor: NICHD

Direct Cost: \$486,646

Dates: 9/24/2013–9/23/2014

Title, scope, and role: Pediatric Trials Network Protocol Development II: Oversee PTN protocol development and start-up activities.

NIH Contract: HHSN-275500025 Pediatric Trials Network Task Order #25

(PI: Benjamin)

Sponsor: NICHD

Direct Costs: \$6,192,715

Dates: 9/24/2011-7/31/2019

Title, scope, and role: “SCAMP.” This study will assess antibiotic safety in infants with complicate intra-abdominal infections

NIH Contract: HHSN-275500026 Pediatric Trials Network Task Order #26

(PI: Benjamin)

Sponsor: NICHD

Direct Costs: \$249,104

Dates: 1/30/14–1/29/2015

Title, scope, and role: “Pharmacokinetics of acute care medications in pediatric and adult subjects with BMI \geq 85th percentile.” We will evaluate published literature and drug labels to ascertain if enough

existing information is available to adequately treat obese children and adults in emergency situations.

NIH Contract: HHSN-275500027 Pediatric Trials Network Task Order #27 (PI: Benjamin)
Sponsor: NICHD
Direct Costs: \$2,658,646
Dates: 6/25/14–2/24/2018
Title, scope, and role: “Pharmacokinetics of understudied drugs administered to children per standard of care (POPS) III.

NIH Contract: HHSN-275500028 Pediatric Trials Network Task Order #28 (PI: Benjamin)
Sponsor: NICHD
Direct Costs: \$864,030
Dates: 9/23/2014 – 9/30/2016
Title, scope, and role: “Baby Tape: Develop and Validate a Tape Methodology Capable in Predicting the Actual Weight of Newborns and Infants up to 3 months of Age.” We will develop and validate a tape methodology capable in predicting the actual weight of newborns and infants up to 3 months of age.

NIH Contract: HHSN-275500029 Pediatric Trials Network Task Order #29 (PI: Benjamin)
Sponsor: NICHD
Direct Costs: \$388,312
Dates: 9/24/2014 – 9/23/2016
Title, scope, and role: Subject matter review and data analysis to evaluate the pharmacokinetics, safety, and efficacy of trimethoprim-sulfamethoxazole and clindamycin for the treatment of skin and soft tissue infections in children. One of my mentees (Dr. Michael Cohen-Wolkowicz) is the PI for this award, and I serve a mentoring role in accordance with my role as Chair of the Pediatric Trials Network and my K24 award.

NIH Contract: HHSN-275500030 Pediatric Trials Network Task Order #30 (PI: Benjamin)
Sponsor: NICHD
Direct Costs: \$1,655,939
Dates: 9/23/2014 – 2/24/2020
Title, scope, and role: “Bioanalytical Analysis for Pharmacokinetics of understudied drugs administered to children per standard of care (POPS).” We will evaluate the pharmacokinetics of understudied drugs currently being administered to children under Task Orders: HHSN27500006 (POPS I), HHSN27500020 (POPS II), and HHSN27500027 (POPS III), entitled “Pharmacokinetics of understudied drugs administered to children per standard of care (POPS).” We will also explore the pharmacodynamics (PD) associated with the administration of these drugs and collect samples for future biomarker exploration.

NIH Contract: HHSN2752010000031 Pediatric Trials Network Task Order #31 (PI: Benjamin)
Sponsor: NICHD
Direct Costs: \$367,714.00
Dates: 9/26/14-9/25/15
Title, scope, and role: Protocol Development III: Oversee PTN protocol development and start-up activities.

NIH Contract: HHSN2752010000032 Pediatric Trials Network Task Order #32 (PI: Benjamin)
Sponsor: NICHD
Direct Costs: \$1,257,265

Dates: 9/26/14-9/25/16

Title, scope, and role: Caffeine Therapy for Apnea of Prematurity

Scope: This is a literature review for premature infants as well as a retrospective cohort study of Pediatrix Medical Group to analyze exposure by GA, length of exposure and safety and a retrospective cohort study of approximately 400 infants at up to 6 sites. We will also apply to obtain primary data to support a CSR submission to FDA from the CAP randomized controlled trial of caffeine citrate vs placebo. I am the co-investigator.

NIH Contract: HHSN2752010000034 Pediatric Trials Network Task Order #34 (PI: Benjamin)

Sponsor: NICHD

Direct Costs: \$943,347

Dates: 8/03/15-8/02/2020

Title, scope, and role: Pediatric Trials Network Program Management Support

NIH Contract: HHSN2752010000031 Pediatric Trials Network Task Order #38 (PI: Benjamin)

Sponsor: NICHD

Direct Costs: \$663,631.00

Dates: 9/25/15 – 9/24/2016

Title: The purpose of this task order is to establish and centralize all protocol development activities to facilitate the timely start-up of the Pediatric Trials Network (PTN) clinical trials.

NIH Contract: HHSN2752010000031 Pediatric Trials Network Task Order #42 (PI: Benjamin)

Sponsor: NICHD

Direct Costs: \$498,298.00

Dates: 9/29/15-12/28/2017

Title, scope, and role: Hospital-acquired and Ventilator-associated Bacterial Pneumonias Pilot Study “PreStudy” Data Collection.

Sponsor: UCB (Schwarz)/UNC: Fellowship in Neurology Clinical Drug Development (PI: Benjamin)

Award \$160,330

Dates 2011–2012

Title, scope, and role: I was the mentor of a junior faculty member whose fellowship in adult neurology and clinical pharmacology were supported by UCB in a grant to Duke University

Sponsor: Division of Quantitative Sciences (PI Benjamin)

Award: \$755,000

I am the PI for the award; the money supports fellowship training in biostatistics, pharmacology, epidemiology, or econometrics

Sponsor: AstraZeneca (PI: Benjamin)

Dates: 2005-2008

Award: \$250,000

I am the PI for the award; 7 fellows supported in 2005–2008 for fellowship training at Duke.

Sponsor: Johnson & Johnson (PI: Benjamin)

Award: \$240,000

Dates 2006-2009

Under-Represented Minority Fellowship Award: from Johnson & Johnson to support an under-represented minority fellow in pediatric cardiovascular research

Sponsor: Pfizer (PI: Benjamin)

Dates: 2009

Award: \$100,000

This investigator initiated study, that I designed, investigated the PK of Anidulafungin in Young Infants and Toddlers; these data were submitted to FDA and EMA

Sponsor Cape Cod Associates Incorporated

(PI: Benjamin)

Date: 2004

Award: \$750,000

Receipt of unrestricted grant worth of kits, reagents, and support for research in early diagnosis of neonatal candidiasis

Sponsor Rockeby Incorporated

(PI: Benjamin)

Award: \$500,000

Date: 2004

Unrestricted grant for investigator initiated study that comprised kits, reagents, and support for research in early diagnosis of neonatal candidiasis

Sponsor: Pfizer

(PI: Benjamin)

Award: \$34,000

Dates: 2008

Investigator initiated study of Pharmacokinetics of Voriconazole in Children, 2008

Sponsor MedImmune Inc

(PI: Benjamin)

Award: \$85,000

Dates 2002-2008

Annual support for investigation into neonatal RSV epidemiology in North Carolina, 2003–2006, and visiting professorships at Duke, and educational research seminars for neonatal infections, and resident-fellow training and education

EDUCATION/TEACHING ACTIVITIES

Educational Program Development:

- 1) **Director, Resident Evidence Based Medicine Morning Report** (weekly conference) 2001-2006
- 2) **Director and Founder, Duke Clinical Research Institute Fellowship Program:** Supervise the education of all medical students, PhD students, residents, and fellows who train for careers in clinical research at the DCRI. Approximately 20–30 fellows and 5 students each year, 2004–2010.
- 3) **Director and Co-Founder, Resident Research Group:** Facilitate the research of 10–12 housestaff each year and lead 6 didactic sessions of the conduct of clinical research (annual), 2005–2012.
- 4) **Director and Founder, Fellows Educational Symposium:** Monthly research conference for Department of Pediatrics fellows and Duke Clinical Research Institute fellows, 2005–2012
- 5) **Director and Founder, Mentorship for Mentors Visiting Professor Program,** 2006–2014
- 6) **Director and Founder, Summer Clinical Research Program for High School and College Students,** (PI) NICHD R25, 2012-present

MENTORING ACTIVITIES

Mentorship of Duke University Medical Faculty: (Resulting scholarship indicated by underline of author's name in the publications above.)

I have been the primary mentor for faculty who have secured K23 support from NIH who are now themselves Distinguished Professors with their own endowments (Cohen-Wolkowicz, Hornik, Smith, Watt, Zimmerman). In addition, I have served as a primary mentor, secondary mentor, or 'mentor-for-the-mentor' for the career development awards (K23, K08, K24, K12, K25) listed below.

- 1) P. Brian Smith—2005–present, Distinguished Professor, with tenure, Department of Pediatrics, Division of Neonatal Medicine (continuous NIH support since 2005; completed K23, PI of R18, R34, and R01, has secured >\$300,000,000 in NIH funding)
- 2) Cassandra Moran—2007–2012, Instructor, Department of Pediatrics, Division of Hematology/Oncology (NIH support 2007-2012 until transition to industry and then FDA)
- 3) Michael Cohen-Wolkowicz—2009–present, Distinguished Professor with tenure, Department of Pediatrics, Division of Infectious Disease (continuous NIH support since 2007; completed K23, K24, PI of R01, U01 and secured >\$180,000,000 in federal grant support from NICHD, NLM, NIAID, NIGMS, NIMHD, OD, FDA, and BARDA)
- 4) Matthew M. Laughon—2010–present, Professor with tenure, University of North Carolina–Chapel Hill, (NIH supported, K23 completed, PI of both UM01 and R01)
- 5) Chiara Melloni, 2010–2019 as Assistant Professor, Department of Medicine, Division of Cardiology; currently Adjunct Associate Professor, Department of Medicine, Division of Cardiology (NIH supported)
- 6) Jeffrey Guptill, 2010–2020 as Assistant Professor, Department of Neurology; currently Adjunct Associate Professor, Department of Neurology (K23 completed; NIH supported)
- 7) Vivian Chu, 2012-2018 as Assistant Professor, Department of Medicine; currently Professor, Department of Medicine (NIH supported)
- 8) Kevin Watt, 2012–2019 as Assistant Professor, Department of Pediatrics, Division of Critical Care Medicine; currently Distinguished Associate Professor in Clinical Pharmacology, Associate Professor of Pediatrics, and Division Chief of Clinical Pharmacology in Department of Pediatrics, University of Utah Health (K23 completed; NIH supported)

- 9) Christoph Hornik, 2013-present, Distinguished Professor and Vice Chair for Research, Department of Pediatrics, Division of Cardiology and Pediatric Critical Care (NIH supported, K23 completed, current K24)
- 10) Kanecia Obie Zimmerman, 2013-present, Distinguished Professor, Department of Pediatrics, Division of Pediatric Critical Care Medicine (K23 completed; NIH support includes >\$60,000,000 in NIH funding from NICHD, NHLBI, NCATS)
- 11) Daniel Gonzalez, 2015-present, Associate Professor, Department of Medicine and Department of Pharmacology and Cancer Biology (K23 completed; NIH supported)
- 12) Rachel Greenberg, 2016-present, Professor, Department of Pediatrics, Division of Neonatology (K24 current, PI of FDA and NIH grants)
- 13) Stephen Balevic, 2018-present, Associate Professor, Department of Pediatrics, Division of Pediatric Rheumatology (K23 completed)
- 14) Angelique Boutzoukas, 2020-present, Assistant Professor, Department of Pediatrics, Division of Infectious Disease, (current K23 NIH support, Benjamin co-mentor)
- 15) Rachel Randell, 2023-present, Assistant Professor, Department of Pediatrics, Division of Pediatric Rheumatology (current K23 NIH support, Benjamin co-mentor)
- 16) Elizabeth Thompson, 2024-present, Assistant Professor, Department of Pediatrics, Division of Pediatric Critical Care (current K23 NIH support, Benjamin co-mentor)

Training Programs (PI or MPI):

- 1) Principal Investigator (PI) NICHD K24 Training Program, Mentorship of early-career pediatricians in quantitative and therapeutic methods 2009-2019
- 2) Principal Investigator (PI or MPI) NIGMS T32 Training Program, UNC-Duke Clinical Pharmacology 2010-present
- 3) Principal Investigator (PI or MPI) NICHD T32 Pediatric Institutional Training Grant Principal Investigator 2012-2019
- 4) Multiple Principal Investigator (MPI) NICHD K12 Pediatric Clinical Pharmacology to support junior faculty 2023-present

Fellowship program development – Clinical Pharmacology:

Also referenced as, Mentoring > Training Programs #2

Over a 15-year period, I collaborated with colleagues at the University of North Carolina Chapel Hill to establish and expand a fellowship training program in pediatric clinical pharmacology and, later, general clinical pharmacology. The initiative began in 2003 with the North Carolina Collaborative Pediatric Pharmacology Research Unit (1U10-HD45962, PI Benjamin), a joint effort between Duke Pediatrics/DCRI and UNC School of Pharmacy. Over the next decade, we trained numerous students, fellows, and junior faculty, with eight junior faculty receiving NIH-sponsored career development awards under my mentorship. We secured a clinical pharmacology fellowship training grant (1T32GM086330, PIs Brouwer and Benjamin) and, in 2016, obtained American Board of Clinical Pharmacology accreditation for the program.

Mentorship of Duke University Fellows:

¹William Steinbach: Pediatric Infectious Disease—2001–2004

Pediatric Physician Scientist Training Grant Recipient

Current Positions: Pediatrician-in-Chief for Arkansas Children’s. Robert H. Fiser, Jr. MD Endowed Chair in Pediatrics, Chair of Pediatrics, and Associate Dean for Child Health at the University of Arkansas for Medical Sciences College of Medicine.

²Harmony Garges: Pediatric Infectious Disease—2002–2005

National Institutes of Health T32 Training Grant Recipient

Current Position: Senior Vice President, Head of Development, Glaxo Smith Klein R&D

¹Angela Wratney: Pediatric Critical Care—2003–2005

National Institutes of Health T32 Training Grant Recipient

Current Position: Chief, Pediatric Critical Care Medicine at SUNY Upstate Golisano Children's Hospital

²Ken Tiffany: Neonatology—2003–2005

Current Position: Assistant Professor, Neonatology Eastern Virginia Medical School

²Brian Smith: Neonatology—2004–2007

National Institutes of Health T32 Training Grant Recipient

Current Position: Distinguished Professor, Department of Pediatrics Neonatology Duke University

²Robert Lenfestey: Neonatology—2006–2008

National Institutes of Health T32 Training Grant Recipient

Current Position: Assistant Professor, Department of Pediatrics, Division of Neonatal Medicine

²Michael Cohen-Wolkowicz: Pediatric Infectious Disease—2006–2009

Lenox Baker Fellow for Neurodevelopmental Research

Current Position: Distinguished Professor with tenure, Pediatrics, Infectious Disease, Duke University

³Annette Ansong: Pediatric Cardiology—2005–2008

Johnson and Johnson Underrepresented Minority Research Fellow (PI Benjamin)

Current Position: Associate Chief, Outpatient Cardiology, Children's National Hospital

³Carissa Baker-Smith: Pediatric Cardiology—2006–2008

National Institutes of Health T32 Training Grant Recipient

Current Position: Professor of Pediatrics (Pediatric Cardiology) at Sidney Kimmel Medical College, Director of Pediatric Preventive Cardiology, at Nemours Children's

²Eric Schultz: Neonatology—2006–2008

Current Position: Provider at Greater Austin Allergy; Adjunct Professor of Pediatrics, Texas A&M College of Medicine

²Lauren Piper: Pediatric Critical Care—2008–2010

Current Position: Assistant Professor Pediatrics, Wake Forest University School of Medicine (Charlotte)

⁴Corbin Downey: Neonatology—2009–2012

Current Position: Assistant Professor Pediatrics, Wake Forest University School of Medicine (Winston-Salem)

²Kevin Watt: Critical Care—2010–2012

Current Position: Distinguished Professor in Clinical Pharmacology, Professor of Pediatrics, and Division Chief of Clinical Pharmacology in Department of Pediatrics, University of Utah Health

⁴Christoph Hornik: Cardiology and Critical Care—2009–2013

Current Position: Distinguished Professor and Vice Chair for Research, Department of Pediatrics, Division of Cardiology and Pediatric Critical Care, Duke University

⁴Jessie Bain: Critical Care—2011–2013

Current Position: Assistant Professor of Pediatrics, Fellowship Director, Pediatric Critical Care, Virginia Commonwealth University

⁴Jan Hau Lee: Critical Care—2011–2012

Current Position: Assistant Professor of Pediatric Critical Care KK Hospital Singapore

⁴Avi Patil: Obstetrics—2011–2013

Current Position: Clinical Assistant Professor, Maternal Fetal Medicine, Eastern Carolina University

⁴Kevin Turner: Neonatology—2011–2013

Current Position: Pediatrician at Pediatrix Neonatology of Florida

⁴Daniela Testoni: Neonatology—2011–2014

Current Position: Clinical Microbiologist and Adjunct Professor of Pediatrics, Paulista School of Medicine, Federal University of São Paulo

¹Mario Sampson: School of Pharmacology, Department of Medicine, UNC, 2011–2013

Current Position: Medical Officer Food and Drug Administration

²Julie Autmizguine: Infectious Disease—2012–2014

Current Position: Associate Professor, Departments of Pharmacology and Physiology, and Pediatrics, University of Montréal

⁴Daniel Gonzalez: 2013-2014

Current Position: Associate Professor, Department of Medicine and Department of Pharmacology and Cancer Biology, Duke University

²Rachel Greenberg: Neonatal-Perinatal Medicine – 2013-2016

Current Position: Professor, Department of Pediatrics, Division of Neonatology, Duke University

²Jessica Ericson—2013-2015

Current Position: Associate Professor, Pediatric Infectious Disease, Penn State Hershey Children's Hospital

²Kanecia Zimmerman—2013-2015

Current Position: Distinguished Professor, Department of Pediatrics, Division of Pediatric Critical Care Medicine

¹Samantha Dallefeld: 2016-2018

Current Position: Fellow, Pediatric Critical Care Medicine

¹Secondary-Mentor (epidemiology and data science) with John Perfect (mycologist), Adult Infectious Disease; Co-Mentor with Ira Cheifetz, Pediatric Critical Care

²Primary Mentor

³Co-Mentor with Jennifer Li, Pediatric Cardiology

⁴Co-Mentor with Brian Smith, Neonatology and Co-mentor with Michael Cohen-Wolkowicz, Infectious Disease

Mentorship of Duke University Pediatric Residents:

- Harmony Garges: 1999–2000
- Kelly Ross: 1999–2000
- Khalil El-Chammas: 2007–2008
- Mehreen Arshad: 2010
- Rachel Greenberg: 2009–2013

Mentorship of Medical Students:

- Lisa Nowell, 2006–2007, Duke University Medical Student and Roadmap Scholar
- Rachel Gottron-Greenberg, 2006–2008, Duke University Medical Student
- Naomi Jean-Baptiste, 2009–2010, Duke University Medical Student
- Kristian Becker, 2013-2015, Duke University Medical Student
- Simon Ascher, 2010–2012, Duke University Medical Student
- Emily Hsieh, 2010–2012, Duke National University Singapore Student
- Rachel Hughes, 2011–2012, Duke University Medical Student
- Nidhi Tripathi, 2011–2012, Duke University Medical Student
- Kristyn Swan, 2012-2013 University of North Carolina School of Medicine

Medical Students (as part of the STAR Program):

Also referenced as, Educational Program Development #6, with participants listed in STAR Program section.

In 2023, I established a program designed to provide medical students with clinical research training during the summer between their first and second years of medical school. This initiative

operates as part of the Summer Training in Academic Research (STAR) Program and targets students who have a particular interest in rural health and rural health research. Our inaugural cohorts in 2024 and 2025 included participants from Montana (through the WWAMI program), Louisiana, and South Carolina. Beginning in 2025-2026, the program expanded to accommodate 30 medical students, recruited nationally.

PhD Committees:

- 1) Souzan Yanni, PhD: Pharmacy, Leuven, Belgium, 2011
- 2) Michael Cohen-Wolkowicz, MD, PhD: School of Pharmacy, University of North Carolina, 2012
- 3) Wendy Carmelo Castillo MD, MSC PhD: School of Public Health, Department of Epidemiology, University of North Carolina, 2013
- 4) Nicole Zane, PharmD, PhD: School of Pharmacy, University of North Carolina, 2014
- 5) Kevin Watt, MD, PhD: School of Pharmacy, doctoral candidate University of North Carolina, 2016
- 6) Kanecia Zimmerman, MD PhD: School of Public Health, University of North Carolina 2021

Master's Thesis Committees:

- 1) Sigrid Berg, MD MPH: School of Public Health, Epidemiology, University of North Carolina, 2001
- 2) Charles Michael Cotten, MD MHS: Duke Clinical Research Training Program, 2003–2005†
- 3) Angela Wratney, MD MHS: Duke Clinical Research Training Program, 2003–2004†
- 4) Elizabeth Fox, MD MHS: Duke Clinical Research Training Program, 2003–2005†
- 5) Jennifer Li, MD MHS: Duke Clinical Research Training Program, 2004–2005†
- 6) Harmony Garges, MD MPH: School of Public Health Epidemiology, University of North Carolina, 2003–2005
- 7) P. Brian Smith, MD MHS: Duke Clinical Research Training Program, 2005–2006†
- 8) Vivian Chu, MD MHS: Duke Clinical Research Training Program, 2005–2006†
- 9) Robert Lenfestey, MD MHS: Duke Clinical Research Training Program, 2006–2008
- 10) Annette Ansong, MD MHS: Duke Clinical Research Training Program, 2006–2008†
- 11) Karol Cortez, MD MHS: Duke Clinical Research Training Program, 2007–2011†
- 12) Jason Johnson, MD MHS: Duke Clinical Research Training Program, 2012
- 13) Daniela Testoni, MD MHS: Duke Clinical Research Training Program, 2012-2014
- 14) Michele Henson, MD MHS: Duke Clinical Research Training Program, 2012-2013
- 15) Adela Rambí Cardones, MD: Duke Clinical Research Training Program, 2017-2018
- 16) Jessica Durkee-Shock, MD: Duke Clinical Research Training Program, 2021†

†Committee chair

Mentorship and Training of College and High School Students:

Also referenced as, Training > Educational Program Development #6

Also detailed in Mentorship > Medical Students (as part of STAR Program)

I am the Director and Founder of Duke's Summer Training in Academic Research (STAR) Program, which exposes up to 30 trainees to clinical research each year and has been continuously supported by NICHD since 2012 (PI: Benjamin). The program initially recruited from the Durham area (2012–2017), expanded to North Carolina (2017–2021), and currently recruits from throughout the United States. In 2023 the program was expanded to include medical students, and in 2026 the program expanded to accommodate 30 students. In 2025-2026, funding was supplied by a NIH grant through the Best Pharmaceuticals for Children Act (BPCA). For the 2026 summer program, there were 1690 applicants from 45 states.

In 2011, our research group started an informal summer program for high school and college students and then applied to the National Institute of Health via an R25 mechanism to start the North Carolina Collaborative Summer Research Program. Each year, 20–25 high school students, college students, and teachers participate in a summer research immersion experience with morning didactic lectures (with homework) on research ethics, neonatology, pharmacology, pediatric infectious disease, statistics, epidemiology, scientific writing, and presentation/professional skills, and afternoon team-based research projects guided by a subspecialty research fellow and a junior faculty member. Trainees produce figures, tables, an abstract, a poster, and a platform presentation; we ensure each trainee meets NEJM requirements for authorship, and projects are transitioned at summer's end to the subspecialty fellow and junior faculty member for publication that academic year (fellow as first author, trainees as middle authors, junior faculty member as senior author). As of 2025, over 260 trainees have participated, with over 95% being a co-author on a submitted and/or published peer-reviewed publication derived directly from their summer project.

STAR Program (formerly known as NCC-Summer Research Program)

2011

Taylor Hughes, Clemson University
Kristian Becker, Columbia University
Nathan Cho, East Chapel Hill High School

2012

Kristian Becker, Columbia University
Nathan Cho, East Chapel Hill High School

2013 (NCC-Summer Research Program)

Amar Patel, Durham Public Schools
Amiri Coleman, Durham Public Schools
Crystal Leonard, North Carolina Central University
Eddie Liu, Duke University
Ele'na Wilson, Durham Public Schools
James Tian, Duke University
Janet Onabanjo, North Carolina Central University
Jomani Cheeseman, North Carolina Central University
Jordan Cho, Stanford University
Jordan Kohman, Durham Public Schools Teacher
Katie Corey, Duke University
Morgan Oh, Voyager Academy
Nathan Cho, Stanford University
Sarah Kaneko, Durham Public Schools Teacher
Shelby Wilson, Durham Public Schools
Taylor Hughes, The Medical University of North Carolina

2014 (NCC-Summer Research Program)

Abdurrauf Muhammad, Durham Public Schools
Adrienne Davis, University of North Carolina
Angela Zhang, Duke University
Brooke Sauer, Durham Public Schools teacher
Chidera Ezume-Igwe, Durham Public Schools
Daniel Ye, Duke University

Francia Fang, Chapel Hill High School
Jiyu Cheong, North Carolina School of Science and Mathematics
John Fitz-Henley II, North Carolina School of Science and Mathematics
Jordan Riggs, Durham Public Schools
Megan Mayers, Durham Public Schools
Octavious Johnson, North Carolina Central University
Robert Morton, Chapel Hill High School
Sybil Robinson, Durham Public Schools
Taylor Blake, Durham Public Schools
Terrance Burgess, Durham Public Schools teacher
William Tuminski, University of North Carolina
Zachary Ao, East Chapel Hill High School

2015 (NCC-Summer Research Program)

Andrew Romaine, University of North Carolina
Briana Davis, North Carolina Central University
Courtney Fennell, North Carolina Central University
David Clark, Chapel Hill High School
Emma Crenshaw, Durham School of the Arts
Emma Morris, Orange High School
Evan Kim, Stuart Hall High School
Isaac Updike, Carrboro High School
Jasmine Perry, North Carolina Central University
Kaitlin Hendershot, Chapel Hill High School
Kaylyn Wright, Durham Public Schools
Khayla Daniel, Durham Public Schools
Madeleine Laughon, Chapel Hill High School
Makaela Johnson, Durham Public Schools
Matt Gilleskie, Chapel Hill High School
Sheikisha Thomas, Durham Public Schools teacher
Spencer Smith, University of North Carolina
Utibe Utin, North Carolina Central University
Vance Kite, Durham Public Schools teacher

2016 (NCC-Summer Research Program)

Alec Koss, Duke University
Alexander Valdez, Durham Public Schools
Andrew Tong, North Carolina State University
Anisha Watwe, Research Triangle High School
Anjali Gupa, Woods Charter School
Blair Gattis, Orange High School
Ciara Williams, North Carolina Central University
Daniel Gorham, Research Triangle High School
Destiny Savage, Southern Granville High School
Douglas Price, Voyager Academy Middle School, Teacher
Glaire Delancy, North Carolina Central University
Katie Guglielmo, Durham Public Schools
Kenya Homsley, North Carolina Central University
Kris Chellani, Chapel Hill High School
Menefese Kudumu-Clavell, Research Triangle High School
Nada Abuzaid, North Carolina Central University

Sabrina Sholomon, North Carolina School of Science and Mathematics
Sreekar Mantena, Green Hope High School
Sreepriya Gayam, University of North Carolina – Chapel Hill
Timothy MacArthur, Durham Public Schools, Teacher
Winsome Andrews, Durham Public Schools

2017 (Duke STAR Program)

Andromeda Crowell, Orange High School, Teacher
Beatrice Jean Wallace, Durham Public Schools – Northern High School, Teacher
Carla Escobar-Tomlienovich, North Carolina School of Science and Mathematics
Caroline Wechsler, Harvard University
Chandler Julianne McMillan, Duke University
Christopher Cortina, University of North Carolina Chapel Hill
Colman Freel, City of Medicine High School
Gabrielle Scales, Durham School of the Arts High School
James Fitz-Henley, North Carolina School of Science and Mathematics
Kathryn L Dudash, Cardinal Gibbons High School
Laura O'Sullivan, East Chapel Hill High School
Layla Shaw, Grimsley High School
Louis Harrison II, Hillside High School
Madeline Fowler, East Chapel Hill High School
Matthew Foster, University of North Carolina Wilmington
Nia Brown, North Carolina School of Science and Mathematics
Nicole Bell, Chapel Hill High School
Olivia Bretzius, Cardinal Gibbons High School
Rawan Fayyad, North Carolina Central University
Rebecca Ssengonzi, Green Hope High School
Simisola Gbadegesin, Durham School of the Arts High School
Sonam Shah, Raleigh Charter High School
Tanasha Owens, North Carolina School of Science and Mathematics
Toby Turla, Jordan High School
Tylah Harrison, Jordan High School

2018 (Duke STAR Program)

Aaliyah Langman, homeschooled
Anastasia (Anna) Ibrahim, Cary Academy
Angibel Tejada, North Carolina Central University
Aryeona Wilson, City of Medicine Academy
Caroline Chivily, Hamilton College
Christopher Laughon, Chapel Hill High School
Cordelia Hume, Woods Charter High School
Dean Tran, University of North Carolina – Chapel Hill
Glenn James, Durham Nativity School, Teacher
Isaias Reyes-Martinez, Durham Academy Upper School
Jonathan Mengistu, Duke University
Kaila Moore, City of Medicine Academy
Kate Lawson, Cardinal Gibbons
Kennedy Hill, Millbrook High School
Laila Jones, Wake STEM Early College High School
Mini Kpa, Durham School of Arts
Obianuju Udemadu, City of Medicine Academy

Robert Treadway, Cardinal Gibbons
Samuel Danquah, Raleigh Charter High School
Sujata Kishanni, Duke University
Taylor McMannen, JF Webb High School

2019 (Duke STAR Program)

Abdulaziz Norbekov, Green Hope High School
Alycia Love, Middle Creek High School
Ashley Lamb, homeschooled
Asia Brannon, University of North Carolina – Greensboro
Bethany Graham, Northern High School
Brianna Murphy, North Carolina State University
Christiana Akinyemi, Wake STEM Early College High School
Clifford Robbins, Durham Nativity School, teacher
Elijah Benjamin, Hargrave Military Academy
Gargi Dixit, Green Hope High School
Jacob Duncan, Wake Tech/ North Carolina State University
Jeffrey Faulkner, CW Stanford Middle School, teacher
Jonathan Greer, Enloe High School
Kalkidan Melaku, Apex Friendship High School
Kareen Taylor, Carrboro High School
Kayla Skinner, Wake STEM Early College High School
Lance Romana, University of North Carolina – Wilmington
Nicholas Paredes, Pine View High School for the Gifted
Nyssa Ndey-Bongo, Wake STEM Early College High School
Phillip Kang, STEM Early College NC A&T State University
Sriya Mantena, Green Hope High School
Stephen Cho, East Chapel Hill High School
Stephen Elliott, Franklin Academy
Sunshine Alvarez, University of North Carolina – Greensboro
Sylvia Murray, Cardinal Gibbons High School

2020 (Duke STAR Program) – cancelled due to COVID-19

2021 Duke STAR Program

Abigail Dickerson, Vance County Community College
Bria Caison, Heritage High School, Wake Forest, NC
Catherine Charles, Chapel Hill HS
Elizabeth Chan, Eastern Carolina University
Glory Kidimbu, Wake Early College High School
Jenny Yan, Riverside High School
Julia Storch, NC State University
Kelsey Lewis, NC Central University
Kristin Keeler, University of North Carolina – Chapel Hill
Mackenzie Telfaire, Enloe High School
Michael Bowen, Holly Springs High School, teacher
Noe Brown, University of North Carolina – Chapel Hill
Rachel Sielaty, University of North Carolina – Charlotte
Sarah (Ama) Kwabia, Middle Creek High School
Taran CoyneSmith, Chapel Hill High School
Toni Darden, University of North Carolina – Chapel Hill

Valerie Girgis, University of North Carolina – Chapel Hill
Vincent Kinduelo, Millbrook High School
William Roberts, Chapel Hill High School

2022 Duke STAR Program

Anh Nguyen, Southern High School of Energy and Sustainability
Anthony Kajencki, Carrboro High School, teacher
Avi Belbase, Tufts University
Chloe-ann Detwiler, Wake Early College of Health and Sciences
Ciara Strausser, University of Georgia
Courage Ndalama, Franklinton High School
Eba Moreda, Green Hope High School
Ezeji Nwanaji-Enwerem, NC Central University
Hannah Won, University of North Carolina – Chapel Hill
Hedille Al-Dhalimy, Wake Early College of Health and Sciences
Ian Troan, NC School of Science and Mathematics
Jai Narayan, Chapel Hill High School
Jennifer An, Stevenson High School, IL
Julia Henegar, Duke University
Katelyn Mann, Wakefield High School
Keshiyen Pieters, Northern High School, teacher
Mary Ha, University of North Carolina – Chapel Hill
Melanie Perez-Romero, City of Medicine Academy
Natalie Rodriguez, University of North Carolina – Chapel Hill
Ogugua Nwaezeigwe, University of North Carolina – Chapel Hill
Pavan Thakkar, Providence High School
Rachel Ssengonzi, Green Hope High School

2023 Duke STAR Program

Anish Paladugu, Green Hope High School
Anisha Roy, Enloe High School
Anjalee Hou, Eastern Carolina University
Athziry Espinso-Santiago, Southern High School of Energy and Sustainability
Bubacarr Jallow, Southeast Raleigh Magnet High School
Cameron Bradley, JD Clement Early College High School
Chay Beeson, North Carolina State University
Christie Dobbin, Leesville High School, teacher
Elijah Jacobs, Garner Magnet High School
Emma Lee, Stanton College Preparatory School, FL
Haley Thomassy, Florida Southern College
Jeffrey Faulkner, Orange Middle School, teacher
Lamece Azzam, Green Hope High School
Leonardo Baquero, Heritage High School
Lindsey Diaz, North Carolina State University
Madison Monteith, Raleigh Charter High School
Mina Cayli, Triangle Math and Science Academy
Rachel Rockwell, Duke University
Ryan Benjamin, Chapel Hill High School
Sarah Rumsey, Heritage High School
Scott Benjamin, Chapel Hill High School

Thomas Roberts, Chapel Hill High School
Veronica Quiett, NC School of Science and Mathematics

STAR Program Expansion 2024

Now includes High School, Undergraduate, Medical, and Graduate Students: 2024-present

In 2024, we expanded our STAR program in two dimensions. First, we expanded the program eligibility to include medical and graduate students. We accepted medical students from Nebraska, South Carolina, and Montana.

Adalia Stephan, Granville Early College
Allison Castro, Montana State University
Andrea Storer, Montana State University
Annalisa Hawk, University Washington School of Medicine – WWAMI
Annika Singh, Georgia Tech
Ansley Pantsari, University South Carolina – School of Medicine
Anthony Agyeman, NC School of Science and Mathematics
Brooke Sauer, Durham School of the Arts, teacher
Calla Castro, Montana State University
Clare Matusевич, Chapel Hill High School, teacher
Courtney Hallock, University of Washington School of Medicine – WWAMI
Isis Chien, Chapel Hill High School
Jessminda DiCello, Montana State University
Jiah Lee, NC School of Science and Mathematics
Kyndal Porter, City of Medicine Academy
Leonardo Baquero, Heritage High School
Manar Bouleqcha, Athens Drive Magnet School
Maya Pattanaik, West Forsyth High School
Melanie Portillo, Cristo Rey Research Triangle High School
Neil Sud, University of North Carolina – Chapel Hill
Noam Cohen, Riverside High School
Shuyan Wang, Leesville High School
Tomas Wayar, Athens Drive Magnet School
Calla Castro—MSU class of 2025
Colman Freel, University of Nebraska
Gargi Dixit, North Carolina State University
Rachel Sielaty, University of North Carolina
Toby Turla, Centers for Disease Control and Prevention

2025 Duke STAR Program

Uma Subrayan, Tulane University School of Medicine
Ella M. Schaffer, Trinity College - CT
Fiona Xu, Duke
Bechorah Aguoru, St. Mary's College – MD
Ava Banionis, Montana State University
Brynne Miller, Montana State University
Lena Richardson, University of South Carolina
Mariam Abdelbarr, Massachusetts Institute of Technology
Shivi Tripathi, Eastside High School - FL
Abigail Varghese, New Hope-Solebury High School
Krish Vakani, Leesville Rd High School
Adhiti Parupalli, Ellington High School

Alix Joseph Meiners, University Texas - Arlington
Conrad Sharp, Duke University
Gauri Murali, Green Hope High School
Lilly McCoy, Episcopal School - Jacksonville, FL
Marianne Baquero, University of North Carolina – Chapel Hill
Alice Lynch, Phoenixville Area High School
Mollie Simmonson, University of Washington School of Medicine
Dillon Demontiney, University of Washington School of Medicine

STAR Program Expansion 2026

The program expanded in 2026 to include an open call for applications from all medical schools in the United States.

ADMINISTRATION

- 1) **Deputy Director, Duke Clinical Research Institute (DCRI), 2020-present:** See role for Associate Director, DCRI; under new Director of the DCRI (Adrian Hernandez)
- 2) **Associate Director, Duke Clinical Research Institute (DCRI), 2010–2020:** the annual budget of the DCRI is approximately \$270,000,000 with pass-through; and over 800 staff. As a member of the Executive Team of the DCRI, the Faculty Associate Director (“FAD”) is responsible for the day-to-day management of Faculty Leaders and operational staff, including personnel management and supervision. I am responsible for overseeing the academic, scientific, financial, strategic, and operational performance of clinical research efforts across all therapeutic areas. I serve as an expert resource and senior executive leader, strategist, and mentor, providing guidance and direction to faculty members and to DCRI staff, including participating in operational decisions with appropriate operational leaders. I lead and support advanced clinical practice and advanced practice providers in their professional and academic development, ensuring all regulatory, accreditation, and clinical standards are met. I participate in the Balanced Scorecard business model development, implementation, and execution. In addition, as the Associate Director I have full authority and responsibility to stand in for and represent the Director of the DCRI at his request or during his absence. My role is to lead scientific and business development initiatives and to develop therapeutic area leaders, junior faculty, and fellows in the following areas: GI/Hepatology, Infectious Disease, Perioperative Medicine, Clinical Events Adjudication, Pediatrics, Neuro-Sciences Medicine, Nephrology, Rheumatology, all emerging areas.
- 3) **Director, DCRI Trials 2012-2019:** I have broad oversight for all federally funded clinical trials conducted at the DCRI. In addition, I am responsible for the oversight of all industry-sponsored clinical trials at DCRI that include <5000 patients. In this role, I am either directly responsible or ‘dotted line’ responsibility for approximately 450 operational staff of the DCRI. In addition, I have ‘dotted line’ reporting relationships with over 100 faculty who conduct their research at the DCRI. In brief, I am accountable for 45% of the \$270,000,000 annual revenue of the DCRI.
- 4) **Chief, Division of Quantitative Sciences, 2007–2010:** I was the original Division Chief and started the division in an agreement with the Department Chair and Dean of the School of Medicine. The division provides analytic support across the Department of Pediatrics, increases the extramural funding for the department, and provides mentorship in analytic methods for junior investigators. Original division size: 3 members; by 2010, the division grew to 5 members and includes expertise in biostatistics, econometrics, epidemiology, health

services research, and pharmacometrics (PK-PD and pharmaco-epidemiology). Four division members are board-certified in general pediatrics, infectious disease, and neonatology. Three division members have PhDs, and two have master's degrees.

5) **Director, Duke Clinical Research Institute Fellowship Program, 2004–2010:**

Also referenced as Training > Educational Program Development #2

I was the original Fellowship Program Director. I supervised the education of all medical students, PhD students, residents, and fellows who train for careers in clinical research at the DCRI. By 2009, the training program had grown to sufficient size that we split medical student training off from the fellowship program. The fellowship had approximately 20–30 fellows and 5 students each year by the time I transitioned to assume the role of Faculty Associate Director of the DCRI.

INVITED PRESENTATIONS

- ¹Children's Hospital of the King's Daughters, 2000, Neonatal Sepsis
- ¹Oakland Children's Hospital, 2000, Neonatal Sepsis
- ¹Wake Forest University, 2000, Neonatal Sepsis
- ²Pediatrics Consensus Conference on Neonatology, 2001, Neonatal Nosocomial Sepsis
- ³Pediatrics World Wide Web Grand Rounds, 2001, Neonatal Candidemia
- ²Drug Information Association, 2003, Neonatal Clinical Trials Design
- ³Hot Topics in Neonatology, 2003, Gram-Positive Infections Clinical Trials Update
- ³Pediatric Global Drug Development, 2004, Neonatal Clinical Trials Design, London, England
- ³Pediatric Global Drug Development, 2004, Operationalizing a Neonatal Clinical Trial, London, England
- ³Pediatric Global Drug Development, 2004, Chair, Neonatal Clinical Trials Design Workshop, London, England
- ²Pediatric Antifungal Clinical Trials Design—Invited Faculty for Antifungal Clinical Trials Symposium: Focus on Fungal Infections, 2004, New Orleans, Louisiana
- ²National Institute of Child Health and Human Development Neonatal Network— Early Diagnosis of Neonatal Candidemia, January 28, 2004, Rockville, Maryland
- ²NICHD/FDA Newborn Initiative Drug Prioritization Committee—March 28, 2004, Baltimore, Maryland
- ²National Institute of Immunology Allergy and Infectious Disease Bacteriology and Mycoses Study Group—Neonatal Candidemia: Clinical Trials Design Pitfalls, April 13, 2004, Bethesda, Maryland
- ²Interscience Conference on Antimicrobial Agents and Chemotherapy—Focus Session Chair: Diagnosis of Invasive Fungal Infections, November 1, 2004, Washington, DC
- ¹Neonatal Candidiasis—Baltimore, Maryland, July, 2004
- ¹Nosocomial Prevention and Care in the Nursery: What works, what doesn't work, and what might work—South Carolina Neonatal Meeting, September, 2004
- ²Interscience Conference on Antimicrobial Agents and Chemotherapy—Focus Session Invited Faculty: Interpretation of Diagnostic Assays in Invasive Fungal Infections, 2004, Washington, DC
- ²Neonatal Nosocomial Infections, Neofest Conference, November 5, 2004, Cincinnati, Ohio
- ¹Neonatal Clinical Research, February 24, 2005, Charlotte, North Carolina
- ²Focus on Fungal Infections: Treatment of Neonatal Candidiasis, March 18, 2005, Miami, Florida, Invited Faculty
- ²Focus on Fungal Infections: Neonatal Candidiasis Prophylaxis, March 18, 2005, Miami, Florida, Invited Faculty
- ²Kinship Conservation Institute: Winning Grants and Contracts, June 20, 2005, Bozeman, Montana, Invited Faculty
- ²Marshfield Clinic: Diagnostic Testing in Neonates, September 2005, Visiting Professor
- ³Infectious Disease Society of America—Current Controversies in Pediatrics; Neonatal Candidiasis, October 2005, Invited Faculty
- ²Neonatal Networks and Drug Development—Baltimore, Maryland, December 2005, Invited Faculty

- ¹California Association of Neonatologists: Neonatal Candidiasis, March 2006, Invited Faculty
- ¹California Association of Neonatologists: Neonatal Meningitis, March 2006, Invited Faculty
- ²Food and Drug Administration: Center for Drug Evaluation and Research Grand Rounds: Dissemination of Data and Peer-Reviewed Publication from Pediatric Exclusivity Trials, May 2006
- ²Food and Drug Administration Center for Drug Evaluation Antimicrobial Division: Neonatal Candidiasis, July 2006, Visiting Professor Program
- ³Neonatal Clinical Trials Design, European Union for Drug Development, April 2007, Invited Faculty
- ³Antifungal Prophylaxis for Neonatal Candidiasis, Society for Pediatric Research, May 2007
- ³Meet the Expert: Neonatal Candidiasis Prophylaxis and Treatment, ICAAC, September 2007, Invited Faculty
- ²Neonatal Infections, Pediatrix Quality Initiative, October 2007, Invited Faculty
- ¹Neonatal Candidiasis, New York State Neonatologist Meeting, October 2007, Invited Faculty
- ¹Neonatal Candidiasis, California State Academic Day for Fellowship Training, November 2007, Invited Faculty
- ¹Neonatal Meningitis, Children's Hospital Orange County, November 2007, Visiting Professor
- ²Neonatal Nosocomial Infections, Neo Conference, Orlando, Florida, February 2008, Invited Faculty
- ¹Pediatric Drug Development and Public Health, Children's Mercy Hospital, March 2008, Visiting Professor
- ³Pediatric and Neonatal Drug Development, DIA EU-FDA Meeting, May 2008, Faculty
- ³Neonatal Candidiasis, International Symposium of Neonatology, Buenos Aires, Argentina, June 2008, Invited Faculty
- ³Neonatal Meningitis, International Symposium of Neonatology, Buenos Aires, Argentina, June 2008, Invited Faculty
- ³Neonatal Nosocomial Infections, International Symposium of Neonatology, Buenos Aires, Argentina, June 2008
- ³Neonatal Candidiasis Infection and Immunity, Keble College, Oxford, England, June 2008, Invited Faculty
- ²Neonatal Candidiasis, NIH-sponsored Infection Workshop, NICHD, Rockville, MD, August 2008, Invited Faculty
- ³Neonatal Infections, International Conference on the Premature Infant, Rome, Italy, September 2008, Invited Faculty
- ³Neonatal Candidiasis, Neonatal Infections, Pavia, Italy, September 2008, Invited Faculty
- ¹Mentorship of Junior Faculty and Fellows, Children's Hospital of Philadelphia, November 2008, Visiting Professor
- ¹Neonatal Infections, University of Arkansas Medical School, February 2009, Visiting Professor
- ²Pediatric and Neonatal Drug Development, Arkansas Children's Hospital, February 2009, Visiting Professor
- ³Neonatal Meningitis, Sao Paulo, Brazil, March 2009, Invited Faculty
- ³Neonatal Candidiasis, Sao Paulo, Brazil, March 2009, Invited Faculty

²National Institutes of Health: Diversify Your Research Portfolio: Lecture to K12 recipients, April 2009, Invited Faculty

³Neonatal Candidiasis and Fluconazole PK, Paris, France, April 2010

³Clinical Pharmacology, Republic of Singapore, December 2010

³Neonatal Candidiasis, Rio Janeiro, Brazil, March 2011

²Drug Development, Emory University, Atlanta, GA, May 2011

³Neonatal Candidiasis, Torino, Italy, March 2011

Data Quality in Clinical Trials, National Institutes of Health (NCR), October 2011

Neonatal Clinical Trials, Food and Drug Administration, November 2011

Neonatal Infectious Disease, (Neo Prep) New Orleans, January 2012

Pediatric Trial Design, American Society Clinical Pharmacology and Therapeutics, March 2012

Pediatric Drug Development, Food and Drug Administration and Brookings Institute, 2012

³Pediatric Drug Development, Lima, Peru, 2012

³Brazilian Perinatology Congress, Curitiba, Brazil, 2012

²Neonatal Candidiasis, Florida, 2013

³Pediatric Drug Development, Prague, Czeck Republic, 2013

³Neonatal Candidiasis, Jeddah, Saudi Arabia, 2013

³Clinical Neonatology, Torino, Italy, 2013

³Neonatal Candidiasis, Oxford, UK, 2013

³Pediatric Drug Development, Bangkok, Thailand, 2013

²Public Workshop on Rare Diseases, Silver Spring, MD, 2014

²Clinical Pharmacology and Anti-Infective Drug Development for Pediatric Patients, ICAAC, 2014

²ASCPT 2014 Career Bootcamp, Georgia, 2014

²Roadmap for Applying Regulatory Science to Neonates, Silver Spring, MD, 2014

²Miami Neonatology, Florida, 2014

²BPCA Annual Meeting, Bethesda, MD, 2014

²NEO: The Conference for Neonatology, Florida, 2015

²NeoPREP, Georgia, 2016

²NEO: The Conference for Neonatology, Florida, 2016

²Pediatric Academic Societies Annual Meeting, Maryland, 2016

²Public Workshop on Pediatric Clinical Investigator Training, FDA/NICHHD, Bethesda, MD, 2016

²Facilitating Anti-Infective Drug Development for Neonates & Young Infants, Silver Spring, MD, 2016

²Pediatric Master Protocols Workshop, Silver Spring, MD, 2016

²UNC Children's Research Institute Retreat: Conducting successful pediatric clinical and translational research, 2016

²DCRI-NIH Collaboratory Presentation - Collaborations and Synergies: CTSA Program/Trial Innovation Network and PCORnet, 2016

²Inclusion Across the Lifespan-II, September 2020

³CanCOVID-Public Health Agency of Canada (PHAC) Sentinel Intelligence (SITE) Exchange on Impact of Delta on Children, expert panel member, October 2021

²Multi-Regional Clinical Trials Center, Advancing Pediatric Platform Trials: Keynote Speaker, Planning Committee, DC, May 2024

²Montana State University Translational Science Summit, Keynote Speaker, Bozeman, MT, September 2025

²2025 Best Pharmaceuticals for Children (BPCA) Stakeholders Meeting, Bethesda, MD, December 2025

²FDA ADEPT 10: Addressing Challenges in Neonatal Product Development, February 2026

²Society for Pediatric Research: Mentorship, Boston MA, April 2026

¹Regional ²National ³International

VISITING PROFESSORSHIPS

1. South Carolina, Neonatal Infections, 2004
2. Kingship Conservation Institute, Montana, Grantsmanship, 2005
3. Marshfield Clinic, Neonatology, Wisconsin, Neonatal Infections, 2005
4. Food and Drug Administration, Maryland, Neonatal Candidiasis, 2006
5. New York, Neonatal Candidiasis, 2007
6. Children's Hospital Orange County, California, Neonatal Infections, 2007
7. Children's Mercy Hospital, Kansas City, Pediatric Therapeutics, 2008
8. Buenos Aires, Argentina, Neonatal Infections, 2008
9. Keble College, Oxford, England, Neonatal Candidiasis, 2008
10. NICHD, Maryland, Neonatal Candidiasis, 2008
11. Rome, Italy, Neonatal Infections, 2008
12. Pavia, Italy, Neonatal Infections, 2008
13. Children's Hospital of Philadelphia, Pennsylvania, Mentorship, 2008
14. University of Arkansas Children's Hospital, Neonatal Infections, 2009
15. University of Arkansas Children's Research Institute, Pediatric Therapeutics, 2009
16. Salt Lake City, Utah, Pediatric Drug Development, 2009
17. Sao Paulo, Brazil, Neonatal Infections, 2009
18. National Institutes of Health, Clinical Research and Pediatric Therapeutics, 2009
19. Armed Services Hospital Maryland, Neonatal Infections, 2009
20. Torino, Italy, Clinical Research and Pediatric Therapeutics, 2009

21. Ghanzhou, China, Invasive Candidiasis, 2009
22. Shanghai, China, Invasive Candidiasis, 2009
23. Beijing, China, Invasive Candidiasis, 2009
24. University of San Diego, California, Neonatal Candidiasis, 2010
25. Singapore, KK Hospital of Singapore, Pediatric Clinical Research, 2011
26. Neonatal Clinical Trials, Tufts Hospital, 2012
27. University British Columbia, Canada, Pediatric Trials, 2012
28. Torino, Italy, Neonatal Candidiasis, 2012
29. Curitiba, Brazil, Catheter Management, 2012

Pandemic Response 2020

- 1) The DSMB for Utah & Hydroxychloroquine outpatient trial (chair)
- 2) DSMB for Utah and Hydroxychloroquine inpatient trial (chair)
- 3) Clinical pharmacology of hydroxychloroquine and partnership with FDA to end the Emergency Use Authorization (reference the publication and the FDA website that has the stopping of the EUA for hydroxychloroquine)
- 4) The DSMB for JHU and convalescent plasma trial (member)
- 5) Coordinating Center PI and Clinical Pharmacology for the ACTIVE-1 Trial.
- 6) Cohort study of 100,000 neonates; in order to describe a cohort exposed to COVID-19 (Pediatrix study with Brian Smith)
- 7) COVID-19 School Advisory Board for North Carolina Public Schools (providing scientific education and interpretation of infection data to 42 North Carolina school districts, and over 2/3rd of the 1.5 million K-12 children in North Carolina)

Meetings with NC Superintendents

County/City	District	Meeting Type	Date Time
Chapel Hill	CHCCS	board	July 21, 2020 @ 1-2pm
Durham	DPS	DPS engagement	July 21, 2020 @ 2-2:30pm
Chapel Hill	CHCCS	board	July 23, 2020 @ 5:30-9:30pm
Durham	DPS	cabinet	July 27, 2020 @ 10:30-11am
Chapel Hill, Durham, Orange	CHCCS, DPS, OCS	board	July 29, 2020 @ 9:15-10:30pm
	NC SSA	executive board	Aug 04, 2020 @ 8-9am
Chapel Hill, Durham, Orange	CHCCS, DPS, OCS	board	Aug 05, 2020 @ 9:15-10:30pm
NC SSA	NC SSA	executive board	Aug 06, 2020 @ 7:15-8:15am
NC SSA	NC SSA	superintendents	Aug 12, 2020 @ 8-8:30am
Chapel Hill, Durham, Orange	CHCCS, DPS, OCS	superintendents	Aug 12, 2020 @ 9:15-10:30pm
Durham	DPS		Aug 14, 2020 @ 9-10pm
Wake	WCPSS		Aug 18 2020 @ 3:30-5:30pm
Chapel Hill, Durham, Orange	CHCSS, DPS, OCS	superintendents	Aug 19, 2020 @ 9:15-10:30pm
			Aug 24, 2020 @ 6-7pm
Chapel Hill, Durham, Orange	CHCSS, DPS, OCS	superintendents	Aug 26, 2020 @ 9:15-10:30pm
North Central Region	District 3		Aug 27, 2020 @ 11am-12pm

Sand Hills and Piedmont Triad Regions	Districts 4 and 5		Aug 28, 2020 @ 10-11am
NCLDC	NCLDC	superintendents	Sep 01, 2020 @ 7-8am
SW & NW Regions	Districts 6 and 7	superintendents	Sep 01, 2020 @ 4-5pm
Chapel Hill, Durham, Orange	CHCSS, DPS, OCS	superintendents	Sep 02, 2020 @ 9:15-10:30pm
Chapel Hill, Durham, Orange	CHCSS, DPS, OCS	superintendents	Sep 09, 2020 @ 9:15-10:30pm
Western Region	District 8	superintendents	Sep 10, 2020 @ 9-10am
Northeast and Southwest Regions	Districts 1 and 2	superintendents	Sep 14, 2020 @ 10:30-11:30am
North Central and Sandhills Regions	Districts 3 and 4	superintendents	Sep 15, 2020 @ 10:30-11:30am
Wake	WCPSS	board	Sep 15, 2020 @ 6-8:30pm
Southwest and Piedmont Triad	Districts 5 and 6	superintendents	Sep 16, 2020 @ 10-11am
			Sep 16, 2020 @ 6-7pm
Chapel Hill, Durham, Orange	CHCSS, DPS, OCS	superintendents	Sep 16, 2020 @ 9:15-10:30pm
Chatham	Chatham	board	Sep 17, 2020 @ 4-5pm
Northwest and Western Regions	Districts 7 and 8	superintendents	Sep 22, 2020 @ 5-6pm
Chapel Hill, Durham, Orange	WCPSS, CHCSS, DPS, OCS	superintendents	Sep 23, 2020 @ 6-7pm
NC Association of Educators (NCAE)			Sep 28, 2020 @ 9:30-10:30am
Northeast and Southwest Regions	Districts 1 and 2	superintendents	Sep 28, 2020 @ 10:30-11:30am
Elizabeth City-Pasquotank Schools	ECPPS	board	Sep 28, 2020 @ 5-7pm
Orange	OCS	board	Sep 28, 2020 @ 7-8:30pm
North Central and Sandhills Regions	Districts 3 and 4	superintendents	Sep 29, 2020 @ 10:30-11:30am
Wake	WCPSS	board	Sep 29, 2020 @ 6-9pm
Piedmont and Southwest Regions	Districts 5 and 6	superintendents	Sep 30, 2020 @10-11am
			Sep 30, 2020 @ 6-7pm

Media Appearances on COVID-19

1. July 25, 2020 [Duke gets NIH grant to track coronavirus transmission in students](#), WRAL, *also carried by WILM-TV
2. Aug 15, 2020 [Wake school board in talks about partnership with Duke scientists who will help the district make decisions on opening](#), WRAL-NBC 5
3. Sep 22, 2020 [No second coronavirus wave in NC because state still not done with first one, experts say](#), WRAL-NBC 5
4. Sep 29, 2020 [Will Orange County Schools return to in-person classes? Decision could come tonight](#), Raleigh News & Observer
5. Oct 02, 2020 [Chapel Hill-Carrboro school board weighs benefits of remote vs. hybrid classes](#), Raleigh News & Observer (Danny Benjamin & Kanecia Zimmerman)
6. Nov 11, 2020 [Duke physician briefs Wake County School Board on expectations for in-school COVID results](#), WTVD ABC-11 (*clip begins @ 12:10:00)
7. Nov 18, 2020 [As COVID-19 soars in many communities, schools attempt to find ways through the crisis](#), Science Magazine (Danny Benjamin & Kanecia Zimmerman)
8. Nov 23, 2020 [Ashe County Schools Hold Virtual COVID-19 Community Information Event](#), Ashe Post and Times (Daniel Benjamin & Kathleen McGann)
9. Dec 02, 2020 [Wake schools adjust dashboard of coronavirus information, but questions remain](#), WRAL NBC-5
10. Dec 05, 2020 [School systems working with Duke, UNC to navigate the pandemic](#), The Henderson Daily Dispatch ((Danny Benjamin & Kanecia Zimmerman)

11. Dec 30, 2020 [Are schools safe? A growing body of evidence suggests that, with the right measures, they contribute little to virus spread.](#), The Washington Post
12. Jan 12, 2021 [‘Stop dangling carrots’: CMS parents, teachers frustrated after months of back and forth](#), WSOC ABC-9 Charlotte
13. Jan 12, 2021 [Duke, UNC study finds low rates of in-school COVID transmission](#), WTVD ABC-11, also carried by WWAY-TV, Wilmington
14. Jan 13, 2021 [CDC: Young adults account for most COVID-19 cases among young people](#), UPI, also carried by Breitbart
15. Jan 17, 2021 [Study shows extremely low rate of coronavirus transmission in school, 0% from child to adult](#), Washington Examiner (MSN)
16. Jan 27, 2021 [Data shows schools can safely reopen if precautions taken](#), WRAL NBC-5
17. Jan 28, 2021 [CDC Researchers Give GOP Fuel for Schools’ Reopening](#), Newsmax, *also carried by 2 additional outlets
18. Jan 28, 2021 [GOP seizes on CDC research to press Biden on schools](#), The Hill, *also carried by MSN News
19. Jan 28, 2021 [Studies Indicate Schools Can Reopen with Proper Precautions](#), WUNC FM-91.5, (*clip begins @ 07:05:34)
20. Feb 02, 2021 [Cooper, Cohen, NC education leaders call for reopening more schools](#), WRAL NBC-5
21. Feb 03, 2021 [Officials say vaccinating teachers isn’t necessary to reopen. What is?](#), Spectrum News, *also carried by NY1-TV, New York
22. Feb 03, 2021 [Author of oft-cited COVID-19 study on schools credits state leaders for ‘interpreting it correctly’](#), WNCN CBS-17
23. Feb 04, 2021 [The Case for Reopening Schools](#), Charlotte Talks w/ Mike Collins, WFAE FM 90.7
24. Feb 04, 2021 [Chapel Hill-Carrboro school board makes decision on bringing students back to school](#), Raleigh News & Observer
25. Feb 08, 2021 [Allison Aubrey talks about COVID and schools, references Duke study](#), NPR, (*clip begins @ 06:39:41), *also carried by at least 25 other NPR outlets including Raleigh-Durham, Tampa and Connecticut
26. Feb 10, 2021 [Why school reopening guidance for elementary students differs from others in NC](#), WTVD ABC-11 (Duke Health, Daniel Benjamin & Ibukun Akinboyo)
27. Feb 11, 2021 [CDC Expected to Publish School Reopening Guidelines Friday](#), Spectrum News Central New York Online, *also carried by at least 5 like Spectrum Bay News and Spectrum Raleigh
28. Feb 15, 2021 Keeping schools open without masks or quarantines doubled Swedish teachers’ COVID-19 risk, Science Magazine
29. Mar 16, 2021 [Duke University is site for clinical trials for AstraZeneca’s COVID-19 vaccine](#), WNCN CBS-17, *also carried by WNCT CBS-9 Greenville
30. Mar 17, 2021 [New study suggest students can be 3 feet, instead of 6, for safe social distancing](#), WNCN CBS-17, *also carried by 3 additional outlets
31. Mar 19, 2021 [Schools prepare to shorten the safe distance between students from six to three feet](#), WNCN CBS-17, (*clip begins @ 05:02:23)
32. Mar 23, 2021 [Teachers union ‘not convinced’ on CDC guidance to reduce classroom spacing](#), The Hill, *also carried by MSN News
33. Apr 07, 2021 [UK variant affecting children, researchers say](#), WRAL NBC-5, David Montefiori
34. Apr 15, 2021 [Schools can open safely during COVID, the latest evidence shows](#), Scientific American
35. May 13, 2021 [How much longer will NC students have to wear masks in school? State isn’t sure yet.](#), Raleigh News & Observer, *also carried by 2 additional outlets

36. May 13, 2021 [Research supports masks in schools as children remain unvaccinated](#), WRAL NBC-5
37. May 13, 2021 [Parents rush to get COVID-19 vaccines for their children](#), Wall Street Journal
38. May 19, 2021 [‘Let them breathe.’ Some protesters call on NC, Wake to end school face mask mandate](#), Raleigh News & Observer
39. May 22, 2021 [Why change school mask rule? It’s not about the kids](#), San Antonio Express
40. Jun 11, 2021 [Can Schools Mandate Covid-19 Vaccines for Children? What We Know](#), The Wall Street Journal, *Also carried by 3 additional outlets
41. Jun 11, 2021 [Teachers Union Shaped CDC School Guidance. Is That a Problem?](#), Medscape
42. Jun 30, 2021 [Duke report to NC lawmakers; Masks, vaccines make full, in-person school safe](#), WRAL NBC-5, Danny Benjamin & Kanecia Zimmerman
43. Jun 30, 2021 [Duke University researchers promote wearing face masks in schools](#), Raleigh News & Observer, Danny Benjamin & Kanecia Zimmerman
44. Jun 30, 2021 [Mask-wearing effective in preventing COVID-19 in North Carolina schools, report says](#), WTVD ABC-11, Danny Benjamin & Kanecia Zimmerman
45. Jun 30, 2021 [ABC Science Collaborative: Face coverings are the best way to stop spread of COVID-19 in schools](#), NC Policy Watch, Danny Benjamin & Kanecia Zimmerman
46. Jun 30, 2021 [Do kids still need to wear mask in school to slow the spread?](#), WPTF Radio, *clip begins at 15:41:30
47. Jul 01, 2021 [NC COVID-19 study on schools finds masking important, social distancing & quarantine less useful when masking](#), WCNC NBC-36 Charlotte, Danny Benjamin, Kanecia Zimmerman
48. Jul 01, 2021 [New research could be a blueprint for what this upcoming school year will look like](#), WCNC NBC-36 Charlotte, Danny Benjamin, Kanecia Zimmerman, (*clip begins @ 05:33:02)
49. Jul 01, 2021 [A new report finds COVID-19 transmission low in classrooms in North Carolina](#), WFAE NPR 90.7 Charlotte, (*clip begins @ 07:06:50)
50. Jul 01, 2021 [A report from Duke University researchers supports mask-wearing in schools](#), WPTF AM-680, Kanecia Zimmerman (*clip begins @ 06:08:10)
- o [*alternate version w/ Danny Benjamin](#), (*clip begins @ 05:32:40)
 - o [6/30 *alternate version w/ Kanecia Zimmerman](#) (*clip begins @ 18:35:15)
51. Jul 01, 2021 [Report shows minimal COVID transmission within NC schools](#), Associated Press, *also carried by:
- i. [WSOC ABC-9 Charlotte](#)
 - ii. [WLOS ABC-13 Asheville](#)
 - iii. [U.S. News & World Report](#)
 - iv. [WAVY NBC-10 Norfolk](#)
 - v. [Greensboro News & Record](#)
 - vi. [The Washington \(NC\) Daily](#)
 - vii. [The Rocky Mount Telegram](#)
 - viii. [The Hickory Record](#)
 - ix. [Winston-Salem Journal](#)
 - x. [Burlington Times](#)
 - xi. *and others
52. Jul 01, 2021 [North Carolina schools did an excellent job stopping COVID-19 transmission](#), Spectrum News Carolinas, Danny Benjamin & Kanecia Zimmerman, (*clip begins @ 06:40:55), *also carried by Spectrum channels state-wide in North Carolina
53. Jul 01, 2021 [North Carolina schools have low transmission of COVID-19 due to mask-wearing, report says](#), WXII NBC-12 (via Associated Press) Greensboro, Danny Benjamin

54. Jul 01, 2021 [Science group says masks protect students. NC lawmakers may no longer require them](#), Raleigh News & Observer, Danny Benjamin & Kanecia Zimmerman, *also carried by [Charlotte Observer](#)
55. Jul 01, 2021 [Schools that mask see little COVID spread](#), MedPage Today, Danny Benjamin & Kanecia Zimmerman
56. Jul 01, 2021 [NC COVID-19 study on schools finds masking important, social distancing & quarantine less useful when masking](#), WCNC NBC-36 Charlotte, Danny Benjamin & Kanecia Zimmerman
57. Jul 5, 2021 [Infectious disease experts say indoor masking may be needed for start of K-12 school year](#), Winston-Salem Journal Online, Danny Benjamin & Kanecia Zimmerman, *also carried by 9 additional outlets
58. Jul 6, 2021 [Opinion: To mask or not to mask: Why's that even a question in schools?](#), Atlanta Journal Constitution, Daniel Benjamin & Kanecia Zimmerman
59. Jul 7, 2021 [How Does the Delta Variant Figure Into Schools' Opening Plans?](#), Education Week, Daniel Benjamin & Kanecia Zimmerman
60. Jul 07, 2021 [Covid and schools: the evidence for reopening safely](#), Nature.com
61. Jul 10, 2021 [Kids are susceptible to delta variant. What should we do?](#), Raleigh News & Observer, *also carried by 6 additional outlets
62. Jul 11, 2021 [CDC Guidance should not be used to mandate masks for kids under 12. They've suffered enough](#), USA Today
63. Jul 12, 2021 [Do you need a vaccine booster and other questions swirling around COVID](#), The Hill Online, *also carried by 1 additional outlet
64. Jul 12, 2021 [Covid-19 turned the last school year upside down. What can kids in the N.C. expect this year?](#), Spectrum News, Daniel Benjamin & Kanecia Zimmerman
65. Jul 12, 2021 [Masks rules vary for school districts](#), WABE NPR 90.1 Atlanta, (*clip begins @ 06:05:02)
66. Jul 13, 2021 [Masking Prevents COVID Transmission in Schools Without Social Distancing](#), WCHL-AM Online
67. Jul 27, 2021 [The Effectiveness of Masks & Return to School, NC Policy Watch](#), Danny Benjamin & Kanecia Zimmerman
68. Aug 2, 2021 [The Delta Variant in Schools: What to Know](#), The New York Times, *also carried by 7 additional outlets
69. Aug 3, 2021 [La variante delta y el regreso a las escuelas](#), New York Times, *also carried by 4 additional outlets
70. Aug 4, 2021 [¿Nuevo efecto de la variante Delta en EE.UU.? Casos de Covid-19 en niños aumentan un 85% en una semana](#), La Tercera (CI), Danny Benjamin & Kanecia Zimmerman, *also carried by 2 additional outlets
71. Aug 4, 2021 [Experts continue to encourage masking in schools as districts vote on policies](#), WNCN CBS-17
72. Aug 4, 2021 [Coronavirus Today](#), North Carolina Health News, Danny Benjamin & Kanecia Zimmerman
73. Aug 4, 2021 [COVID concerns remain high as high school sports set to kick off soon](#), WGHP FOX-8 Greensboro, Danny Benjamin & Robin Gurwitch
74. Aug 4, 2021 [Delta and vaccinated parents: What people with kids under 12 need to know](#), NBC News, *also carried by NBC affiliates nationally
75. Aug 4, 2021 [Doctors weigh in on best way to get kids back in the classroom safely](#), Spectrum News Carolinas, Danny Benjamin, Kanecia Zimmerman & Robin Gurwitch
76. Aug 4, 2021 [Health experts reinforce importance of masks for upcoming school year](#), WRAL NBC-5, Danny Benjamin, Kanecia Zimmerman & Robin Gurwitch
77. Aug 4, 2021 [Masks not required for students, staff in Yadkin County Schools](#), Winston-Salem Journal

78. Aug 4, 2021 [N.C. experts worry children may die if schools don't require masks](#), Raleigh News & Observer (AP), Danny Benjamin & Kanecia Zimmerman, **also carried by 31 additional outlets*
79. Aug 4, 2021 [Duke experts discuss pandemic challenges in the classroom](#), WRAL NBC-5, Danny Benjamin, Kanecia Zimmerman, Robin Gurwitch & Harris Cooper
80. Aug 5, 2021 [As debate over masks in public schools continues, experts say the answer is clear](#), NC Policy Watch, Danny Benjamin & Robin Gurwitch
81. Aug 5, 2021 [As hospitalizations of children grow amid Delta surge, Florida leading U.S. in admissions](#), Newsweek, Danny Benjamin & Kanecia Zimmerman
82. Aug 5, 2021 [NC medical experts worry as more schools won't require masks](#), WSOC ABC-9 Charlotte, Danny Benjamin & Kanecia Zimmerman
83. Aug 5, 2021 [COVID-19 news round-up](#), Associated Press, Danny Benjamin & Kanecia Zimmerman, **also carried by 689 additional outlets*
84. Aug 6, 2021 [School COVID-19 clusters intensifies 'mask optional debate between parents, school boards](#), WCNC NBC-36 Charlotte
85. Aug 9, 2021 [As debate over masks in public schools continues, experts say the answer is clear](#), Indyweek (NC Policy Watch), Danny Benjamin & Robin Gurwitch
86. Aug 9, 2021 [Teacher's union plans next move on mandatory vaccines](#), Politico, **also carried by 1 additional outlet*
87. Aug 9, 2021 [Opinion: Buckle up. Mask up.](#) Atlanta Journal Constitution
88. Aug 10, 2021 [Opinion: We studied one million students. This is what we learned about masking.](#), New York Times, Danny Benjamin & Kanecia Zimmerman
89. Aug 10, 2021 [Opinion: We're doing COVID-19 wrong. We should mandate vaccines for teachers, not mask kids](#), USA Today (YahooNews)
90. Aug 11, 2021 [Duke Health study supports masking up in schools](#), WNCN NBC-36 Charlotte, Danny Benjamin & Kanecia Zimmerman
91. Aug 11, 2021 [Ministers of death: Republic governors leave kids 100% defenseless against delta surge](#), Daily Kos, Kanecia Zimmerman & Danny Benjamin
92. Aug 11, 2021 [New York Times promotes study on child masking that has one massive flaw](#), Daily Caller, Kanecia Zimmerman & Danny Benjamin
93. Aug 11, 2021 [We are watching the data: Newport County on superintendents still waiting on mask decision](#), Newport (RI) Daily News, Danny Benjamin & Kanecia Zimmerman
94. Aug 11, 2021 [1 million students studied – masking works](#), CNN New Day, Kanecia Zimmerman & Danny Benjamin (**clip begins @ 06:14:57*)
95. Aug 11, 2021 [Local doctors say mask mandate is key to making classrooms safe for students](#), WRAL NBC-5
96. Aug 11, 2021 [As millions of students return to the classroom, parents remain divided on mask mandates](#), PBS News Hour
97. Aug 11, 2021 [Six answers to parents' COVID-19 questions as kids return to school](#), Science News, Danny Benjamin & Kanecia Zimmerman
98. Aug 12, 2021 [Guilford protest against school mask requirement features passion and misinformation](#), NC Policy Watch, Kanecia Zimmerman & Danny Benjamin
99. Aug 12, 2021 [Los niños deben usar cubrebocas en las escuelas. Esta es la razón.](#), New York Times, Kanecia Zimmerman & Danny Benjamin, **also carried by 1 additional outlet*
100. Aug 12, 2021 [Are mask requirements in schools necessary to control COVID-19?](#), Reason Magazine, Danny Benjamin & Kanecia Zimmerman, **also carried by 1 additional outlet*
101. Aug 13, 2021 [Do Masks Work? A Doctor Weighs In as Children Return to School](#), Here & Now NPR, **also carried by NPR stations nationally*
102. Aug 14, 2021 [The great school mask debate](#), CNN Smerconish
103. Aug 14, 2021 [We studied one million students. They should wear masks to school.](#), Salt Lake City Tribune (NYT), Kanecia Zimmerman & Danny Benjamin

104. Aug 15, 2021 [Mississippi Gov. Refuses School Mask Mandates, Compares COVID-19 in kids to 'sniffles'](#), Rolling Stone, **also carried by 24 additional outlets*
105. Aug 15, 2021 [With coronavirus cases rising, D.C. schools prepare to outline safety protocols for new academic year](#), Washington Post
106. Aug 16, 2021 [What's going on with COVID surveillance testing at schools](#), Washington City Paper
107. Aug 17, 2021 [No mandatory vaccines, testing instead for Orange County Schools](#), WPTF 680-AM, (**clip begins @ 08:45:15*)
108. Aug 19, 2021 [¿Cambiará la variante delta del COVID-19 las políticas de regreso a clases en EE. UU.?](#), VOA, **also carried by 2 additional outlets*
109. Aug 20, 2021 [Duke expert says he's worried about school districts without mask mandates](#), WRAL NBC-5
110. Aug 20, 2021 [More than 430 coronavirus cases reported in Wake County schools ahead of first day of classes](#), WRAL NBC-5
111. Aug 20, 2021 [Researcher involved in developing mask guidance in NC schools shares what led to the decision](#), WSOC ABC-9 Charlotte
112. Aug 20, 2021 [Science behind masking in schools under debate](#), Washington Examiner, Danny Benjamin & Kanecia Zimmerman
113. Aug 29, 2021 [UAB doctor: Masking in schools is essential in reducing COVID-19 transmission](#), AL.com (AI), Kanecia Zimmerman & Danny Benjamin
114. Aug 31, 2021 [Are schools quarantining too many students?](#), Education Week, Danny Benjamin & Kanecia Zimmerman
115. Aug 31, 2021 [The New York Times assumes a scientific consensus on school mask mandates that its own reporting shows does not exist](#), Reason, Kanecia Zimmerman & Danny Benjamin
116. Sep 1, 2021 [Explaining COVID clusters during back-to-school week](#), WTVD ABC-11, (**clip begins @ 06:06:10*) **alternate version*
117. Sep 7, 2021 [Wake school board discusses COVID-19 testing program and recommended new protocols](#), WRAL NBC-5
118. Sep 7, 2021 [Which policies best protect students & school staff from COVID-19](#), WQOW ABC-18, Eau Claire (WI), (**clip begins @ 06:03:06*) **also carried by 7 additional outlets*
119. Sep 8, 2021 ['Seems a little weird': CNN reporter presses superintendent over mask policy](#), CNN Newsday
120. Sep 8, 2021 [No masks during recess. But Wake schools may require COVID testing, vaccinations](#), Raleigh News & Observer, **also carried by 1 additional outlet*
121. Sep 9, 2021 [2nd NC school district requires teachers and other staff to get COVID-19 vaccines](#), Raleigh News & Observer, **also carried by 1 additional outlet* Yahoo News
122. Sep 13, 2021 [Why don't kids tend to get as sick from COVID-19?](#), Smithsonian Magazine
123. Sep 16, 2021 [Fact check: In pediatrician's video pushing for masks in schools, the numbers add up](#), WNCN CBS-17, **also carried by 2 additional outlets*
124. Sep 17, 2021 [Basic mitigation strategies can cut COVID-19 transmission in schools](#), Medscape
125. Sep 23, 2021 [New Florida order makes quarantine optional for asymptomatic children exposed to virus](#), Washington Post, **also carried by 2 additional outlets including Yahoo News*
126. Sep 23, 2021 <https://www.wnyc.org/story/does-masking-schools-work> WYNC Radio: Brian Lehrer Show
127. Sep 24, 2021 <https://www.youtube.com/watch?v=I6H7urz-HgA> The Daily Show with Trevor Noah

128. Sep 24, 2021 [Pediatric COVID-19 cases rose faster in countries without school mask requirements, CDC says](#), The Washington Post, **also carried by 2 additional outlets*
129. Sep 25, 2021 [2 CDC analyses show lower spikes in masked schools](#), Arkansas Democrat Gazette, **also carried by 4 additional outlets*
130. Sep 27, 2021 Secretary of Education, Miguel Cardona, mentioned the work of The ABC Science Collaborative in a series of tweets he released regarding the importance of “following the science” when it comes to protecting our students in school.
131. Sep 29, 2021 [Parents, health experts disagree on optional masking at Harnett County schools](#), WRAL NBC-5
132. Sep 29, 2021 Dr. Radio Interview with Dr. Dan Rauch, SiriusXM  [Doctor Radio interview w Dr Danny Benjamin 9-29-21.mp3](#)
133. Oct 04, 2021 [NC lawmaker 'flat-out wrong' about COVID vaccines](#), WNCN CBS-17, ABC Science Collaborative, **also carried by 1 additional outlet*
134. Oct 08, 2021 [For NC school staffs, vaccine mandates are few and far between](#), WUNC 91.5 FM, ABC Science Collaborative, **also carried by 2 additional outlets*
135. Oct 08, 2021 [Masks in the classroom work, and here's the proof, Duke researchers say](#), Spectrum News Carolinas, Kanecia Zimmerman, Danny Benjamin, **also carried by Spectrum News outlets nationally*
136. Oct 11, 2021 [Study finds improved outcomes for schools with mask mandates](#), WGHP FOX-8 Greensboro, Duke University School of Medicine, ABC Science Collaborative (*clip begins @ 12:08:10)
137. Oct 28, 2021 [Even without mask mandate, coronavirus infections among Harnett students drop](#), WRAL NBC-5
138. Oct 29, 2021 [Illegal mask mandates? Cancer-causing COVID tests? Misinformation persists in emails sent to Cooper, Cohen](#), WNCN CBS-17, Cameron Wolfe, ABC Science Collaborative
139. Nov 05, 2021 [Masks could soon no longer be a part of the classroom, health experts say](#), WRAL NBC-5
140. Nov 05, 2021 [NC schools awash in billions of COVID relief dollars, with most cash unspent](#), Raleigh News & Observer, **ABC Science Collaborative**, **also carried by 6 additional outlets including WRAL NBC-5, UNC 91.5 FM & Durham Herald Sun*
141. Nov 12, 2021 [When can kids take their masks off in school?](#), NPR, **also carried by at least 55 additional outlets including in Atlanta, Baltimore & San Diego*
142. Nov 23, 2021 [Hindsight 20-20 on pandemic remote learning](#), Blue Ridge Public Radio
143. Dec 07, 2021 [School board votes to keep mask mandate until January](#), Daily Reflector/Standard (NC), **ABC Science Collaborative**
144. Dec 13, 2021 [Few take part in weekly coronavirus testing in Wake schools](#), WRAL NBC-5
145. Dec 29, 2021 [New research suggests NC schools with mask mandates could loosen quarantine rules](#), WRAL NBC-5, **Danny Benjamin, Kanecia Zimmerman**
146. Dec 29, 2021 [Keeping kids in school after getting COVID](#), WSOC ABC-9 Charlotte, (*clip begins @ 17:38:12)
147. Dec 29, 2021 [How to safeguard children from COVID when school returns](#), WXII NBC-12 Greensboro (*clip begins @ 11:03:52) **also carried by WCWG CW-20, Greensboro*
148. Dec 30, 2021 [COVID rapid testing & schools in 2022](#), USA Today, **also carried by Yahoo News, MSN News*
149. Dec 30, 2021 [“Test to Stay” protocols for the new year recommended](#), Spectrum News, (*clip begins @ 02:35:20)
150. Dec 30, 2021 [Concerns about student safety in school after the holiday break addressed](#), WXII NBC-12 Greensboro, (*clip begins @ 04:35:08)

151. Dec 30, 2021 [Keeping kids safe from COVID when returning to school](#), WITN NBC-7 Greenville, (*clip begins @ 06:04:00)
152. Dec 30, 2021 [Rapid tests, lots of rapid tests: How US schools plan to reopen amid omicron-fueled COVID-19 surge](#), USA Today
153. Dec 30, 2021 [COVID-19 vaccine side effects rare in children ages 5-11, CDC says](#), UPI
154. Jan 02, 2022 [A testing strategy could be a better alternative to automatic quarantining for COVID-19 and schools](#), WNCN CBS-17, (*clip begins @ 06:34:04)
155. Jan 03, 2022 [Opinion: Georgia schools embrace wait-and-see approach to omicron](#), Atlanta Journal-Constitution
156. Jan 04, 2022 [New year, new COVID-19 variant: Omicron, revised CDC guidelines and more](#), Education NC, **ABC Science Collaborative**, Duke University School of Medicine, Duke Clinical Research Institute
157. Jan 04, 2022 [Pediatricians answer parents' questions as kids return to school, daycare amid COVID-19 omicron surge](#), Good Morning America
158. Jan 04, 2022 [Children's hospitals overwhelmed by omicron surge](#), Anderson Cooper 360, CNN (*entire interview clip begins @ 6:28)
 - o [Dr. Benjamin interview clip](#)
159. Jan 05, 2022 [Board approves Duke University's test-to-stay strategy to keep students in school](#), The Stanly News & Press (NC)
160. Jan 05, 2022 [There's no excuse for using COVID to shut down schools again](#), Fox News Opinion, **also carried by Fox News affiliates nationally*
161. Jan 06, 2022 https://www.heraldsun.com/news/local/education/article257062942.html?ac_cid=DM589397&ac_bid=-1435187677
162. Jan 09, 2022 [Omicron threatens to upend classrooms](#), The Hill, **also carried by 5 additional outlets including Yahoo News*
163. Jan 11, 2022 [A deceptive COVID study, unmasked](#), Wall Street Journal Opinion, ABC Science Collaborative, **also carried by 2 additional outlets*
164. Jan 13, 2022 [More than 1,000 SCS teachers and students quarantined last week amid Omicron surge](#), Stanly Press, ABC Science Collaborative
165. Jan 19, 2022 [Tensions rise as Mass. Changes school COVID measures for 'current state of pandemic'](#), Boston Globe
166. Jan 25, 2022 [The end of K-12 contact tracing? Some schools say symptoms, not exposure, should spur tests](#), The 74 Million
167. Jan 25, 2022 [Dr. Jennifer Ashton answers questions about raising kids amid COVID-19](#), Good Morning America
168. Jan 28, 2022 [After 2 years, growing calls to take masks off children in schools](#), NPR News
169. Feb 09, 2022 ['Test to Stay' COVID protocol trial at SCHS](#), Taylorsville Times (NC)
170. Feb 10, 2022 ["Test to Stay" was well underway in NC prior to CDC announcement](#), North State Journal, **ABC Science Collaborative**
171. Feb 11, 2022 [As COVID cases drop, Duke experts says schools could drop mask mandates soon](#), WRAL NBC-5
172. Feb 16, 2022 [Half of NC school districts have dropped mask mandates. And more may follow soon](#), Raleigh News & Observer, **also carried by 5 additional outlets including Yahoo News*
173. Feb 18, 2022 ['Let the masks come off:'. Doctors say vaccinated kids at low risk in unmasked classrooms](#), WRAL NBC-5
174. Feb 22, 2022 [Unvaccinated students 8 times more likely to contract COVID-19](#), WNCN CBS-17, Duke Health, ABC Science Collaborative, (*clip begins @ 17:06:32)

175. Feb 23, 2022 [As two big states eye unmasking in schools, a pair of studies lay out the number of cases that could trigger](#), The 74, **also carried by Around the World Journal*
176. Feb 28, 2022 [Does science support lifting school mask mandates?](#), The Scientist
177. Mar 09, 2022 [Universal masking in schools shown to reduce spread of COVID-19, study finds](#), WRAL NBC-5, Danny Benjamin and Kanecia Zimmerman, **also carried by 16 additional outlets including in Boston, Denver & Salt Lake City*
178. Mar 09, 2022 [Do masks in school work? As the mandates fall, a pair of new studies may finally put debate to rest](#), Danny Benjamin and Kanecia Zimmerman, **also carried by Yahoo News*
179. Mar 09, 2022 [Study: Masking greatly reduces COVID-19 spread in schools](#), WUNC NPR 91.5, Danny Benjamin and Kanecia Zimmerman
180. Mar 09, 2022 [NC Senate Republicans fail to override veto of 'Free the Smiles' act](#), WNCN CBS-17
181. Mar 15, 2022 [School mask mandates in the U.S. reduced coronavirus transmission](#), Science News, **also carried by 3 additional outlets*
182. Mar 17, 2022 [Editorial: Mask Choice](#), Barre Montpelier Times Argus (Vt), **also carried by 3 additional outlets*
183. Mar 18, 2022 [School mask mandates in the U.S. reduced delta variant transmission by 72%](#), Cleveland Scene
184. Jun 21, 2022 [The wish of pediatricians: More medications deemed safe for kids](#), AAMC
185. Aug 10, 2022 [5 things to know about the new school year as COVID numbers climb again in NC](#), Spectrum Local News
186. Sep 30, 2022 [Has the FDA fallen short with its new draft guidance for paediatric clinical trials?](#) Clinical Trials Arena
187. Aug 23, 2023 [Kentucky school district cancels classes 2 weeks into year due to COVID-19, flu and strep outbreaks](#), The Today Show
188. Aug 24, 2023 [COVID chaos in classrooms: Kentucky school district sends students home less than two weeks into year due to 'triple-demic' of COVID, flu and strep outbreaks](#), Daily Mail UK, **also carried by Vigour Times*
189. Aug 25, 2023 [School's Out: New fears as US schools close due to 'triple-demic' of COVID, flu and Strep A outbreaks](#), The U.S. Sun, **also carried by 5 additional outlets*
190. Jan 09, 2024 [The F.D.A. warned an asthma drug could induce despair. Many were never told](#), New York Times, **also carried by NYT affiliates, Sky News, [En Español](#)*